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Abstract
The processing of antigens for presentation to CD8+ T-cells in association with MHC 
class I molecules involves many chaperones and accessory proteins in the ER. Once 
processed into a trimeric complex of beta-2-microglobulin (p2m), heavy chain and 
antigenic peptide the MHC class I molecule is complete and can traffic to the cell surface 
where it interacts with the T cell receptor of CD8+ T-cells.
The main focus of this work is the use of MHC class I fusion proteins, which by means of 
a covalent linker form partially assembled class I molecules. Using a fusion protein in 
which an antigenic HLA-A2 binding peptide is linked to p2m (PB), it has been possible to 
show by immunoprecipitation that class I molecules can continue to interact with the 
peptide-loading complex after high affinity peptide has bound. This data is further 
supported by peptide release assays in which class I molecules are not released from the 
peptide-loading complex upon provision of high affinity peptide.
The expression of fusion proteins in which p2in is linked to the heavy chain alleles 
HLA-B44 (P2m-B44) or HLA-A2 (P2in-A2), has highlighted an allelic difference in the 
requirement of MHC class I molecules for chaperones in the antigen processing pathway. 
Specifically it has been possible to show that while P2m-A2 is able to express in murine 
fibroblast K41 cells, p2m-B44 is not. This inability to express is not as a result of the 
absence o f human tapasin, as previously reported, but because of some other unknown 
factor that is present in human cells but not in murine K41 cells. Interestingly the 
expression o f p2m-B44 in K41 cells also disrupts native MHC class I expression implying 
that the construct may be occupying chaperone molecules in the ER and delaying 
processing of mouse class I molecules. Furthermore, in the same system it has been 
possible to show that the major function of calreticulin is not the recruitment of P2in to 
heavy chain, since the p2m-A2 fusion protein, like normal class I expressed 8-10 fold less 
well in calreticulin deficient cells than in ‘wild type’ cells.
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1 Introduction
1.1 Immunity
1.1.1 The Immune System
The immune system is vital to the survival of complex organisms such as humans, but 
its job is highly complex and challenging. To function properly the immune system 
must effectively detect and eradicate ‘foreign’ bodies such as bacteria, viruses and 
mutated cells in the body, whilst tolerating healthy cells, food antigens and commensal 
organisms. However, since even the more complex ‘adaptive’ arm of the immune 
system has evolved alongside these various antigens for about 500 million years 
(Kasahara et al., 1995), most of the time it is able to distinguish correctly between 
harmful and harmless antigens and to act accordingly. Innate immunity, which has 
existed for even longer is common to all multicellular organisms studied (Beutler, 2004) 
and relies on the production of non variable molecules and receptors, which are able to 
recognise features common to a range of pathogens (Medzhitov and Janeway, Jr.,
2002). Specific adaptive immunity, on the other hand, relies on the generation by 
somatic diversification of a huge and diverse repertoire of receptors, which can 
potentially recognise any foreign antigen (Burnet, 1959).
In order to infect and replicate in their host, microbes first have to pass the physical 
barrier of the epithelium. This in itself could be considered the first line of defense 
against infection, since the structure of epithelium with its tight junctions is designed to 
exclude pathogens. Beyond this physical barrier, the innate immune system possesses 
‘chemical weapons’ including acids -  fatty acids in the skin and hydrochloric acid in the 
stomach, enzymes such as lysozyme (Ogawa et al., 1971) and antimicrobial peptides 
such as defensins (Selsted et al., 1985). If these first lines of defense are breached then 
an immediate response to infection can be triggered by stimulation of pattern 
recognition receptors, which are able recognise motifs common to a range of pathogens. 
Pattern recognition receptors can be expressed on the cell surface, within cells or 
secreted into the bloodstream. Secreted proteins such as mannan binding lectin 
(MBL)(Super et al., 1989) and C-reactive protein (CRP)(Berman et al., 1986) are 
produced by the liver and bind to extracellular pathogens, typically resulting in 
stimulation of the complement pathway, leading to opsonisation and either lysis of the 
pathogen or engulfment by phagocytes. Cells of the innate immune system that express
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pattern recognition receptors include macrophages, Dendritic Cells (DCs), mast cells, 
neutrophils, eosinophils and Natural Killer (NK) cells. Macrophages, dendritic cells and 
neutrophils are involved in the engulfment of bacteria and other opsonised material by 
phagocytosis. Through direct pattern recognition receptors, and more commonly via 
receptors for opsonins such as complement molecules, these phagocytes are important 
in the clearance of extracellular microbes. NK cells are involved in the recognition of 
infected cells: the mechanisms by which they do this will be discussed in further detail 
in section 1.1.5.
Ligation of pattern recognition molecules on cells of the innate immune system usually 
triggers them to initiate an inflammation response. This recruits and stimulates more 
cells of both the innate and adaptive immune systems. Stimulated cells of the innate 
immune system typically develop into short-lived effector cells whose chief aim is to 
clear the infection.
During the first few days of an infection while the innate immune system is attempting 
to clear or control the invading pathogen, the body also generates an ‘adaptive’ immune 
response. Adaptive responses are mediated by B cells, which produce antibodies that 
opsonise and lead to the destruction of extracellular foreign material, and by cytotoxic T 
cells, which are able to clear intracellular pathogens by killing the host cell. The 
adaptive response is triggered early during infection; usually in the draining lymph node 
whither antigen is transported from the site of infection by antigen presenting cells. 
However, on first encounter of a foreign antigen an adaptive response takes 5-7 days to 
develop. The chief reason for this delay lies in the very nature of the receptors involved. 
Because adaptive immunity uses such a wide range of receptors in order to be able to 
recognise any invading pathogen, the body cannot afford to produce each of these 
receptors at a high enough frequency to fight an infection. Instead, when the first 
encounter with antigen is made specific T and/or B cells proliferate, creating a pool of 
cells all carrying receptors specific for the pathogen. Only when sufficient numbers of 
antigen specific ‘effector’ cells have been produced can the adaptive response begin to 
fight the infection. However, once a response has developed the adaptive immune 
system is able to recognise pathogens through highly specific receptors and 
subsequently to form a memory compartment so that subsequent encounters with the 
same pathogen can be cleared more quickly.
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The adaptive immune system relies on the innate immune system to alert it to infection 
and to direct its response. The key players in this process are thought to be dendritic 
cells (Nussenzweig and Steinman, 1980). Because dendritic cells are able to 
phagocytose pathogens and antigens, and to initiate either cytotoxic or humoral 
immunity in the lymph nodes by T cell stimulation, they are able to direct the immune 
response. Dendritic cells take up antigens at the site of an infection and in response to 
cytokines (primarily type I interferons), upregulate co-stimulatory proteins such as 
CD80 and CD86, increasing their potency as antigen presenting cells and driving 
stimulation of adaptive immune responses by presenting antigens to T cells.
Among the receptors of the innate immune system found on dendritic cells are the Toll­
like receptors or TLRs. These were first discovered in Drosophila (Hashimoto et al., 
1988) but soon after human equivalents were also found, which have been shown to be 
important in innate immunity (Anderson, 2000). To date 13 TLRs have been identified 
in mammals recognising a diverse range of microbial products such as lipids (TLRs 1,2 
and 6), nucleic acids (TLRs 3, 7, 8 and 9) including double stranded RNA (dsRNA) and 
CpG DNA, and bacterial lipopolysaccharide (LPS) (TLR4) (Beutler et al., 2006). 
Stimulation of TLRs acts as a danger signal and often leads to inflammation and 
recruitment of other immune cells. When a dendritic cell is stimulated by TLR ligation, 
it may also influence the kind of adaptive response that it stimulates. Dendritic cells that 
recognise viral double stranded RNA (dsRNA) through TLR3 may be more likely to 
stimulate a response via IFNy (Interferon y), leading to cytotoxic T cell immunity. 
Whereas if TLR4 is ligated by bacterial LPS the production of an antibody mediated B 
cell response may be stimulated (Saint-Vis et al., 1998). By these mechanisms dendritic 
cells not only work in the innate immune system to destroy pathogens at the site of 
infection, but also direct responses of the adaptive immune response.
1.1.2 The Major Histocompatibility Complex
The Major Histocompatibility Complex (MHC) is a region of the genome, which is 
heavily involved in the function of the immune system. In humans it is a region located 
at chromosome 6p, of about 4Mbp (4 million base pairs) and is divided into three main 
regions: the class I region, found nearest to the telomere, followed by the class III and 
class II regions (The MHC Sequencing Consortium, 1999). The MHC plays a key role 
in disease resistance and susceptibility with linkage analysis showing that it has an 
influence on many autoimmune diseases including type 1 diabetes and rheumatoid
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arthritis (Davies et al., 1994;Rotter and Landaw, 1984;Deighton et al., 1989), and some 
infectious diseases such as malaria and AIDS (Hill et al., 1991;Kaslow et al., 1996). In 
all there are about 60 genes within the MHC that code for proteins with immune 
functions, including most of the key genes necessary for antigen presentation. Antigen 
presentation by MHC class I and class II molecules is responsible for the stimulation of 
T cells, and is therefore central to the initiation of adaptive immune responses. The 
genes encoding MHC class I and class II molecules are highly polymorphic, in fact 
HLA-B (Human Leukocyte Antigen) is the most polymorphic locus so far identified in 
the human genome (Miretti et al., 2005). This variation is thought to have been driven 
by episodes of selection for resistance to infection, related to the ability of MHC alleles 
to present peptides derived from pathogens. Not surprisingly then, much of this 
variation is focused on the antigen binding groove of MHC molecules (van Bleek and 
Nathenson, 1991). Genes within the MHC region code not only for both class I and 
class II genes but also for vital genes in the antigen processing pathway of class I and 
class II molecules, including the Transporter associated with Antigen Processing (TAP) 
(Trowsdale et al., 1990;Deverson et al., 1990;Spies et al., 1990), tapasin (Herberg et al., 
1998) and HLA-DM (Morris et al., 1994). Other genes in the region include 
complement proteins, TNF a  (Tumour Necrosis Factor a )  and within the extended 
MHC region genes coding for histones, tRNAs (transfer RNAs) and olfactory receptors. 
The high degree of polymorphism of the MHC region combined with strong linkage 
disequilibrium has stimulated much interest among immunologists and geneticists, since 
it indicates the evolutionary importance of genes within this region (Miretti et al., 
2005;Traheme et al., 2006;Stenzel et al., 2004). Exactly how important antigen 
processing genes have been in driving linkage disequilibrium over evolution is not 
clear, since the presence of important housekeeping genes such as histones and tRNAs 
in adjacent regions may also have influenced the evolutionary process (Horton et al., 
2004). Notwithstanding this, it is clear that the MHC region has been key to the 
evolution and functions of the adaptive immune system.
1.1.3 T cells
T cells are involved in the recognition of foreign antigens present in the body. The 
majority of antigens recognised by the T cell receptor (TCR) are in the form of peptide 
bound to a major histocompatibilty complex (MHC) molecule. T cells are generally 
classified in terms of their surface markers (or clusters of differentiation CD), and the
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major subtypes of mature T cells are CD4+ and CD8+ T cells. Antigens can be 
presented to CD8+ T cells by MHC class I molecules, which are present on the surface 
of virtually all nucleated cells, and to CD4+ T cells by MHC class II molecules, which 
are found on the surface of professional antigen presenting cells, such as dendritic cells 
and B cells.
T cells precursors are made in the bone marrow and then migrate to the thymus, from 
which they take their name and where most of their early development occurs 
(MILLER, 1961;Cordier and Haumont, 1980). When T cells reach the thymus they are 
not yet committed to a particular lineage and are termed ‘double negative’ as they do 
not yet express CD4 or CD8 (Fowlkes et al., 1985); unlike T cells in the periphery, 
double negative T cells are also CD3 negative (Petrie et al., 1990). Key to the 
development of T cells in the thymus is the production of a functional T cell receptor 
(TCR) by the rearrangement of either the a  and (3 chains, or the y and 6 chains of the 
TCR. In order to produce such a wide range of antigen specificities, TCRs are formed 
by the somatic rearrangement of the TCR gene loci. In the development of the a p  T 
cell, which represents about 95% of the T cell output of the mature thymus, the p chain 
is the first to rearrange. The gene locus of the p chain codes for the variable regions 
made up of 3 segments known as V, D and J and a constant C region. The locus 
contains multiple different versions of each of the V, D and J segments and these can be 
combined in different combinations to create variation (Table l.l)(Rowen et al., 1996). 
This variation is further increased by random nucleotide addition or deletion at each 
junction by the activity of TdT (Terminal deoxynucleotidyl Transferase). Although this 
leads to some out of frame rearrangements, the increase in diversity it creates is 
immense. Because of the arrangement of the TCR p locus and the presence of 2 copies 
of the gene locus, several possible attempts at rearrangement are possible increasing the 
chance of creating functional rearranged genes. If it is successfully rearranged, the p 
chain can then coexpress at the cell surface with the invariant pre-Ta chain and the CD3 
complex. Expression of this pre-T cell receptor is essential for the survival of 
developing T cells (Fehling et al., 1995). T cells exhibit a ‘double positive’ (CD4+, 
CD8+) phenotype before rearrangement of the a  chain (Mombaerts et al., 1992), which 
occurs in a similar fashion to p chain rearrangement, although the a  chain contains no D 
segment. Once the TCR is fully rearranged and expressed, commitment of the T cell to 
a CD4+ or CD8+ lineage can be made according to the specificity of the TCR. T cells 
must be positively selected at this stage by interaction with MHC molecules on stromal
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cells of the thymus and those T cells that are not positively selected, i.e. fail to interact 
with either class I or class II molecules expressed on the thymic epithelium, will die by 
apoptosis (Huesmann et al., 1991).
Conversely T cells expressing TCRs that weakly interact with either MHC class I or 
class II molecules in the thymus continue to develop. The interaction between the TCR 
and the MHC/peptide complex on its own is weak, so accessory receptors are also 
required to help in cell-cell adhesion. The most important co-receptors expressed on T 
cells are CD4 and CD8 proteins. Like the TCR these receptors interact with MHC 
molecules, but instead of binding to the antigenic regions, CD8 and CD4 bind to the 
non variable regions of MHC class I and class II molecules respectively. During thymic 
development those T cells that are reactive to MHC class II in cooperation with CD4, 
down regulate CD8 and visa-versa so that T cells that are released into the periphery 
express either CD4 or CD8 but not both (Kaye et al., 1989). The e, 6, and y chains of the 
CD3 complex are also vital for the expression and stability of the T cell receptor at the 
surface and the £ chain is important for intracellular signalling upon recognition of 
antigens presented by MHC molecules. As well as undergoing positive selection via the 
TCR, T cells are also negatively selected in the thymus in a process known as central 
tolerance (Kappler et al., 1987). This negative selection involves the deletion of T cells 
whose TCR strongly recognises self-antigen in association with MHC molecules. This 
is thought to be a safety mechanism, which protects against autoimmunity.
Table 1.1. The number of variable gene segments encoding the 
Immunoglobulin and T cell receptor genes. Adapted from ‘im m unobiology’ by 
Janeway, Travers and Walport.
Immunoglobulin genes 
Heavy chain k/X light chains
T cell receptor genes 
a  chain p chain
Variable segments (V) 65 None -7 0 None
Diversity segments (D) 70 6 52 13
Joining segments (J) 27 5/4 2 61
T cells leave the thymus in a naive state and in order to become activated they require 
TCR recognition of an MHC-peptide complex in the presence of the appropriate co­
stimulatory molecules (Liu and Janeway, Jr., 1992). This stimulation generally occurs 
in peripheral lymphoid organs such as draining lymph nodes and involves antigen
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presentation by dendritic cells or other professional antigen presenting cells. Once 
activated T cells can proliferate and differentiate into a pool of effector and memory 
cells. Effector cells are strongly active cells, which persist during the infection but are 
gradually lost in the few weeks following clearance. Memory cells, as their name 
suggests, persist for much longer in the periphery although whether they can persist in 
the absence of antigen for the remainder of life is controversial (Kassiotis et al., 
2003;Ciurea et al., 1999).
CD8+ Cytotoxic T lymphocytes (CTL) play an important role in recognition and 
elimination of cells expressing non-self proteins. MHC class I molecules are found on 
the surface of virtually all nucleated cells and each CD8+ CTL produced in the thymus 
carries a different TCR capable of recognising peptide antigen complexed with MHC 
class I. MHC class I molecules generally present intracellular antigens. On recognition 
of MHC class I carrying specific antigen, an activated CTL can kill the target cell, either 
by the release of granules containing perforin and other cytotoxic molecules, or via Fas- 
Fas ligand induced apoptosis. In this way CTLs can eradicate pathogen infected cells 
carrying foreign proteins and in some cases, transformed cells presenting mutated or 
overexpressed proteins.
CD4+ T cells do not directly kill pathogens or infected cells, but are required for 
effective B cell responses, and assist in the development of cytotoxic T cell responses. 
CD4+ T cells recognise peptide antigens associated with MHC class II and these 
antigens are generally derived from extracellular proteins. Only specialised cells such as 
dendritic cells, macrophages and B cells express MHC class II and this reflects the 
specialised role of CD4+ T cells in helping other branches of the immune system. CD4+ 
T ‘helper’ cells are generally categorised as being ThO, Thl or Th2 (Mosmann and 
Coffman, 1989) (Kamogawa et al., 1993) although the point at which their lineage 
becomes committed to either Thl or Th2 from the ‘neutral’ ThO precursor remains 
unclear (Grogan and Locksley, 2002). Thl cells are induced by cytokines such as 11-12 
and IFN-y and they produce IFN-y and IL-2, which activate macrophages and assist in 
the development of a cytotoxic T cell response. Thl cells also suppress the production 
of 11-4 and 11-10 by surrounding cells, cytokines that promote a Th2 response. Th2 
responses produce IL-4,11-5 and 11-10, which are important for the development of the 
humoral response, stimulating B cells into differentiation and class switching (Berton et 
al., 1989).
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Dendritic cells are probably the major stimulators of naive CD4+ T cells since they are 
able to present antigen along with powerful co-stimulation (Nussenzweig and Steinman, 
1980). Dendritic cells that have picked up antigen at the site of an infection are likely to 
be particularly potent stimulators since they will have upregulated co-stimulatory 
molecules such as CD80 and CD86 as discussed in section 1.1.1. They may also 
influence CD4+ T cells into stimulation of either a Thl response assisting CD8+ T 
cells, or a Th2 response assisting B cells. The requirement of CD4+ T cell help for the 
activation of naive B cells and CD8+ T cells is important in directing the correct type of 
response. CD4+ T cell help also allows powerful stimulation of effector B and T cells 
when and only when harmful antigen is detected. The requirement of this second signal 
of stimulation for naive effector cells also guards against autoimmunity. For instance, if 
a B cell has encountered and endocytosed bacteria or other material because of 
recognition of its B cell receptor it can present antigens derived from the endocytosed 
material on class II molecules (see 1.2.1). Activated CD4+ Th2 T cells can then 
recognise this antigen and stimulate the B cell to proliferate producing effector cells and 
to differentiate allowing optimisation of the antibody response.
Finally, a more recent finding and area of intense work in recent years are T regulatory 
(Treg) cells. Unlike most other T cells, Tregs typically do not respond to antigen by 
proliferation in vitro, and are therefore termed anergic. Their role appears to be in the 
suppression of the response of other T cells. Several different subtypes of Treg have 
now been identified but all are implicated in the production of peripheral tolerance. The 
most well characterised subset is the CD4+ CD25+ thymically generated Treg, which 
can both decrease the severity of autoimmunity (Asano et al., 1996;Sakaguchi et al., 
1996) and play a role in controlling immune responses to pathogens (Suvas et al.,
2003).
1.1.4 B cells
Unlike T cells, which migrate to the thymus from the bone marrow to undergo their 
early development, the production of immature B cells occurs in the bone marrow. 
During this process, somatic rearrangement of the immunoglobulin (Ig) gene loci takes 
place. The rearranged genes then code for a functional immunoglobulin receptor (IgM) 
made up of a 2 identical heavy chains and two identical light chains (either k  or X)
22
(Edelman, 1970). The variable sections of both heavy and light chains contribute to the 
antigen specificity of the two identical antigen binding sites on the folded Ig molecule. 
Like the T cell receptor, the great variation in the specificity of different 
immunoglobulins is made possible by the great number of possible rearrangements of 
the gene loci (Tonegawa, 1983) (Table 1.1).
Development of B cells in the bone marrow occurs independently of antigen, so B cell 
tolerance relies on negative selection in the periphery. Immature B cells, which 
recognise antigen in the periphery are either eliminated or become anergic. Those that 
survive this selection procedure go on to become naive B cells expressing both IgM and 
IgD. Different isotypes of immunoglobulin such as IgM and IgD have the same 
specificity but differ in their avidity and in their properties of opsonisation, complement 
activation and other interactions with the immune system owing to differing ‘Fc’ 
domains coded for in the C region of the Ig genes (Morgan and Weigle, 1987). In order 
to be stimulated to produce antibody, B cells must bind to antigen and receive 
stimulatory signals either from CD4+ T-helper cells (Claman and Chaperon, 1969) or 
by recognition of microbial constituents. T cell help can cause proliferation, 
differentiation, class switching and antibody production by B cells.
Antibodies are soluble forms of immunoglobulin, which can be secreted from B cells 
and eliminate disease in several ways. 1) They can neutralise pathogens which normally 
reside within cells but which must spend some of their life cycle outside cells in order to 
reproduce or move to other cells. 2) They can opsonise extracellular pathogens, leading 
to the recruitment of complement and either lysis of the pathogen or engulfment by 
phagocytic cells. 3) They can bind to and neutralise toxins. 4) They can release 
cytokines and recruit other cells of the immune system to the site of infection (Janeway 
et al., 1999).
Activated B cells do not necessarily only produce one specific antibody in their 
lifespan, but with CD4+ T cell help can undergo somatic hypermutation in germinal 
centres (French et al., 1989). During this process the DNA sequences coding for the 
variable loops of immunoglobulin are randomly mutated to modify their specificity. 
Although most mutations may result in loss of affinity, it can be seen from the 
development of antibody responses that high affinity antibodies are positively selected. 
In this way antibody responses increase in affinity during an infection or on multiple 
exposure to the same antigen. Because there is a B cell memory pool, cells producing
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high affinity antibody are available to eliminate pathogens quickly and efficiently upon 
second encounter with antigen.
1.1.5 Natural Killer Cells
Natural Killer (NK) cells are able to recognise and kill a wide range of both mutated 
and infected cells. NK cells can eradicate cells either through antibody dependent cell 
cytotoxicity (ADCC) or through ‘natural killer’ activity. The exact signals and 
mechanisms upon which they carry out the second of these functions is not clear but it 
is thought that NK cell killing is controlled by a balance between activating and 
inhibitory signals received through its cell surface receptors. NK cells display a range of 
germline encoded receptors able to recognise proteins such as MHC class I on the 
surface of other cells. It is thought that NK cells can kill target cells which are not 
expressing class I molecules (Ljunggren and Karre, 1990). NK cells recruited to the site 
of an infection often become activated by cytokines such as IL-12 and Type I 
interferons. When activated, NK cells produce IFNy, which is known to upregulate 
MHC class I on bystander cells. This may offer help to cytotoxic T cells, since they rely 
on recognition of antigen in association with class I molecules. But it may also allow 
easier detection of virally infected cells that are evading CD8+ T cell immunity through 
downregulation of surface MHC class I expression. Many viruses downregulate native 
protein synthesis in their host cells and may be detected and eliminated by NK cells 
early during infection. Other viruses specifically downreglate MHC class I in their host 
cell to evade cytotoxic T cell killing, however if these cells fail to respond to IFNy and 
instead maintain low cell surface class I, then NK cells may be able to detect and kill 
these cells. The major class of receptors on NK cells are known as Killer Inhibitory 
receptors (KIRs) and although many of the proteins are based on fundamentally 
different protein folds in humans and mice, the proteins seem to fulfil very similar roles 
(Martin et al., 2002). It is interesting that like the MHC region the major coding regions 
for NK receptors are highly polymorphic and have also been shown to have some 
disease association, suggesting that they may have been important during evolution as 
well as for our current immunity (Tay et al., 1999;van der Slik et al., 2003).
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1.2 Overview of Antigen Presentation
The role that antigen presentation plays is absolutely vital to the adaptive immune 
response and has been extensively reviewed (Immunological reviews. Vol 
207;Villadangos et al., 2005;Flutter and Gao, 2004). Unlike B cells, which recognise a 
whole variety of antigen types including those on live bacteria, T cells usually recognise 
small processed peptide antigens presented to them by MHC molecules. The contrasting 
roles of CD4+ and CD8+ T cells are reflected in the origin of peptide antigens that are 
presented by MHC class II and class I molecules.
1.2.1 MHC class I and class II
MHC class I antigen presentation occurs in virtually all nucleated cells of the body and 
allows peptide antigens from a random sample of proteins expressed within the cell, to 
be seen at the cell surface by passing CD8+ T cells. This presentation of intracellular 
antigens allows T cells to detect infected or mutated cells and take action against them.
MHC class II antigen presentation occurs on only a specialised subset of cells known as 
professional antigen presenting cells. These are mainly dendritic cells, macrophages and 
B cells as well as epithelial cells of the thymus involved in the development of T cells. 
Class II molecules interact with CD4+ T cells, whose major job it is to stimulate 
responses by either CD8+ T cells or B cells that have come into contact with their 
specific antigen. It therefore makes sense that class II molecules present antigens 
derived from extracellular proteins that have been taken up into the cell by phagocytosis 
or endocytosis. Endocytosed material is broken down in the phago-lysosomal pathway 
and developing class II molecules are exported from the ER to intercept this pathway. 
Class II molecules are therefore able to load peptide antigens at the site where they are 
created. Peptide antigens displayed by class II molecules are generally 13-17 amino 
acids in length, although because they can overhang from the binding groove of class II 
molecules they are not constrained in length.
1.2.2 Cross-presentation
Given that the function of CD8+ T cells is to kill infected cells, it is logical that MHC 
class I molecules should present intracellular antigens to CD8+ T cells, and early in 
vitro experiments on class I presentation seemed to confirm this (Morrison et al., 1986).
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However, this presents a problem in the initial activation of naive cells, since if only 
intracellular antigens are presented on class I molecules, CD8+ T cell responses to a 
virus would have to be stimulated by cells infected with that virus. In contrast to 
professional APCs, such infected cells may not have the capacity to stimulate naive T 
cells. Similarly, it did not fit with in vivo data that clearly showed that when exogenous 
antigen was administered, reactive CD8+ T cells could be generated which were 
specific for the given antigen, presented on MHC class I (Bevan, 1976). Subsequently it 
has been shown that presentation of exogenous antigen on MHC class I molecules, 
termed ‘cross-presentation’, occurs in a small subset of cells, principally macrophages 
and dendritic cells (Rock et al., 1993).
Dendritic cells are thought to be by far the most important cells in cross-presentation, 
and two different mechanisms have been identified by which it can occur. In the first, 
antigen is exported from the endosome into the cytosol and then enters the classical 
pathway for class I antigen presentation (see section 1.3) (Kovacsovics-Bankowski and 
Rock, 1995). In the second pathway, it is proposed that class I molecules might be 
loaded with antigen in the phago-lysosmal pathway rather like the loading of class II 
molecules (Pfeifer et al., 1993). Recently it has been shown that there is a ‘donation’ of 
membrane from the ER to the phagosome during phagocytosis, and that class I 
molecules and all the accessory proteins necessary for antigen processing are present in 
the ‘donated’ membrane (Gagnon et al., 2002;Ackerman et al., 2003). Class I molecules 
are therefore able pick up antigen in the phagocytic pathway. However, since the 
proteasome and the Transporter associated with Antigen Processing (TAP) (see section 
1.3.3) seem to be important for cross presentation in vivo, it is hypothesised that in the 
majority of cases, antigen is still exported into the cytoplasm for degradation, before 
being imported back into the phagosome and associating with class I (Huang et al., 
1996).
Some researchers still argue that although cross-presentation can be demonstrated in 
vitro or in vivo using artificial antigens heavily laden with adjuvants, it is not likely to 
be a process that is important in natural immunity against viruses (Zinkemagel, 2002). 
They propose that the requirement for dendritic cell stimulation in the response results 
from the importance of CD4+ T cell help and that CD8+ T cell stimulation does indeed 
involve antigen presentation by infected cells. Among the evidence supporting this
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theory is the absence of cross priming shown in some allogeneic cell transfer 
experiments (Kundig et al., 1996).
1.3 MHC class I
The importance of MHC molecules was first noticed in 1974 when Zinkemagel and 
Doherty found that virus specific cytotoxic T lymphocytes only attacked infected cells 
bearing the same MHC class I molecules as the CTL itself (Zinkemagel and Doherty, 
1974). This phenomenon is known as MHC restriction, and the implication behind the 
finding was that MHC class I molecules have a role in CTL recognition of infected 
cells. However, the mechanism behind MHC restriction remained unclear for some 
years. In 1982, Alain Townsend at Oxford University showed that CTL clones specific 
for influenza A proteins could respond to target cells expressing incomplete viral 
glycoproteins (Townsend and Skehel, 1982), and then showed that specific CTLs could 
kill non-infected cells simply by pulsing the cell with specific peptides from proteins of 
the flu vims (Townsend et al., 1986). From this it was deduced that the antigenic 
determinant of the vims was not full length protein, but short peptides derived from 
proteins expressed in the cell. These data, along with the concept of MHC restriction, 
suggested that MHC class I molecules play a role in CTL recognition by facilitating the 
presentation of peptide antigens.
1.3.1 Class I structure
In 1987, Pamela Bjorkman and Don Wiley solved the crystal structure of the MHC 
class I complex and noticed an area of electron dense material in a groove formed by 
the MHC class I molecule (Bjorkman et al., 1987a). By refolding the class I complex 
with homogenous peptide they then confirmed that this electron dense region was 
bound peptide. Shortly after this, naturally processed viral peptides were isolated from 
infected cells by acid extraction and sequenced. It was shown that the peptides eluted 
from the cell depended upon the MHC class I alleles present (Rotzschke et al., 1990).
The highly polymorphic genes, which code for the MHC class I heavy chain are found 
at 3 loci within the MHC. Therefore each individual carries up to 6 different heavy 
chain alleles (three from each parent). In contrast, the light chain or p-2-microglobulin 
(p2m) as it is more commonly known, is relatively non polymorphic and is invariant 
within the complex. The final component of the trimeric MHC class I complex 
expressed at the cell surface is the bound peptide; this is the antigenic element of the 
complex and can potentially be derived from any protein resident within the cell. The
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crystal structure o f the class I molecule has greatly enhanced our understanding of how 
peptides binds to class I and has helped to explain how each allele o f class I can interact 
with many peptide antigens (Bjorkman et al., 1987a). There are 4 protein domains in the 
MHC class I heterodimer three of which, the a l ,  a2 and a3 domains are formed by the 
heavy chain while P2 m forms the 4th domain. The a l  and a2 domains share a very 
similar structure consisting o f 4 antiparallel p-strands followed by one long a-helix. The 
two domains interact in such a way that the 8 p-strands form one large p-sheet crossed 
by two a-helices leaving a long groove down the centre. This long groove, bounded by 
the p-sheet at its base and a-helices at either side, forms the peptide binding site (Fig. 
1.1).
Figure 1.1. Ribbon diagram showing the crystal structure of HLA-A2. Top
view of HLA-A2 showing the peptide groove, formed at its base by the p-sheet 
and at the sides by the a-helices of the a1 and a2 domains (cyan). a3 domain 
shown in blue. Adapted from - Cellular and Molecular Immunology 1 No.1; Flutter,B. Gao,B. 
MHC Class I Antigen Presentation - Recently Trimmed and Well Presented
The bound peptide in the class I complex is generally 8-10 amino acids in length and 
forms hydrogen bonds with residues of the groove at both its N and C-termini. Other 
interactions at certain key anchor residues securely bind the peptide to the class I 
molecule (Falk et al., 1991). The anchor residues are determined by the shape of the 
peptide groove and vary from one heavy chain allele to another. Although binding to 
the heavy chain requires certain anchor points in the peptide sequence, often more than 
one amino acid can act as the anchor residue. There is much more flexibility in the other 
amino acids o f the peptide meaning that each heavy chain allele can bind to a wide
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range o f peptide sequences. It is no surprise to find that the majority of the polymorphic 
residues of class I are found around this peptide groove allowing variation in the shape 
and electrostatic properties of the groove so that each heavy chain allele can bind a 
different array of peptides by means of different anchor residues. This maximises the 
number of peptide antigens which an individual can present as each of the six alleles 
carried will be able to bind and present a different repertoire of peptides (Bjorkman et 
al., 1987b).
1.3.2 TCR recognition of class I
TCR recognition of the peptide bound to the groove of the MHC class I molecule is the 
key to the specificity of the immune response made. Specific peptide sequences 
recognised by T cells are usually known as epitopes (although some researchers argue 
that this usage is not strictly accurate, since the term epitope originally referred to 
residues recognisable at the surface of a protein (Yewdell, 2005)). However, the 
stimulation of T cells by antigen, requires not only interactions between the TCR and 
the bound peptide, but also key interactions with residues of the class I molecule itself. 
The importance of these interactions was highlighted by Ajitkumar and co-workers, in 
1988, who showed by site directed mutagenesis, that unlike antibodies to the mouse 
class I allele H2-Kb, which recognise randomly distributed residues on the class I 
surface, TCRs recognise multiple residues located exclusively on the surface of the a- 
helices which surround the peptide antigen (Ajitkumar et al., 1988). In 1996 two 
separate groups published crystal structures of the docking of an MHC class I peptide 
complex and the TCR confirming the multiple interactions between the TCR and both 
the antigenic peptide and the surrounding residues of the class I molecule (Garcia et al., 
1996;Garboczi et al., 1996).
30
Figure 1.2. Ribbon diagram showing the crystal structure of a TCR 
docking with class I. Crystal structure of HLA-A2 (heavy chain - dark blue, 
p2m -  cyan) bound with tax peptide (red) docking with antigen specific TCR (a 
chain -  yellow, f3 chain — green). Adapted from - Cellular and Molecular Immunology 1 
No.1; Flutter,B. Gao,B. MHC Class I Antigen Presentation - Recently Trimmed and Well 
Presented.
1.3.3 Production and Provision of peptides for class I
1.3.3.1 MHC class I presentation failure
In 1986, Peter Cresswell’s lab reported a mutant cell line 174XCEM.T2 (T2) in which 
MHC class I heavy chain and p2 m are expressed normally within the cell, but fail to 
form dimers that are processed and transported to the cell surface. They proposed that 
an additional molecule, absent from T2 cells, and encoded by an HLA-linked gene is
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necessary for efficient assembly of class I (Salter and Cresswell, 1986). Cerundolo and 
Townsend demonstrated th a t. 174, a parent cell line of 174XCEM.T2 has lost a function 
required for presentation of intracellular viral antigens with class I molecules of the 
major histocompatibility complex (MHC), but retains the capacity to present defined 
epitopes as extracellular peptides. They mapped the genetic defect of .174 cells to a 
position within the MHC locus on human chromosome 6 (Cerundolo et al., 1990) and 3 
separate groups soon located 2 genes in the class II region of the MHC encoding a 
putative ABC transporter (Trowsdale et al., 1990;Deverson et al., 1990;Spies et al., 
1990). By transfecting genes for these putative transporters into deficient cell lines it 
was possible to show that both genes were necessary for class I antigen presentation 
(Spies and DeMars, 1991) (Powis et al., 1991). The Transporter associated with Antigen 
Presentation or TAP, as the transporter became known is a heterodimeric protein of 
TAPI and TAP2. TAP deficient cell lines such as the human B cell line T2, display low 
cell surface expression of class I, despite normal expression of both heavy chain and 
p2m. Peptides targeted to the endoplasmic reticulum (ER) by means of a signal 
sequence restore cell surface expression of class I indicating that the mutant cell suffers 
because of an absence of available peptides in the ER (Anderson et al., 1991). After it 
was shown in deficient cell lines that TAP was vital for class I presentation (Salter and 
Cresswell, 1986;Powis et al., 1991;Cerundolo et al., 1990), further study revealed that 
TAP translocates peptides from the cytoplasm to the ER in an ATP dependent fashion 
(Androlewicz et al., 1993). Therefore, the function of TAP is to transport peptides from 
the cytoplasm where they are generated (see section 1.3.3.2) to the ER where newly 
synthesised class I molecules are located. Pulse chase analysis showed that without 
provision of peptide by TAP, class I molecules do not traffic to the Golgi body but 
instead are slowly degraded in the ER (Knittler et al., 1999).
1.3.3.2 Generation of peptides
Peptides for class I loading are produced from proteins in the cytoplasm, which are 
constitutively degraded by the proteasome at variable rates. The proteasome generally 
breaks down proteins of the cell that have been marked for degradation by 
ubiquitination (Kloetzel, 2004). This is a constitutive process, which allows the turnover 
of cellular proteins. However, in some cases proteins may be specifically tagged for 
degradation by the proteasome at an increased rate. It has been hypothesised that the 
majority of antigens presented by class I molecules may actually be derived from
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defective ribosomal products (DRiPs) (Reits et al., 2000). In other words, they may 
arise from newly synthesised non-functional proteins, and this is supported by the fact 
that inhibition of protein synthesis seems to affect class I presentation (Khan et al., 
2001). However, DRiPs cannot be the only source of antigens for class I, since peptides 
can also be presented from whole proteins introduced into permeabalised cells. 
Furthermore, cross-presentation cannot be carried out by presentation of DRiP derived 
antigens, since by definition cross-presented antigens are derived from exogenous 
material.
The degradation products of proteins are dependent on the components present in the 
proteasome involved in protein cleavage. Stimulation by the cytokine IFNy alters the 
components of the 26S proteasome by incorporating the subunits LMP2, LMP7 and 
MECL-1 and producing an “immunoproteasome” (Gaczynska et al., 1993). This 
immunoproteasome tends to produce longer peptides and cleaves after hydrophobic and 
basic residues, which are transported more easily by TAP and are more suitable for 
binding to MHC class I. In this way the carboxyl terminus of peptides which bind to 
class I is produced directly by the proteasome. In contrast the proteasome does not seem 
to cut peptides exactly to size at their amino terminus. Since peptide epitopes vary, this 
presumably allows the proteasome to produce a wide range of peptide precursors, while 
it would be much more difficult to produce the exact peptide for class I binding. The 
dominant epitope of wild type ovalbumin presented by Kb is SEINFEKL, and both 
ovalbumin and SIINFEKL are commonly used as model antigens for class I 
presentation. Using a modified ovalbumin molecule, the relative quantities of the 
related peptide epitope SIINFEHL and its amino-extended precursors have been 
analysed (Paz et al., 1999). It was shown that although the peptide that is loaded onto 
class I and presented to T cells is the 8-mer SIINFEHL the levels of this peptide within 
the cell are very low. The 9-mer KSIINFEHL is present at significantly higher levels 
but localises only to the ER and its production is dependant on functional TAP. The 10- 
mer and 11-mer precursors of the peptide on the other hand are found at higher levels 
still and mainly reside in the cytoplasm. These findings suggest that the proteasome 
produces amino-extended versions of the peptide, which are subsequently trimmed at 
their amino terminus to produce peptides for class I binding.
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1.3.3.3 ER Aminopeptidase associated with Antigen Processing
Recent work has shown that the main enzyme involved in peptide trimming is located 
within the ER (Serwold et al., 2002;Saric et al., 2002;York et a l, 2002). This enzyme, 
the ER Aminopeptidase associated with Antigen Processing (ERAAP or ERAP1), was 
isolated from mouse spleen cells by ion exchange chromatography and its activity was 
assayed using leucine /?-nitroanilide (Serwold et al., 2002). The isolated protein had a 
molecular mass of roughly 100 kDa and its aminopeptidase activity was inhibited by 
leucinethiol. By trypsin digestion and mass spectrometry the peptide fingerprint was 
determined and used to search the National Centre for Biotechnology Information 
database of proteins. The matched protein was a murine leucine aminopeptidase. 
Serwold et al. went on to show that this protein was Endo H sensitive, colocalised with 
the ER proteins BiP and gp96, and that the level of protein in different tissue types 
correlated well with MHC class I expression. Not only this but like heavy chain, 
tapasin, TAP and other components of the class I pathway, expression of ERAAP was 
also increased 10-fold in fibroblasts when cultured with IFNy. Concomitant with this 
increase in expression is an increase in aminopeptidase activity (Saric et al., 2002). 
Assays on the activity of ERAAP show that it cleaves peptides of > 10 amino acids at a 
high rate, cleaves 9 amino acid peptides at a reduced rate and has little or no activity for 
peptides of < 8 amino acids (Saric et al., 2002). This range of cleavage specificity ought 
to be ideal for the production of the 8-9 amino acid peptides, which form the majority of 
epitopes presented by class I molecules.
Using RNA interference (RNAi) two groups have recently succeeded in suppressing the 
activity of ERAAP (York et al., 2002;Serwold et al., 2002). This work has confirmed 
that ERAAP is important in producing the peptide repertoire for class I presentation. 
Interestingly, although in some cases suppression of ERAAP correlates with the loss of 
peptide presentation and specific CTL response, certain epitopes appear to be produced 
and presented more efficiently in the absence of ERAAP (Serwold et al., 2002). This 
may reflect the fact that some peptides are produced independently of ERAAP and they 
may face less competition for class I binding when ERAAP is suppressed and 
consequently present better.
York et al. noticed that surface expression of Kb in HeLa cells was actually increased 
when ERAAP was suppressed using RNAi. They also showed by pulse chase 
experiments that the rate of assembly of HLA-A, B and C was increased under RNAi to
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ERAAP. They attributed this to the destruction of peptides by ERAAP that bind to class 
I molecules. In this situation provision of peptide is presumably limiting the rate of 
class I trafficking and hence, loss of any peptides which can bind to class I will decrease 
surface expression. In fact a low level of aminopeptidase activity either from the 
remaining ERAAP or from other aminopeptidases, might be ideal as it will slowly trim 
precursors that require processing without destroying epitopes which already bind to 
class I. Conversely when cells are stimulated with IFNy, although the proteasome seems 
to produce little or no more peptides of the correct length for binding, it does produce 2- 
4 fold higher rates of amino-extended versions of the peptides (Cascio et al., 2001). 
Peptides now cease to be limiting and may frequently require trimming before being 
loaded onto class I. ERAAP will trim peptides that are imported by TAP and produce 
the correct epitopes to bind to class I. Although some epitopes may be destroyed and 
presented at a lower level (Serwold et al., 2002) the overall amount of surface class I is 
now as high or higher than when ERAAP is suppressed (York et al., 2002). Crucially, 
the range of peptides presented may also be increased which is an important factor in 
development of immune response during infection and inflammation, when IFNy is 
high.
Paz et al. (Paz et al., 1999) found that the trimming of the Kb binding peptide precursor 
KSIINFEHL was strongly increased in the presence of Kb, but not with the irrelevant 
Kd. Along with evidence from Saric et al (Saric et al., 2002) that ERAAP is responsible 
for trimming amino-extended versions of the very similar SHNFEKL peptides, we are 
led to the intriguing possibility that ERAAP may cleave peptides which are already in 
association with class I. This suggests that ERAAP may be recruited to the loading 
complex in order to trim peptides with a high affinity for the specific class I alleles 
present in the complex. However, TAP immunoprecipitates do not seem to include 
ERAAP suggesting that any interaction it has with the peptide-loading complex is weak 
and transient (Ackerman et al., 2003).
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1.3.4 MHC class I trimeric complex
As shown from extensive work on class I antigen processing, including the crystal 
structure showing the docking of class I with the TCR (Garcia et al., 1996;Garboczi et 
al., 1996), recognition of antigen by T cells requires a trimeric class I complex of p2m, 
heavy chain and peptide. The folding of this complex occurs in the endoplasmic 
reticulum (ER) and involves three crucial stages: synthesis and folding of the heavy 
chain and p2m, provision of peptides for class I loading, and the loading onto heavy 
chain of peptide with high affinity for the peptide groove1. Only once these processes 
have occurred, can loaded class I molecules be exported to the cell surface for 
surveillance by T cells (Fig. 1.3).
1.3.4.1 Folding of the peptide receptive fcm-HC heterodimer
Shortly after or during synthesis in the ER, heavy chain is bound by the molecular 
chaperone calnexin (cx) (Degen and Williams, 1991;David et al., 1993), which may act 
to stabilise and protect it from degradation (Williams, 1995) or facilitate folding and 
association with p2m. Calnexin is a membrane bound molecular chaperone containing a 
lectin site which recognises monoglucosylated N-oligosaccharides (Hammond et al., 
1994). Human class I molecules contain one N-glycan site whilst mouse class I 
molecules have two or three such sites, and this may explain differences in the observed 
binding of calnexin to developing class I molecules. Thus, in human cells calnexin is 
predominantly found associated with free heavy chain, and upon binding of p2m to 
heavy chain, calnexin is dropped in favour of another similar chaperone calreticulin 
(crt) (Sadasivan et al., 1996). In contrast, in mouse cells the interaction with calnexin 
can persist beyond p2m binding and possibly right up until class I export from the ER 
(Degen and Williams, 1991). Although most heavy chain molecules appear to associate 
with calnexin transiently in human cells and for longer in mouse cells, it is important to 
note that in both human and mouse cells with calnexin deficiency, class I peptide 
loading and cell surface expression are normal (Scott and Dawson, 1995) (Sadasivan et 
al., 1995). This leads to the conclusion that calnexin is dispensable in class I processing, 
possibly owing to some ER chaperone redundancy through calreticulin or BiP. What 
does seem to be clear is that only once the heavy chain has been assembled into a dimer
1 Here and in other places in this thesis, the term ‘high affinity’ refers to the binding 
affinity of the peptide for the binding groove of the MHC class I molecule and is not 
related to the affinity of the interaction between the T cell receptor and the 
MHC/peptide complex.
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with P2111 can it bind to calreticulin (Fig. 1.3B) and progress to the peptide-loading 
complex (PLC) (Farmery et al., 2000).
1.3.4.2 The peptide-loading complex
Interestingly not only is TAP necessary for the provision of peptides to class I 
molecules, but it also immunoprecipitates with both class I heavy chain and p2m 
(Androlewicz et al., 1994). In vitro this interaction is lost upon binding of peptide to 
class I suggesting that the P2m-HC heterodimer is in complex with TAP before it is 
loaded with peptide, but that on peptide binding it is released to traffic to the cell 
surface (Suh et al., 1994). More detailed immunoprecipitation work has shown that at 
least three other proteins are also bound to TAP and class I prior to peptide loading. 
Together these proteins form what is known as the peptide-loading complex (PLC). The 
PLC is centred on the TAP1-TAP2 dimer and contains the p2m-HC class I dimer and 
tapasin (tpn) at a stoichiometry of 1 TAP: 4 tapasin: 4 heavy chain (Ortmann et al., 
1997). As well as this other components including the chaperones calreticulin, calnexin 
(in murine cells) and the protein disulfide isomerase ERp57 (Endoplasmic Reticulum 
protein 57) are also found in the complex (Fig. 1.3C).
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Figure 1.3. Class I antigen presentation pathway.
A) Heavy chain (HC) disulfide bridges form and it associates with fom (B2-m) 
allowing calreticulin (Crt) to bind. B) The class I molecule enters the mature 
complex and binds to peptides provided by TAP (T1 and T2). Tapasin is found 
disulfide bonded to ERp57. C) Once loaded with peptide, class I is released 
from the loading complex and traffics to the cell surface via the Golgi network. 
ERAAP - ER Aminopeptidase associated with Antigen Processing.
Plasma M em brane
Im ported
Protein
Golgi 
A pparatus
Cross Priming
ERp 57
Endosome
ERAAP
Tapasin
m ProteasomeMHC Class I
Peptides
Cytosolic
Protein
Adapted from  - Cellular and Molecular Immunology 1 No.1; Flutter,B. Gao,B. MHC Class I 
Antigen Presentation - Recently Trimmed and Well Presented
Intuitively we would expect that the loading o f peptides onto class I for antigen 
presentation must be a balance o f two main factors. On the one hand, the peptides 
bound to class I should have a high enough binding affinity for the heavy chain alleles 
present, to avoid extensive peptide dissociation from class I at the cell surface. On the 
other hand, the class I molecules o f the cell must be able to bind a large enough number 
o f different peptide sequences, that the cell is able to present antigen from almost any 
cellular protein to passing T cells.
A correlation has been found between the length of time that class I molecules spend in 
the ER and the extent to which they are loaded with peptide implying that this balance 
must be carefully controlled (Lewis et al., 1996). This is probably one of a number of
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functions carried out by the proteins in the PLC, which clearly has a role in the ‘quality 
control’ of class I exported from the ER. The fact that the majority of peptide free p2m- 
heavy chain in the cell is found in the PLC, supports the theory that peptide binding 
almost certainly occurs in the PLC. In contrast, a much smaller proportion of peptide 
bound P2111-HC is found in the PLC, suggesting that free p2m-HC is recruited to the PLC 
and that peptide binding allows release from the PLC (Ortmann et al., 1994).
1.3.4.3 The role of TAP in the PLC
The PLC is centred on TAP, however TAP does not interact directly with heavy chain, 
but associates with it via tapasin. Although the presence of TAP in the PLC is 
topologically convenient (as it allows peptides to enter the ER in close proximity to 
heavy chain) it does not appear to be essential that TAP is present in the PLC for 
peptide loading. TAP mutant cell lines in which TAP does not associate with tapasin, 
still contain a PLC in which tapasin associates with heavy chain. When peptide is 
provided to this TAP-deficient PLC in permeabalised microsomes, class I molecules 
appear to become loaded with peptide and dissociate from tapasin in the normal way 
(Paulsson et al., 2001).
1.3.4.4 Tapasin
By immunoprecipitation of TAPI it has been shown that class I heavy chain forms a 
complex with both TAP, and another molecule tapasin (TAP associated protein) 
(Androlewicz et al., 1994). The gene for tapasin maps to the class II region of the MHC 
close to the genes for TAP (Herberg et al., 1998), and the tapasin mutant cell line 
LCL721.220 (.220) shows significant defects in antigen presentation and the overall cell 
surface expression of class I is reduced (Greenwood et al., 1994). The mutation 
responsible for this defect is a simple base substitution 2 nucleotides from the 5' end of 
intron two of the gene coding for tapasin (Copeman et al., 1998). The GT nucleotide 
sequence, which is invariant in 5' splice sites, has thus been altered to GC, and as a 
result exon 3 splices directly to exon 1, excising exon 2 from the messenger RNA in the 
process. When wild type tapasin is reintroduced in to .220 cells the phenotype is 
rescued, cell surface expression of class I returns and the association between heavy 
chain and TAP is restored (Ortmann et al., 1997). It is apparent from this and other 
work that tapasin is required for interaction between the p2m-HC heterodimer and TAP
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(Sadasivan et al., 1996) (Ortmann et al., 1997) and this highlights the importance of 
tapasin in the formation of the PLC by acting as a bridge between TAP and class I.
Unlike in TAP negative cells, where the loss of cell surface expression arises from a 
lack of peptide translocation into the ER rather than from the absence of TAP in the 
PLC, it is essential that tapasin is both expressed and that it incorporates into the PLC to 
facilitate peptide loading. A mutant HLA-A*0201 class I heavy chain molecule known 
as T134K, in which threonine is replaced by lysine at position 134, is unable to interact 
with tapasin. As a result although T134K forms a heterodimer with in the normal 
way, it is not found in association with tapasin or TAP (Peace-Brewer et al., 1996). 
T134K traffics to the cell surface at an increased rate either in a peptide receptive state 
or with a low affinity peptide bound. Hence, it is unable to present endogenous viral 
epitopes to T cells (Lewis et al., 1996).
Since the discovery of tapasin and the demonstration of its importance in MHC class I 
antigen presentation, our understanding of its role has been complicated by the finding 
that cell surface levels of class I in human tapasin knockout cell lines are somewhat 
allele specific (Peh et al., 1998). Thus, whereas HLA-B*4402 is almost completely lost 
from the cell surface in .220 cells, HLA-B27 alleles seem to be normally expressed at 
the cell surface even in the absence of tapasin. This allelic difference has been 
pinpointed to residue 114 of the class I heavy chain (Park et al., 2003). Alleles with a 
histidine residue at position 114 express in the absence of tapasin, whereas alleles with 
a glutamic acid residue at position 114 are dependant on tapasin. Because of this, HLA- 
B27 and a number of other alleles, which still express at the cell surface in tapasin 
deficient cell lines, are often referred to as ‘tapasin independent’ alleles. However, it is 
interesting to note that even the HLA-B27 is found in the loading complex in normal 
tapasin proficient cells and hence, although it does not require tapasin association per se 
for cell surface expression, tapasin is still involved in its normal trafficking and may 
still play some role, for instance in the loading of certain peptide epitopes.
There are two main reasons postulated for the loss of surface class I in the absence of 
tapasin. One possibility is that class I cannot become properly loaded with peptide in 
the absence of tapasin and as a result does not traffic to the cell surface, but is degraded 
in the ER. This is supported by the finding that in .220 (tapasin deficient) cells, p2m-HC 
heterodimers are retained for longer in the ER before trafficking or degradation (Tan et
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al., 2002). Alternatively, it may be that class I heterodimers leave the ER as normal but 
that in the absence of tapasin, instead of loading with high affinity peptides, many of the 
class I molecules leave the ER loaded with low affinity peptides which dissociate easily 
either during trafficking or at the cell surface. When class I molecules become 
unloaded, heavy chain quickly dissociates from p2m and the empty heavy chain 
molecules are internalised and marked for degradation: this would account for the low 
surface levels of class I. This latter situation appears to be the case in murine 
experiments where as expected, overall class I expression is low in tapasin knockout 
cells, but trafficking of Kb and Db molecules measured by acquisition of endo H 
resistance is similar in spleen cells from tapasin /' and tapasinV mice (Grandea, III et 
al., 2000;Garbi et al., 2000). It is likely that both mechanisms play a part in the low cell 
surface expression of class I in the tapasin mutant and the effect may vary from one 
class I allele to another.
An artificial soluble tapasin without transmembrane and cytoplasmic domains has also 
been used to rescue the deficiency of the .220 cell line. Although there is no association 
between TAP and class I in the rescued cells, cell surface levels of class I are restored 
(Lehner et al., 1998) supporting evidence from TAP mutant cells showing that TAP is 
not a necessary component of the PLC. However, Gao et al. have shown that although a 
similar, truncated form of tapasin restores normal class I surface expression on .220 
cells, the peptides loaded on the surface of rescued cells are suboptimal. This indicates 
that the transmembrane and cytoplasmic fragments of tapasin involved in its association 
with TAP, are required for the full function of tapasin (Gao et al., 2004).
Interestingly a recent study comparing the peptide profile of HLA-B8 in tapasin 
proficient and tapasin deficient cell lines has found that contrary to expectation, the 
binding affinity of class I in the absence of tapasin is as high as or higher than in the 
presence of tapasin. The implication of this is that tapasin acts to facilitate the binding 
of a wider range of peptides, rather than acting to ensure the binding of only high 
affinity peptides. This gives rise to the view that rather than being a peptide editor for 
class I tapasin is a facilitator of peptide loading (Zarling et al., 2003).
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1 .3 .4 .5  E R p 5 7
ERp57 is a member of the Protein Disulfide Isomerase (PDI) family with a MW of 
57kDa, whose functions include disulfide bond isomerisation, reduction and oxidation 
(Gilbert, 1997;High et al., 2000;Ellgaard and Helenius, 2001). The catalytic activity of 
this family of proteins is dependent on the cysteine residues in 2 CXXC motifs (Hirano 
et al., 1995;Urade et al., 1997). ERp57 forms complexes with either calnexin or 
calreticulin, and together they ensure the correct folding and disulphide bond formation 
of monoglucosylated polypeptides in the ER (Oliver et al., 1999;Tan et al., 1997). It is 
not surprising then, that ERp57 is found with class I heavy chain in the early complex 
where calnexin is present, and also in the peptide-loading complex with TAP, class I, 
tapasin and calreticulin (Hughes and Cresswell, 1998;Lindquist et al., 1998;Morrice and 
Powis, 1998). There are two disulphide bonds within the folded heavy chain molecule 
one of which is found inside the peptide groove of class I. ERp57 is a likely candidate 
for the correct formation of these bonds, and there is now evidence that the presence of 
ERp57 within the complex may be crucial to correct peptide loading. It has been shown 
that ERp57 can specifically reduce partially folded peptide receptive MHC class I 
molecules while showing little or no activity for peptide loaded class I molecules 
(Antoniou et al., 2002). It is possible then that ERp57 may be important in the unfolding 
of MHC class I molecules, by reduction of heavy chain disulfide bonds when they 
remain in a peptide receptive state for a prolonged period, for example when peptide 
supply is poor. More interestingly, it was shown recently that ERp57 forms an 
intermediate in which tapasin is disulfide bonded to ERp57 (Dick et al., 2002).
Mutation of cysteine residue 95 of tapasin to alanine, abolishes formation of this 
disulfide bond intermediate and also seems to prevent complete oxidation of class I. As 
a result the C95A tapasin mutant is only able partially to restore class I expression in 
.220 (tapasin deficient) cells compared with a full recovery when normal tapasin is 
transfected into these cells (Dick et al., 2002). The implication of this is that formation 
of this last disulfide bond of class I in the loading complex may require both ERp57 and 
tapasin, and that this step is somehow crucial in the quality control process of peptide 
loading onto class I. In 2006 work was published in which ERp57 knockout cells were 
studied, and this will be discussed further in chapters 3 and 7 (Garbi et al., 2006).
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1 .3 .4 .6  C a lr e t ic u l in
The ER chaperone calreticulin has two well characterised basic functions. Firstly, it has 
a vital function in intracellular calcium homeostasis and as a result, deletion of 
calreticulin causes a lethal impairment of cardiac development during embryogenesis 
(Mesaeli et al., 1999). Secondly, it is an important ER chaperone in the folding of newly 
synthesised glycoproteins such as class I molecules. It has been established by 
immunoprecipitation that calreticulin is present in the PLC and that this interaction 
relies on the presence of TAP and tapasin (Sadasivan et al., 1996;Lewis et al., 
1998;Hughes and Cresswell, 1998). However, the role of calreticulin in class I antigen 
processing is much less well characterised than that of tapasin or TAP.
The calreticulin deficient mouse fibroblast cell line K42 has allowed some assessment 
of the role of calreticulin in the PLC. Although loss of calreticulin does not appear to be 
as severe in antigen processing as a loss of tapasin, K42 cells show a 50-80% loss in 
cell surface expression of class I as compared with wild-type K41 cells. When either 
exogenous peptide or P2in is added to K42 cells, surface expression is increased 4.5 fold 
compared to just 1.2 fold in K41 cells (Gao et al., 2002). This suggests that loss of class 
I surface expression in K42 cells is due to loss of unstable class I molecules at the 
surface, which can be rescued by high affinity peptides or by an excess of p2m. Pulse 
chase analysis shows that in the absence of calreticulin, heavy chain traffics to the cell 
surface at an increased rate (Gao et al., 2002) rather like the mutant HLA-A*0201 allele 
T134K (Lewis et al., 1996). This increased rate of trafficking could result in poor 
peptide loading within the ER. There is further evidence that peptide loading within the 
ER is defective in K42 cells; conformation dependant antibodies show that a much 
greater proportion of class I molecules in the ER remains in the peptide receptive state 
in K42 than in K41 cells. Not only this, but impaired T cell recognition was observed 
for 3 out of 4 peptide epitopes presented by K42 cells. However, heavy chain is still 
found in association with TAP, tapasin and ERp57 in the loading complex of K42 cells, 
indicating that the PLC can still form in the absence of calreticulin (Gao et al., 2002). 
The exact role of calreticulin therefore remains unclear, but it may be that the presence 
of calreticulin in the loading complex stabilises interactions between the other 
molecules and consequently, that heavy chain is retained for longer allowing better 
optimisation of peptide binding. One other attractive possibility is that calreticulin 
chaperones peptides from TAP to the peptide groove of class I. Cross linking 
experiments have shown that calreticulin can bind to peptides delivered to the ER via
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TAP (Spee and Neefjes, 1997). It is known that peptides are found bound to chaperones 
such as heat shock proteins in the cytosol, (Paz et al., 1999;Udono and Srivastava,
1993) and it is possible that calreticulin could fulfil a similar role within the ER.
1.3.5 Export of class I to the cell surface.
It has been convincingly shown that premature export of class I from the ER to the cell 
surface results in poor surface expression and reduced antigen presentation to cytotoxic 
T lymphocytes (Lewis et al., 1996;Gao et al., 2002). However, the mechanism for the 
export of class I from the ER is not entirely clear.
The Bulk Flow model of ER export postulates that ER resident proteins are maintained 
in the ER by means of retention and retrieval signals. Other proteins, which do not have 
such signal sequences, traffic from the ER by default to the Golgi (Wieland et al.,
1987). Under this model, class I would be retained in the ER whilst it was in contact 
with the peptide-loading complex (PLC), because of the presence ER retention signals 
carried by chaperone molecules. Conversely, class I molecules that were not bound by 
chaperone molecules would exit the ER. Consequently the rate of export would depend 
on the rate of release of class I from the PLC. This would explain the poor loading of 
class I molecules that bind poorly to the PLC such as T134K mutants and in tapasin 
deficient cell lines.
However, several studies show that an increase in the rate of release of peptide loaded 
class I from the PLC, induced by provision of an excess of high affinity peptide, has no 
effect on ER to Golgi transport (Suh et al., 1996;Marguet et al., 1999;Spiliotis et al., 
2000). Furthermore, it has also been shown that peptide loaded class I molecules 
accumulate at ER exit sites, and that they associate with a putative cargo molecule 
BAP31 (Spiliotis et al., 2000). These findings point towards a selective model of class I 
export involving recruitment of peptide loaded class I into COPII vesicles, which 
transport them out of the ER and to the Golgi network. In this situation the export is 
limited by the rate of incorporation of class I molecules into COPII vesicles and not on 
release of class I from the PLC. In this model it is still important that the PLC retain 
poorly loaded class I, since although the overall rate of export of loaded class I does not 
rise concomitantly with release of class I from the PLC, the ratio of poorly loaded to 
well loaded class I molecules will increase if the PLC does not retain class I molecules
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until they are loaded with high affinity peptide. As a result the proportion of stable class 
I being released from the ER will fall, and surface expression of class I and antigen 
presentation will be reduced.
Paulsson et al. (Paulsson et al., 2002) propose a further level of export control where 
poorly loaded class I can be returned to the ER from the Golgi. In their work they show 
that tapasin is present in the Golgi body and that it is able to associate with both the p 
and y chains of the coatamer COPI. The COPI coatamer mediates retrograde Golgi to 
ER transport (Harter and Reinhard, 2000) and could therefore provide a mechanism for 
class I molecules which have lost their peptide during ER to Golgi transport to be 
returned to the ER, where they can be reloaded with peptide. They argue that the build 
up of class I molecules in the ER in TAP mutant cells is not due to lack of export of 
class I from the ER to the Golgi, but results from the return of unloaded class I 
molecules from the Golgi to the ER. This hypothesis is supported by the observation 
that levels of class I in the Golgi body of TAP negative are similar to those in wild type 
cells (Baas et al., 1992).
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1.4 Outstanding questions and approaches for studying MHC 
class I antigen processing
Much is now known about the mechanisms of peptide loading and MHC class I 
trafficking to the cell surface. However, there remain a number of interesting 
outstanding issues to address:
The association of calnexin with heavy chain does not seem persist after the binding 
P2111 in human cells (Sadasivan et al., 1996). However, there is no formal proof of the 
trigger for the release of calnexin. It is possible either that binding of p2m to heavy 
chain destroys the interaction between heavy chain and calnexin, or that once heavy 
chain is bound to P2111 the interaction with calreticulin dominates and so calnexin is lost. 
At an early stage in the assembly of class I molecules, heavy chain associates with p2m. 
Since the recruitment of p2m to class I heavy chain occurs at the same time as 
association with calreticulin (Sadasivan et al., 1996), it is possible that calreticulin is 
required for the efficient formation of the P2in-HC heterodimer. Alternatively, the 
pairing of p2m and heavy chain may happen automatically or other molecular 
chaperones may facilitate the process.
Once formed, the class I p2m-HC heterodimer traffics to the peptide-loading complex, 
where it picks up its peptide cargo. Although many of the components of the peptide- 
loading complex have now been characterised, the functions of chaperones such as 
calreticulin, ERp57 and tapasin in peptide loading remain unclear. Possible roles for 
these proteins include: the maintenance of the folded P2m-HC class I heterodimer, 
disulfide bond isomerisation within the peptide groove of class I molecules, peptide 
editing, and controlling the release of loaded class I molecules from the peptide-loading 
complex. Finally, at the time this work began, little was known about the importance or 
function of ERp57 in MHC class I antigen presentation.
In chapter 3 attempts are made to suppress the expression of the chaperone ERp57 in a 
mouse cell line using RNA interference. The presence of ERp57 in the peptide-loading 
complex and its covalent interaction with tapasin imply that it may be important in class 
I antigen processing, but its function still remains unknown. Additionally it is known to 
be present in the ‘early complex’ and may play a role in the degradation of class I 
molecules that fail to load with peptide. By suppressing ERp57 it would be possible to 
assess its importance in class I peptide loading and its effect on the interactions between 
other proteins involved in class I assembly.
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In chapters 4-6 MHC class I fusion constructs are used to investigate the roles of 
chaperone molecules in the folding of heavy chain, p2m and peptide. Fusion proteins 
were made by joining together different components of the trimeric class I complex 
with flexible linker sequences as follows:
P2111: (human) ‘P2m \
PB: ‘peptide - linker 1 - p2m \
BA: ‘p2m - linker 2 - HLA-A*0201’.
BB: ‘p2m - linker 2 - HLA-B*4402\
PBA: ‘peptide - linker 1 - p2m - linker 2 - HLA-A*0201\
Where ‘linker 1’ codes for GGGGGGSGGSGGSGG, ‘linker T  codes for 
GGGGSGGGGSGGGGS and ‘peptide’ codes for the HLA-A2 binding peptide 
GILGFVTTL derived from influenza virus matrix protein (Fig. 1.4). The BA construct 
was provided by Prof. W Bodmer (Oxford University, UK). Dr. Bin Gao created and 
expressed the fusion constructs PB, BA and PBA in HCT cells and created the BB 
construct from BA by replacing HLA-A2 with HLA-B*4402 (HLA-B*4402 was kindly 
provided by Dr. C Peh. Oxford University, UK).
These fusion proteins may be thought of as partially assembled class I molecules and as 
such can be used to investigate the folding of wild type class I molecules:
Fusion proteins in which P2in is linked to heavy chain such as p2in-A2 and p2m-B44 
will be used to investigate the interaction of human class I heavy with calnexin, and the 
function of chaperone molecules in the recruitment of p2m. If the main function of 
calreticulin in class I antigen processing is the formation of the P2m-HC heterodimer, 
then expression of p2m-A2  or P2H1-B44 ought to be as strong in calreticulin deficient 
cells as it is in wild type cells. Conversely, the chaperone tapasin is thought to have a 
key role in peptide binding and so linkage of p2m to heavy chain is unlikely to rescue 
the expression of class I in a tapasin deficient cell line such as .220.
The fusion protein PB (in which p2m is linked to antigenic peptide) can be used 
similarly to investigate the process of peptide loading. Once PB is paired with HLA-A2 
heavy chain, all 3 components of the fully folded class molecule have been brought 
together. If the binding of peptide to class I triggers release from the peptide-loading 
complex then the PB construct would not be expected to traffic the peptide-loading 
complex.
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The fusion protein PBA takes this concept one stage further, since it already contains all 
three components of a fully assembled class I molecule. As a result it may have no 
requirement for chaperones.
48
Figure 1.4. Schematic representations of MHC class I fusion proteins.
a) Schematic representation of the genomic structure of class I fusion proteins. 
Leader -  ER leader sequence, pCMV -  promoter for transcription from 
cytomegalovirus, pA -  polyadenylation signal, b) Schematic representation of 
the protein structure of class I fusion proteins, i) Native class I trimer, ii) peptide 
linked p2m (PB), Hi) (32m-HC fusion proteins, iv) Single chain class I trimer PBA. 
p2m -  brown, heavy chain -  green, antigenic peptide -  blue, linker sequences -  
black.
a)
p2m
PB
BA
BB
pCM V Leader PA
d CMV
-PCMV Leader L2
L1 -  Linker 1 
L 2 -  Linker 2
Leader L1 pA
pA
pCMV Leader
PBA[ pCMV Leader L1 L2 PA
b)
0
P2m
Hi)
H) iv)
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The human colon carcinoma cell line HCT is p2m deficient and as a result expresses no 
cell surface class I (Dexter et al., 1979). In chapter 4, and the class I fusion 
constructs PB, BA and PBA are expressed in HCT cells. The aim of this is to 
demonstrate that class I fusion constructs can rescue the phenotype of HCT cells in 
terms of: expression of cell surface class I and class I antigen presentation to T cells. If 
the fusion constructs can rescue class I expression in HCT cells then it can be assumed 
that they fold into a structure similar to wild type class I molecules. It is then reasonable 
to test the properties of fusion proteins as partially assembled class I molecules.
BB (p2m-B44), PB (peptide linked - p2m) and p2m are also cloned into a lentivirus 
construct. High titre virus is produced and tested which allows the constructs to be 
expressed easily in a variety of cell lines. In order to investigate the role of calreticulin 
in P2m recruitment, the p2in-B44 construct is introduced into murine cell line K41 and 
its calreticulin deficient counterpart K42 (Mesaeli et al., 1999). Stable cell lines are 
generated by drug selection and expression of p2m-B44 is verified in stable cell lines by 
western blot.
In chapter 5 the pathway of antigen presentation is examined in HCT cells expressing 
fusion constructs using immunoprecipitation and other techniques. The objective of the 
work carried out in this chapter is to investigate the involvement of different chaperone 
molecules in the different steps of class I antigen processing. The rate of trafficking of 
the ‘partially assembled’ assembled fusion proteins PB, BA and PBA is compared with 
wild type class I to determine whether their processing is accelerated.
The interaction of BA with calnexin is studied in order to investigate the trigger for 
release of class I molecules from the ‘early complex’.
The mechanism of release of class I molecules from the peptide-loading complex is also 
investigated. The interactions of chaperone molecules with the PB construct, is tested to 
determine whether binding of peptide to HLA-A2 disrupts its interaction with tapasin 
and TAP. Similarly, the provision of high affinity peptide is tested for its ability to 
release the BA construct or wild type p2m from the peptide-loading complex.
In chapter 6 a detailed study is made of the expression of class I in K41 and K42 
(calreticulin deficient) murine cells expressing the human class I fusion protein p2m- 
B44. p2m-A2 is also expressed in these cells and compared to the expression of p2m- 
B44. The aim of expressing these constructs is primarily to assess the importance of 
calreticulin in the recruitment of p2m to class I heavy chain. But an assessment is also
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made of the expression of these fusion proteins and of the compatibility of murine cells 
for the expression of human class I molecules.
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2 General Methods
2.1 Cell Culture
2.1.1 Medium
Unless otherwise stated all cell culture growth medium was supplemented with 
Penicillin/Streptomycin lOOUml'1/ lOOpgml'1 (Life Technologies) and 10% Heat 
inactivated Foetal Calf Serum (FCS) (Insight Biotechnology, lot no. A01120-650).
2.1.2 Growth conditions
Unless otherwise stated all cells were grown at 37°C, 5%CC>2 in a humidified incubator 
(Jencons-PLS). Cells were cultured in sterile tissue culture flasks and plates were 
purchased from Coming.
2.1.3 Mycoplasma testing
All cell lines used were tested for Mycoplasma using either a fluorescence test and an 
agar culture test by Cancer Research UK, Clare Hall Laboratories (South Minims, UK), 
or in house using a mycoplasma enzyme detection assay (MycoAlert). Cells were 
grown in the absence of antibiotics for 7 days before testing. Lines which were found to 
be positive for Mycoplasma were replaced by clean lines from Clare Hall laboratories 
or the ATCC where possible, or treated in house.
2.1.4 Mycoplasma treatment
Cell lines requiring mycoplasma treatment (HCT, K41 and K42) were cultured in the 
presence of 0.5|iig/nil Mycoplasma Removal Agent (ICN) for 14 days or with BM- 
cyclin (Roche Diagnostics). Cells were then cultured for a further 28 days before 
retesting for mycoplasma.
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Table 2.1. Cell lines
Cell Line Description Known class 
I related 
deficiency
Medium Reference
HEK 293 Human Embryonic 
Kidney
None D-MEM (Graham et al., 
1977)
HEK
293FT
Human Embryonic 
Kidney
None D-MEM Invitrogen -  
derivative of 
HEK 293
NIH 3T3 Mouse embryonic 
fibroblast
None D-MEM (Jainchill et al., 
1969)
K41 Mouse fibroblast None RPMI 1640 (Mesaeli et al., 
1999)
K42 Mouse fibroblast Calreticulin
deficient
RPMI 1640 (Mesaeli et al., 
1999)
HCT
NK92
Human colon 
carcinoma 
Human Natural 
Killer-like cell line
p2in deficient RPMI 1640 (Dexter et al., 
1979)
(Gong et al., 
1994)
CEM.NKR
(NKR)
Human T cell Calnexin
deficient
RPMI 1640 (Howell et al., 
1985)
K562 Human
undifferentiated 
hematopoietic cell 
line
None RPMI 1640 (Lozzio and 
Lozzio, 1975)
C T L flu Human T cell clone. None T-media
(see
methods)
N/A. Obtained 
from Xiaoning 
Xu (Oxford, 
UK)
LCL
721.174
(.174)
Human B cell TAP deficient 
and class II 
deficient
RPMI 1640 (Salter et al., 
1985)
LCL
721.220
(.220)
Human B cell Tapasin
deficient
RPMI 1640 (Greenwood et 
al., 1994)
Daudi Human B cell P2111 deficient RPMI 1640 (Klein et al., 
1968)
BM9 Human B cell RPMI 1640 European 
Collection of 
Cell Cultures.
TK143 Human osteosarcoma RPMI 1640 (Rhim et al., 
1975)
D-MEM (Dulbecco’s Modified Eagles Medium) including Glutamax I, 4,500 mg/L D- 
glucose and 1 lOmg/L sodium pyruvate (Gibco BRL) and RPMI 1640 including L- 
Glutamine (Gibco BRL) were supplemented with FCS and penicillin/streptomycin as 
indicated in Section 2.1.1.
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2.1.5 Splitting adherent cell lines
Adherent cell lines were generally grown to around 90% confluence and then split by a 
factor of 2-10. In order to split cells, old medium was removed from the cells and the 
flask was gently washed twice with PBS (Gibco BRL). Trypsin/EDTA was added to 
cover the cells and incubated until the cells had lifted from the flask. An equal volume 
of medium containing FCS was added to quench the trypsin and the cells were 
centrifuged at 300g for 5 minutes, diluted and resuspended in an appropriate volume of 
fresh prewarmed medium and returned to culture flasks.
2.1.6 Splitting non-adherent cell lines
Non-adherent cell lines were split when necessary as determined by the colour of the 
medium and the density of cells. Typically cells were divided when they reached a 
concentration of around 106 cells/ml. 3-5 volumes of fresh medium was added to the 
medium containing cells. The diluted medium was then transferred to fresh culture 
flasks (Coming Life Sciences) of an appropriate size. Every 7-8 days or every third 
split, whichever was sooner; the cells were centrifuged at 300g and resuspended in fresh 
medium.
2.1.7 Counting viable cells
Cells were counted by adding a lOpl sample of cell suspension to lOpl of trypan blue 
0.4% (Sigma). lOpl of this was then added to a counting chamber (Neubauer) and cells 
were counted under the microscope. The viable (unstained) cells in the 25 square field 
(0.1 pi) were counted and the total multiplied by 20,000 to give the cell density in the 
original suspension in cells/ml. If counts were outside the range of 50-100 then the 
concentration of the cells suspension was adjusted and the count repeated to ensure 
accuracy.
2.1.8 Long term storage of cell lines
For long term storage, cell lines were preserved under cryogenic conditions in liquid 
nitrogen. Cells were counted, centrifuged and then resuspended at 107 cells/ml in FCS 
supplemented with 10%v/v Dimethyl Sulphoxide (Sigma). Cells were then divided into 
cryovials (Nunc) in 1ml aliquots and put into a freezing pot (Nunc) using isopropanol as
coolant. When placed in a -80°C freezer, the freezing vessel enables cells to cool at a 
rate of 1°C per minute. After 12-24 hours the cryovials were transferred to liquid 
nitrogen.
2.1.9 Thawing of frozen cells
Cryovials were removed from liquid nitrogen and warmed quickly in a 37°C water bath. 
Once thawed the cell suspension was added dropwise to 2ml of prewarmed 37°C FCS 
in a universal tube. The tube was topped up with medium and centrifuged at 300g for 6 
minutes. Cells were resuspended in medium at 0.5 x 106 cells/ml and incubated 
overnight. The following day medium was replaced or cells split if  necessary.
2.1.10 Cell Transfection
Cells were transfected using Lipofectamine 2000 (Life Technologies). Cells were 
seeded into 24-well plates 24 hours before transfection. Typically, on day of 
transfection, lpl of lipofectamine was added to 50pl of Optimem 1 medium (Gibco- 
BRL) and incubated at room temperature for 5 minutes. 1 fig of plasmid DNA or 2(il of 
T7 synthesised dsRNA (see section 3.2.3) was added to 50pl of Optimem 1. The 
Nucleic acid solution and the lipofectamine solution were mixed and incubated at room 
temperature for 20 minutes. Medium was removed from the cells, and cells were 
washed once in Dulbecco’s PBS (Gibco BRL). Cells were then given 0.8ml of fresh 
Optimem 1 medium (with 10% FCS but without P/S). After incubation the 
lipofectamine nucleic acid mix (lOOpl) was added to the cells. Cells were incubated for 
5 hours or overnight and the transfection medium was removed and replaced with 
normal growth medium.
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2.2 Fluorescence Activated Cell Sorting (FACS)
2.2.1 FACS facility
FACS was carried out on a Becton Dickinson FACScan running CellQuest™ or Cell 
Quest Pro™ software. Cells were gated according to size as measured by forward 
scatter, and by light scattering properties as measured by side scatter. Typically 20,000 
-  50,000 events were collected for each condition. FACS files were analysed either in 
Cell Quest™ or WinMDI.
2.2.2 Solutions
PBS: 1 PBS tablet (Oxoid) in 100ml ddH20 .
FACS buffer: PBS, 1% FCS, 0.1% Sodium Azide (Sigma).
PERM buffer: FACS buffer, 0.1% saponin (Sigma)
PFA: 4g paraformaldehyde (Sigma) was dissolved (by heating in a fume hood to 65°C 
for 45 minutes) in 100ml PBS, allowed to cool and frozen in 2.5ml aliquots.
FIX buffer: FACS buffer, 1% formaldehyde (Sigma)
2.2.3 Preparation for Cell Staining
Cells were re-suspended to a concentration of 106 cells/ml in cold FACS buffer and 
lOOpl aliquots were added to wells in a round bottomed 96-well plate (Merck). The 
plate was centrifuged at 300g for 5 minutes, the supernatant flicked off gently and the 
plate vortexed to loosen the cells.
2.2.4 Staining for cell surface markers
Cells were resuspended in 25-50pl of FACS buffer containing the appropriate 
antibodies at their optimal dilution (determined by antibody titration see table 2 .1). 
Cells were incubated with antibody in the dark at 4°C for 30-60mins. Cells were then 
centrifuged at 300g for five minutes and the supernatant was discarded. The cells were 
then washed 2 times in FACS buffer by vortex, resuspension and centrifugation. Where 
necessary the cells were then resuspended in 25-50pl of FACS buffer containing
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secondary antibody and incubated as above and then washed twice in FACS buffer. 
Cells were washed one final time in FACS buffer, resuspended in lOOpl of FIX buffer 
and transferred to LP2 tubes (Al Lab Supplies).
2.2.5 Staining for intracellular proteins
Prepared cells were resuspended inlOOpl of chilled PFA and incubated at room 
temperature for 10 minutes. Cells were washed twice in PBS and then once in PERM 
buffer. Antibody staining was carried out as in section 2.2.4 except antibodies were 
diluted in PERM buffer. After the final wash cells were resuspended in lOOpl of FACS 
buffer and transferred to LP2 tubes.
Table 2.2. Antibodies for FACS
Antibody Target Cone.,
Dilution
Source;
type
Conjugation Reference /
Obtained
from.
W6.32 Human MHC 5-10p,g/ml Mouse; None (Parham et
class I with (32m (sup’n), 1/2 mAb al., 1979)
BBM1 Human P2111 5-10p,g/ml 
(sup’n), 1/2
Mouse;
mAb
None (Brodsky et 
al., 1979)
DAKOp Human p2m EC staining Rabbit; None DAKO
ahp2m 1/20 0 .
IC staining 
1/ 1,000 .
pAb
BB7.2 HLA-A2 0.5mg/ml,
1/200
Mouse;
mAb
None (Parham and
Brodsky,
1981)
ERp57 Mouse ERp57 Unknown,
1/100
Rabbit;
pAb
None Dr. B. Gao 
(UCL, UK)
a-mouse Mouse IgG Unknown, Sheep; PE Sigma
PE 1/200 pAb
a-mouse Mouse IgG 1.1 mg/ml, Sheep; FITC Sigma
FITC 1/400 pAb
a-rabbit Rabbit IgG 200pg/ml, Goat; PE Caltag
PE 1/50 pAb
N.B. Concentration of hybridoma supernatants (sup’n) was not tested but is normally in 
the range 5-10pg/ml.
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2.3 SDS PAGE and Western Blotting
2x SDS loading buffer: (Tris-Cl pH 6 .8 , 4% w/v SDS (Sodium Dodecyl Sulphate), 
0.2% w/v bromophenol blue (Sigma) and 20 % v/v glycerol)
5x SDS loading buffer -  10% SDS with other reagents as for 2xSDS loading buffer.
Lysis buffer: 1% Triton X-100 in PBS
1% digitonin lysis buffer: digitonin (Calbiochem) was dissolved in water at 5% w/v by 
boiling for fifteen minutes. Solution was stored at 4°C overnight and then filtered 
through 0.22pm PVDF filter (Millipore). Before use, solution was adjusted to 1% w/v 
in PBS and lOpl/ml of protease inhibitor cocktail (Sigma) was added.
Run buffer: 0.025M tris, 0.192M glycine, 0.1% SDS
Transfer buffer: 0.02M tris, 0.15M glycine, 20% methanol
PBST: PBS, 0.05% tween (Sigma)
Enhanced chemiluminescence (ECL) fluid (Pierce): 1ml super signal dura west luminal 
enhancer solution, 1ml stable peroxide buffer.
2.3.1 SDS Poly Acrylamide Gel Electophoresis (SDS-PAGE)
106 cells were centrifuged at 300g for 5 minutes, the supernatant discarded and the 
pellets were used immediately or frozen at -20°C for up to 2 weeks. Cells were 
resuspended in lysis buffer to a final concentration of 107 - 108 cells/ml and incubated 
on ice for 10 minutes. Cells were centrifuged at 13,000 rpm for 15 minutes at 4°C in a 
micro centrifuge (Eppendorf centrifuge 5415R) and the supernatant was added to an 
equal volume of 2x SDS loading buffer and heated to 94°C for 5 minutes. lOpl samples 
were added to the wells of 10-14% SDS protein separating gels made using Flowgen 
Protogel (Flowgen) and were run in an X-cell SureLock mini Cell System (Invitrogen) 
according to the manufacturer’s instructions, for 1 hour at 200V or until samples had 
separated sufficiently. High Molecular Weight Rainbow Marker (Amersham) was run 
alongside the samples to allow analysis of the size of the detected protein.
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2.3.2 Western Blotting
Following SDS PAGE the gel was blotted on to Hybond C Extra membrane 
(Amersham) using the X-cell SureLock mini Blot module (Invitrogen) at 20V for 2 
hours. The membrane was carefully removed and blocked in 10 ml of PBS 5% Marvel 
(Premier International Foods) on a plate rocker (Stuart Gyro Rocker STR-9). The 
membrane was washed 3 times in PBS and transferred to 10 ml of PBST 5% Marvel 
containing the primary antibody. After 1 hour of rocking in primary antibody the 
membrane was washed 3 times in PBS for 1 minute and transferred to PBST 5% Marvel 
containing the secondary HRP conjugated antibody and rocked for 1 hour. The 
membrane was washed twice in PBST and twice in PBS. The membrane was dabbed 
dry with a paper towel and 2ml of enhanced chemiluminescence fluid was added evenly 
to the membrane. After 5 minutes the fluid was pipetted off and the membrane dabbed 
dry. The membrane was then wrapped in cling film and attached to one side of an 
exposure box with tape. Photographic film (Kodak Biomax) was exposed to the 
membrane for 10 seconds to half an hour. Film was developed by immersing in X- 
OMAT Developer for 30-60 seconds washing in water and fixing with X-OMAT fixing 
solution for 1 minute.
2.3.3 Immunoprecipitation
lx l0 7 cells were counted and washed twice in chilled PBS (4°C). Cells were lysed by 
suspending in 1% digitonin lysis buffer and incubating on ice for 20 mins. Samples 
were centrifuged at 16,000g for 10 minutes and the supernatant was then added to the 
appropriate antibody. A small sample of lysate was kept for western blot. Samples were 
incubated for 1 hour with gentle mixing at 4°C after which, 40pl of protein G Agarose 
(Pierce) was added and the incubation was repeated. The formed protein G 
immunocomplexes were then washed 5 times in cold 0.1% digitonin. (Centrifugation 
was carried out at low speed 4,000g for 90 seconds to maintain the integrity of the 
protein G slurry.) Proteins were then eluted by adding 40pl of 5xSDS loading buffer, 
mixing thoroughly and heating to 94°C for 5 minutes. Samples were then centrifuged 
and used for SDS-PAGE and western blot immediately or stored for up to one week at - 
20°C.
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Table 2.3. Antibodies for Western Blot and Immunoprecipitation
Antibody Target Source, 
conc. if 
known
Dilution 
for WB; 
volume for 
IP.
Species;
Type
Conj. Reference /
Obtained
from.
BBM.l H fcm Hybridoma
supernatant
1/2; N/A M; mAb None (Brodsky et 
al., 1979)
BBM.l H f^m Purified.
4mg/ml
N/A. IP 
25pl
M; mAb None (Brodsky et 
al., 1979)
HC10 H class I
heavy
chain
Hybridoma
supernatant
1/2; N/A M; mAb None (Stam et al., 
1986)
DAKOp
ahP2m
H fcm Purified 1/ 1,000 ;
N/A
R; pAb None DAKO
ERp57 Rat ERp57 Serum 1/2 ,0 00 ;
N/A
R; pAb None Dr. B. Gao
CX R calnexin Serum 1/2 ,000 ; 
IP 40pl
R; pAb None Dr. B. Gao
CRT R
calreticulin
Serum 1/2 ,000 ;
N/A
R; pAb None Dr. B. Gao
RB4 H TAP Serum N/A. IP 
lOpl
R; pAb None Dr. P. Wang
Tap A H tapasin Serum N/A. IP 
20pl
R; pAb None Dr. P. Wang
Rabbit
Serum
None Serum N/A. IP 
2 0 pl
R; pAb None Dr. B. Gao
am -  
HRP
M IgG Serum 1/ 10,0 00 ;
N/A
G; pAb HRP Sigma
RG96-
HRP
RIgG Purified 1/5,000;
N/A
M; mAb HRP Sigma
H - Human, G - Goat, R - Rabbit, M - mouse, HRP - Horse Radish Peroxidase, 
mAb - monoclonal antibody, pAb -  polyclonal antibody, IP -  
Immunoprecipitation, Conj. -  conjugation. Where indicated antibodies were 
kindly provided by Dr. B. Gao (University College London, UK) or Dr. P. Wang 
(The Royal London School of Medicine and Dentistry, UK).
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2.4 Molecular cloning
2.4.1 DNA extraction and purification
Plasmid DNA was extracted from E. coli strains DH5a and TOP 10™ (Invitrogen) using 
mini/maxiprep kits (Qiagen) according to the manufacturers instructions.
DNA fragments were purified from restriction endonucleases and other molecular 
biology reagents using a PCR purification kit (Qiagen).
DNA fragments were purified from agarose gels using Qiaquick Gel Purification kit 
(Qiagen)
DNA/RNA concentration and purity were assessed by measuring the light absorption at 
260 and 280 nm using a spectrophotometer (Hitachi U1800). Concentration is 
calculated using the formulae:
DNA concentration = A26o x 50pg/ml 
RNA concentration = A26o x 40pg/ml 
Purity is assessed by calculating A26o: A28o- For DNA in low salt buffer pH 7.5 - 8 this 
ratio should be about 1.8 . For RNA the ratio at neutral pH should be between 1.9 and 
2.3.
2.4.2 DNA modifying enzymes
The following DNA modifying enzymes were used according to manufacturer’s 
instructions.
Restriction endonucleases (Promega): Typically l-2pg DNA was incubated for 1 hour 
with 1-2 units of enzyme, 5 pi lOx reaction buffer, 0.5pl BSA and sterile water to a total 
of 50pl.
T4 DNA Ligase (Promega): Typically, plasmid and insert were mixed at a molar ratio 
of 1:3 and incubated overnight at 16°C with 2 units of enzyme and 1.2pl lOx reaction 
buffer in a total volume of 12pl.
Klenow DNA Polymerase large fragment (Promega). This enzyme was used to blunt 
unwanted overhanging single stranded DNA, which is a common product of restriction 
digests.
Calf Intestinal Alkaline Phosphatase (Promega). This enzyme was used to remove the 
activated phosphate groups at the ends of dsDNA fragments and is useful to avoid the 
self-ligation of blunt ended plasmids.
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2.4.3 Agarose Gel separation of DNA/RNA
5Ox TAE: 2M Tris-Acetate, 0.5M EDTA pH 8.3 (Eppendorf)
Ethidium bromide stock solution: lg  EtBr in 100ml ddH2 0 . (Stored in the dark at RT) 
Working TAE buffer: 1/50 dilution of 50x TAE
1% agarose gel: lg  agarose (Sigma), 100ml TAE buffer. Heated by microwave and 
allowed to cool to 65°C before pouring.
2pi of 6x loading buffer (Promega) was added to lOpl of DNA/RNA sample.
DNA/RNA samples were then run alongside a 1Kb Ladder (Promega) in TAE buffer 
through 1% agarose gels at 100V for 20-40mins. Gels were stained in 200ml TAE 
buffer with lOpl ethidium bromide stock solution and visualised using an Alphalmager 
system (Alpha Innotech).
2.4.4 Polymerase Chain Reaction (PCR)
Reagents for PCR were mixed in a total volume of 50pl as laid out in the table below. 
According to the desired product either PfU Ultra (Stratagene) or Taq (Invitrogen) DNA 
Polymerase was used. PCR was typically carried out for 30 cycles on a Gene Amp PCR 
System 9700 (PE Applied Biosystems):
1) Denaturing (initial) 94°C 5 mins.
2) Denaturing (cycle) 94°C 30 secs.
3) Annealing (cycle) 40-60°C (according to primers) 45-60 secs.
4) Polymerisation (cycle) 72°C 60-90 secs.
5) Polymerisation (final) 72°C 5 mins.
6 ) 4°C
Table 2.4. Reagents for standard PCR
Reagent Stock
Concentration
Volume (pi) Final concentration
PCR buffer (Tris-Cl 10X (200mM, 5 lx (20mM, 50mM)
(pH 8.4), KC1) 500mM)
MgCl2 50mM 1.5 1.5mM
dNTP (Invitrogen) Each at 5mM 2 0.2mM
Primer 1 12.5pM 1 0.25pM
Primer 2 12.5pM 1 0.25pM
DNA polymerase (Taq 5U/pl 0.2 - 0.5 1-2.5 units
or PfU)
H20 38 - 38.3
Total 50
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2.4.5 Bacterial Growth
Sterilisation of broth and agar was carried out by autoclaving at 120°C for 90 mins. 
Luria-Bertani (LB) broth -  16 LB capsules (Bio 101) were added to 1 litre of ddFLO and 
sterilised. (Final formulation -  lOg tryptone, 5g yeast extract, 0.5g NaCl, 1 litre H2O) 
LB agar -  lOg/litre of select agar (Gibco BRL) was added to LB broth before 
sterilisation. Agar was allowed to cool and was remelted by microwaving. It was then 
placed in a 45°C water bath to cool slowly before adding the appropriate antibiotic and 
pouring 15ml aliquots into 10cm agar plates (Sterlin).
SOB (Super Optimal Broth) - 20g tryptone, 5g yeast extract, 0.5g NaCl, 5g 
MgS0 4 .1H2 0  (Bio 101 formulation) in 1 litre distilled water.
SOC (Super Optimal Catabolite repression) - filter sterilised glucose was added to 
autoclaved SOB to a final concentration of 20mM
Stock ampicillin -  500pl aliquots of 50mg/ml ampicillin (Sigma) were kept at -20°C. 
Stock ampicillin was diluted 1/1000 into LB broth and LB agar as required.
Stock blasticidin - 500pl aliquots of lOmg/ml blasticidin (Invitrogen) were stored at - 
20°C.
2.4.6 Transformation of chemically competent E. coli
Competent cells were thawed slowly on ice (~30 mins) and gently resuspended. lOOpl 
of cells was dispensed into a pre cooled eppendorf and ~10ng supercoiled plasmid DNA 
or l-5pl of T4 ligation product was added. Cells were incubated with the DNA on ice 
for 30 mins before heat shocking for 30 secs at 42°C on a heat block (Grant QB2T). 
Cells were put back on ice and topped up with 0.5 ml of prewarmed SOC (37°C). Cells 
were shaken vigorously for 1 hour at 37°C to allow the bacteria to recover. 100 - 250pl 
of transformed bacteria was then spread on LB agar containing the appropriate 
antibiotic for selection. Agar plates were incubated overnight at 37°C.
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2.5 T cell methods
2.5.1 T cell expansion
The CTL clone specific for influenza matrix protein derived peptide GILGFVFTL, was 
obtained from Xiaoning Xu (Institute of Molecular Medicine, Oxford). It was expanded 
in vitro in 2 week cycles as follows:
T-media: 50% Ex Vivo 15 media (Cambrex), 50% RPMI 1640 supplemented with 5% 
FCS, 5% Filter sterilised Human AB serum (Sigma) and 55pM 2-mercaptoethanol 
(Sigma).
Irradiated PBMCs: PBMCs were isolated from 3 donor Buffy Coat Residue samples 
(Colindale blood bank) by density centrifugation using Lymphoprep (Axis-Shield). 
Cells were counted and resuspended in 50ml of T-media at 4xl06 cells/ml and then 
irradiated with a dose of 25 Greys.
48 hours after thawing or 2 weeks after previous stimulation, T cells clones were 
counted and lx l0 6 cells were suspended in 50ml T-media and mixed with 50ml 
irradiated PBMCs. T cells were stimulated with 40ng/ml monoclonal antibody OKT-3. 
24 hours after stimulation media was supplemented with 200units/ml of IL-2. 
Subsequently, every 3 days half the media was removed and fresh T-media 
supplemented with 200units/ml IL-2 was added. Cultures were maintained at l-2xl06 
cells/ml throughout. For long term storage, cells were frozen at 12 days after 
stimulation.
2.5.2 Enzyme Linked Immuno-Spot assays (ELISpots)
ELI Spot assays can be used to measure the number of cells in a population secreting
specific factors such as IFNy. IFNy is a marker released by activated T cells, therefore 
an IFNy ELISpot can be used to determine the number of T cells in a population that are 
activated to a given stimulus.
2.5.2.1 Plate preparation
96 well polyvinylidine difluoride (PVDF) (Millipore, Bedford, MA, USA) plates were 
coated for 2 hours at 37°C with 50pl per well of 15p,g/ml anti-human IFNy mouse IgGl 
(clone D1K, Mabtech). This was diluted in PBS (w/o Mg and CaHC03, GIBCO™,
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USA) from the stock. Following incubation the wells were washed x8 in 200pl PBS 1% 
FCS in sterile conditions using a vacuum pump to aspirate (Vaccubrand, GmbH). lOOpl 
complete medium (RPMI plus 10% v/v FCS) was then added to each well and 
incubated for 1 hour at 37°C to block.
2.5.2.2 Preparation of target cells or CTL stimulus.
When CTLs were to be stimulated by peptide pulsed target cells, the targets were 
washed and suspended in complete medium containing lOpM peptide at 1 x 106 cell/ml. 
Cells were mixed thoroughly with peptide and incubated at 37°C for 1 hour. After 
incubation cells were washed x8 in PBS 1% FCS to ensure no free peptide remained. 
Medium was aspirated out of the plate and 5 x 104 peptide pulsed target cells were 
added to each of the relevant wells in lOOpl of RH10 (RPMI 1640 (Gibco BRL) with 
10% Human AB serum (Sigma) and 100 units/pl IL-2). Stimuli other than target cells, 
such as peptide were added to wells at 2x final concentration in 100pi of RH10.
2.5.2.3 CTL stimulation
CTL were thawed into T-media (see section 2.5.1) + 100 units/ml IL-2 24 hours before 
the assay and incubated overnight at 37°C. On the day of the assay cells were re­
suspended at 9 x 104, 3 x 10 4 or 104 cells/ml in RH10 + 10 units/ml IL-2. lOOpl was 
transferred to each well. The plates were then incubated for 16 hours at 37°C. Following 
incubation the cells were discarded and wells were washed x8 in PBS as before.
2.5.2.4 Detection of activated T cells
After plate washing, 50pl of lpg/ml biotinylated mouse IgGl anti human IFNy (clone 
7-B6-1, Mabtech) was transferred to each well and the plate was then incubated for 2 
hours at 37°C. The plate was then washed x8 with PBS and 50pl of lpg/ml streptavidin 
alkaline phosphatase (Sigma) added to each well. The plate was incubated again for 1 
hour at 37°C and was washed again x8 with PBS. For detection of cytokine production 
the wells were developed using 5-bromo-4-chloro-3-indolyphosphate and nitroblue 
tetrazolium (BCIP/NBT) substrate (BioRad). This was combined just prior to use as per 
the manufacturer’s instructions and diluted in substrate buffer. lOOpl of this was added 
per well and left at room temperature for 5 minutes or until dark blue spots appeared in
65
the wells. Running the plate under tap water for 3 minutes arrested the development of 
colour.
2.5.2.5 Phorbol 12-Myristate 13-actetate (PMA)
PMA (Sigma) is a Phorbol ester and a specific activator of protein kinase C. It is a good 
positive control for this assay as it stimulates release of IFN y from T cells. Stocks of 
PMA were prepared in ethanol and stored at 1 mg/ml at -20°C. PMA was used at a final 
concentration of 1 pg/ml.
2.5.2.6 Assessment of developed plate.
After air-drying the developed plates over night at room temperature, the spots were 
counted using a video analyser (BioReader 3000, BioSys, GmbH). Pre-optimised 
reading methods, created by Dr. Katy Newton using the BioSys software were utilised. 
Triplicate or quadruplicate wells were read and the mean and standard deviation of the 
number of spots was determined for each condition.
2.5.3 T cell killing assays -  (Chromium 51 release)
All work using the radioactive isotope Chromium 51 up to the T cell incubation was
carried out in a designated room with appropriate lead shielding.
2.5.3.1 Target cell labelling
5xl05 target cells, supplemented with lpg/ml of peptide where necessary, were 
suspended in 50pl of normal growth medium in a 15ml falcon tube. 2MBq of Cr51 
labelled sodium chromate (Amersham) was added and incubated in a water bath at 37°C 
for 1 hour with occasional gentle mixing.
Cells were washed 3 times in 10ml of normal growth medium and then resuspended in 
10ml normal growth medium. (Final concentration of 5x10s cells/ml).
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2.5.3.2 T cell preparation
48 hours after thawing, or 10-14 days after stimulation, T cells were counted and 
resuspended in T-media at 3 different concentrations -  typically 0.5xl06, 1.5xl06 and 
5xl06 cells/ml. For each target cell to be tested T cells were then plated in a round well 
96-well plate in triplicate. Triplicate wells were also set up for spontaneous release -  
lOOpl T-media alone, and 100% release lOOpl of T-media supplemented with 2% 
Triton X-100.
2.5.3.3 T cell -  Target Cell incubation
lOOpl of the prepared target cells was then added to each well and mixed gently by 
pipetting. Cells were incubated together for 4 hours.
2.5.3.4 Measuring Chromium release
After incubation, plates were centrifuged at 1400rpm for 5 minutes. During 
centrifugation 175 pi of Optiphase Supermix was added to each well of a scintillation 
plate (Perkin-Elmer). After centrifugation 25 pi samples of supernatant were carefully 
removed and added to the scintillation plate. Plates were sealed and left for at least 15 
minutes to allow mixing of the liquids. Plates were then gently vortexed to complete 
mixing and read on a beta scintillation counter (1450 Microbeta, Perkin-Elmer). Results 
were normalised for each target using the values for spontaneous release and 100% 
release.
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3 Attempted suppression of ERp57 using RNA 
Interference
3.1 Introduction
3.1.1 ERp57 - An interesting target
In this chapter the technique of RNA interference is used to suppress the expression of 
Erp57 in order to study its functions in MHC class I antigen processing.
The ER resident protein disulfide isomerase ERp57 cooperates with the chaperones 
calnexin and calreticulin in the folding of polypeptides with monoglucosylated N-linked 
oligosaccharides (Oliver et al., 1999;Tan et al., 1997). Calnexin and calreticulin interact 
with class I at different stages of its development, but ERp57 is present in both the 
‘early complex’ and in the peptide-loading complex (PLC) of MHC class I assembly 
(Hughes and Cresswell, 1998;Lindquist et al., 1998;Morrice and Powis, 1998).
However, it is believed that Erp57 may have different functions at these 2 stages of 
development since the interactions it makes seem to be very different.
Human class I molecules in the ‘early complex’ can be immunoprecipitated with the 
monoclonal HC10 antibody and are not thought to be fully folded or associated with 
p2m. These class I molecules have been shown to be disulfide bonded directly to ERp57 
(Lindquist et al., 2001) and there is some evidence that its function in this early 
complex may be to fully reduce class I molecules that fail to fold, marking them out for 
retrotranslocation (Antoniou et al., 2002). In contrast, class I molecules 
immunoprecipitated with TAP or tapasin are not found to be disulfide bonded to 
ERp57. Instead Erp57 is now found disulfide bonded to tapasin and so its association 
with class I is probably indirect. Disruption of the interaction between tapasin and 
ERp57 by site directed mutagenesis of tapasin results in poor antigen processing for 
HLA-B44 and possibly other class I alleles (Dick et al., 2002). In 2002-3 when the work 
in this chapter was undertaken there was no published ERp57 gene knockout work. By 
using RNA interference it was hoped that the expression of ERp57 could be inhibited 
and more information about the exact functions of ERp57 could be obtained. If existing 
models were shown to be correct the suppression of ERp57 in a mouse deficient 
cell line would allow an analysis of its function in the early complex of class I 
maturation. Suppression would be expected to lead to inhibition of the 
retrotranslocation and degradation of free class I heavy chain, which usually occur in
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these cells. If ERp57 cooperates with tapasin in peptide loading, then suppression of 
ERp57 in normal cells might lead to a phenotype similar to that in tapasin deficient 
cells. Surface expression of class I would be reduced and antigen presentation would be 
impaired especially for alleles such as HLA-B44, which is particularly reliant on tapasin 
(Peh et al., 1998;Dick et al., 2002).
In this work, ERp57 expression was targeted in mouse cell lines in the hope that a novel 
phenotype could be described, particularly in relation to MHC class I antigen 
processing. If successful this system would also allow ERp57 inhibition in the 
calreticulin deficient K42 cell line and by studying this “double knockout” it might be 
possible to assess the degree to which these molecules work cooperatively in MHC 
class I peptide loading.
3.1.2 Discovery of RNA interference
RNA interference (RNAi) is a sequence specific method of gene suppression, which 
acts at the level of translation by destroying messenger RNA (mRNA). In 1990, 
Jorgensen and colleagues tried to enhance the colour of petunias by introduction of 
additional pigment-producing genes into petunia (Napoli et al., 1990). To their surprise, 
instead of the expected deep purple colour, many of the flowers appeared patterned 
white or completely white. They named the observed phenomenon "cosuppression". At 
the same time, Alexander van der Krol et al. observed a similar phenotype when they 
introduced pigmentation genes into flowers; about a quarter of plants demonstrated 
reduced floral pigmentation, accompanied by a dramatic reduction in the expression of 
both the introduced gene and the homologous endogenous gene (van der Krol et al., 
1990).
Guo and colleagues produced a similar loss-of-function or gene-knockout phenotype in 
C. elegans by direct injection of antisense siRNA (small interfering RNA) to the par-1 
gene, and showed that a similar inhibitory effect on par-1 gene function could be 
elicited by the injection of sense siRNA. (Guo and Kemphues, 1995). In 1998, Fire and 
colleagues reported that double-strand RNA was more potent as a silencing trigger than 
either antisense or sense RNA alone (Fire et al., 1998). Following on from work 
showing that introduction of sense RNA could be as effective as antisense RNA in the 
suppression of gene expression; they used sense and antisense RNA both individually
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and in synergy. They found that when sense and antisense RNA were used together the 
gene suppression was at least 100-fold higher than the individual use of either sense or 
antisense RNA. Not only this, but they also showed that only a few copies per cell of 
double stranded RNA were needed to suppress gene expression, which led them to 
suggest that the process was in some way catalytic.
Using plants cells where the analogous process of “Post Translational Gene Silencing” 
(PTGS) occurs, it was shown that mRNA could be degraded in the presence of short 
RNA molecules of 21-25 nucleotides (Hamilton and Baulcombe, 1999). In an in vitro 
Drosophila system it was then demonstrated that “21-22 nucleotide [dsRNA] fragments 
are the sequence-specific mediators of RNAi” (Elbashir et al., 2001a).
The natural use of RNA interference in higher organisms may be mainly as a defence 
against viruses rather than in cellular gene expression (Jensen et al., 1999) (Ratcliff et 
al., 1999). At some point within their life cycle, genetic elements such as transposons, 
and many viruses, such as those of the retrovirus family including HIV, produce 
dsRNA. Cells of higher organisms do not normally produce large pieces of dsRNA and 
hence have evolved to use of RNA interference as a viral defence mechanism, by 
destroying mRNA with sequence complementary to that of the double stranded RNA 
present (Jensen et al., 1999). Although naturally RNA interference may be primarily 
used as a viral defence mechanism, it can also be used effectively to suppress cellular 
gene expression making RNA interference an extremely useful tool in the study of gene 
function (Serwold et al., 2002).
3.1.3 Mechanism of RNA interference
In Drosophila large pieces of dsRNA are digested in an RNase Ill-like mechanism 
yielding 21-23 nucleotide dsRNA fragments with a 3’ overhang of 2 nucleotides at each 
end (Elbashir et al., 2001a). The protein responsible for this cleavage is known as Dicer 
and contains both helicase and RNase activity (Bernstein et al., 2001). The 21-23bp 
dsRNA products are not randomly produced but rather, regular segments of dsRNA 
product are formed, which are able to guide cleavage of the corresponding mRNA at 
21-23 nucleotide intervals.
The sequence specific degradation of mRNA relies on nuclease activity, this has been 
localised to the cytoplasm in a complex known as RISC (RNA induced silencing 
complex). RISC consists of both protein and a short piece of RNA (Bernstein et al., 
2001) derived from the dsRNA. RISC somehow picks up the short fragments of dsRNA
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produced by Dicer and uses them to capture complementary mRNA and then degrade it. 
It is known that Dicer digests long pieces of dsRNA into regular fragments of around 
21-23bp and it has also been noticed that the digestion pattern of mRNA occurs at 
intervals of 21-23 nucleotides strengthening the link made between the two processes. 
RISC cuts the mRNA, 11 or 12 nucleotides along the complementary RNA that it holds 
in the complex. It is not currently clear whether the RNA guiding cleavage is still 
double stranded at this point or whether the complex simply retains one strand of the 
dsRNA.
3.1.4 In vitro synthesis of dsRNA for RNA interference
To avoid the problems of activation of the interferon system by long pieces of dsRNA 
in mammalian systems it is better to use small pieces of dsRNA or small interfering 
RNAs (siRNAs) which can be used directly by RISC. This also has the advantage that it 
does not rely on the Dicer activity of the cell, which has been shown to be markedly 
lower in mammalian cells than in Drosophila. However, the difficulty with this is that it 
provides the RISC with only one species of dsRNA to act as a template and hence there 
is no certainty that the sequence of RNA chosen will suppress the gene effectively. In 
order to increase the chances of a successful gene knockdown, in this work three 
sequences were chosen against ERp57, and one published sequence which suppresses 
eGFP (Caplen et al., 2001) was chosen in order to demonstrate the viability of the 
technique.
A system of generating siRNAs has been demonstrated using T7 RNA polymerase to 
synthesise the two strands of RNA individually from a DNA template before annealing 
them to make the complete siRNA (Donze and Picard, 2002). The advantage of using 
T7 RNA polymerase is that the T7 promoter is very short and requires no downstream 
elements. As a result the DNA required consists simply of a short dsDNA sequence 
comprising the 18 nucleotide T7 promoter followed by the 21-23 nucleotide reading 
strand for RNA synthesis. DNA oligonucleotides were obtained from commercial 
sources, (Sigma-Genosys) and annealed to make such templates, and by designing the 
template sequences correctly 21 -23 nucleotide RNA molecules were produced with 
complementary sequences containing 2 base 5’ overhangs necessary for efficient RNAi 
(Fig. 3.1). In this way large quantities of several dsRNA were synthesised to allow 
screening of different sequences within the target mRNA. The siRNA against GFP of
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the same sequence used is now also available commercially (Dharmacon, USA), 
allowing comparison with the sample prepared in our laboratory.
Figure 3.1. T7 Transcription of dsRNA. Schematic representation of in 
vitro synthesis of dsRNA.
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3.2 Materials and Methods
3.2.1 Handling of RNA
When using RNA, commercially produced RNase free plastic (Fisher) was used 
wherever possible and all solutions and reagents used in the preparation of RNA were 
RNase free. A dedicated set of Gilson pipettes was used for RNA work. Two pairs of 
latex gloves were worn during work involving RNA.
3.2.2 Design of dsRNA sequences
Little is known about the best target sequences to use for RNA interference in 
mammalian cells. For this reason three different sequences were designed in the hope 
that at least one sequence would effectively inhibit ERp57 gene expression. The 
following criteria were taken into account in dsRNA sequence design:
1) The sequence should be homologous with part of the open reading frame of the gene 
of interest (i.e. ERp57).
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2) The sequence should not be homologous to any other known mRNA sequence in the 
mouse genome. (A BLAST search was performed to check putative target sequences.)
3) DsRNAs should be 19-22 nucleotides long and have a 3’ overhang of 2 nucleotides 
at each end, as this corresponds to the species created by Dicer protein (Elbashir et al., 
2001b).
4) It has been suggested that an even distribution of the different nucleotides may be 
beneficial (Dykxhoom et al., 2003) and that CG content should be between 30 and 70%.
5) All ssRNAs produced by the T7 transcription protocol of (Donze and Picard, 2002) 
begin with Guanine. Hence a sequence must be found of the format GN17.19C; the 
resulting sense and antisense sequences will then read: 5’ GN17.19CNN 3’ (Fig. 3.1).
The final dsRNA will read: 5’ GN17.19 CNN 3’
3 ’ NNCM17-19G 5 ’
Sequences were chosen at positions 68-91, 135-158 and 358-381 downstream from the 
start codon. Elbashir et al (Elbashir et al., 2001b) have suggested that sequences 50-100 
bases downstream of the start codon are good targets; therefore one sequence has been 
chosen in this region. Other groups have not been able to confirm such an association 
and so the other sequences were chosen from other positions in the coding region of the 
mRNA. (Dykxhoom et al., 2003)
3.2.3 Synthesis of double stranded RNA (dsRNA) with T7 RNA 
polymerase
Sense and antisense RNA molecules were synthesised individually and then annealed to 
produce dsRNA molecules as described (Donze and Picard, 2002).
3.2.3.1 T7 RNA polymerase template preparation
Desalted DNA oligonuceotides for the T7 recognition sequence (5’- 
TAATACGACTCACTATAG-3’) and for its complementary sequence, followed by 
template for RNA synthesis (e.g. GFP sense 5’ as in Caplen et al. (Caplen et al., 2001). 
5’-ATGAACTTCAGGGTCAGCTTGCTATAGTGAGTCGTATTA-3’), were 
synthesised commercially (Sigma-genosys, St. Louis, Missouri, USA), lnmol of the T7 
recognition sequence was mixed with lnmol of template DNA in 50pl of RNase free
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water. The DNA was then annealed by heating the solution to 95°C on a heat block. 
After 2 minutes the block was switched off and the reaction was allowed to cool slowly.
3.2.3.2 Transcription
A 50pl reaction mix was prepared containing lx T7 Transcription buffer, ImM rNTPs, 
100U of T7 RNA polymerase (Promega) and 200pmol of dsDNA (10pl of sample 
prepared above). The samples were incubated at 37°C for 2 hours. DNA was then 
removed by adding 1U of RNase free DNase (Promega) and incubating at 37°C for 15 
minutes.
3.2.3.3 RNA annealment
Individually synthesised crude preparations of sense and antisense RNA were mixed 
and annealed by heating to 95°C for 5 minutes followed by incubation at 37°C for 1 
hour. The mixture was adjusted to 0.2 M sodium acetate pH 5.2 and precipitated with
2.5 volumes of ethanol. The sample was then centrifuged, washed with 70% ethanol, 
dried and resuspended in 50pl of nuclease free water. RT^V concentration and purity 
were quantified by spectrophotometry.
3.2.3.4 RNA interference of GFP (used as control)
Transfection of human embryonic kidney (HEK) 293 cells and mouse fibroblast 
NIH3T3 cells was optimised using a GFP expressing plasmid. To assess the 
effectiveness of the synthesised dsRNA, cells were simultaneously transfected with a 
plasmid expressing GFP and with either dsRNA against GFP or irrelevant dsRNA, 
using lipofectamine 2000 (see section 2.1.10). Fluorescence was observed using an 
Olympus 1X70 microscope and images were taken with an Olympus Vamedia C-3040 
digital camera attached via C-3040-ADU and U-CMT adaptor units. Fluorescence was 
also detected by flow cytometry (see section 2.2).
3.2.3.5 RNA interference of ERp57
NIH3T3 Cells transfected with the 3 dsRNA sequences against ERp57 or against the 
irrelevant GFP were assessed for expression of ERp57 by Western Blot and by 
intracellular FACS.
3.3 Results
3.3.1 Good quality dsRNA is synthesised by T7 RNA Polymerase
Sense and antisense RNA sequences were synthesised by T7 polymerase and annealed 
to produce dsRNA and assessed by spectrophotometry. The four sequences of dsRNA 
produced were shown to be of good yield -  between 9 and 25 mg/ml (Table 3.1). The 
high ratios of 2.3 between the absorbance at 260nm and 280nm suggest good purity, 
with little or no contamination with DNA. Sequences I, II and IV target sequences in 
ERp57, whereas sequence III is the sequence directed against GFP and used as a 
control.
Table 3.1. Concentration of synthesised T7 dsRNA
RNA sequence Dilution; A26o RNA concentration A28O A 260-A280
1 1/900 ; 0.677 25 mg/ml 0.293 2.3
II 1/400 ; 0.570 9 mg/ml 0.245 2.3
III 1/400 ; 0.683 11 mg/ml 0.299 2.3
IV 1/400 ; 0.807 13 mg/ml 0.348 2.3
3.3.2 RNA interference suppresses GFP expression in HEK293 cells.
HEK293 cells were used to show the effectiveness of the RNA produced. These cells 
transfect easily, with at least 90% of cells expressing GFP after transfection of GFP 
expressing plasmid (Fig. 3.2). HEK293 cells were simultaneously transfected with GFP 
expressing plasmid, and either T7 dsRNA III or a commercially available dsRNA 
sequence against GFP (Dharmacon, USA). Both of these dsRNAs contain the same 
sequence complementary to the mRNA of GFP and would be expected to suppress the 
expression of GFP by destroying the mRNA. Effective suppression of GFP was seen 
with both these dsRNA sequences (Fig. 3.2). Suppression with Dharmacon dsRNA 
(commercial) was less marked than with T7 dsRNA, but it should be noted that the 
RNA concentration used was over 10-fold lower. Dharmacon dsRNA was used at this 
concentration according to the manufacturer’s instructions; T7 dsRNA was used 
according to the methods outlined by Donze and Picard (Donze and Picard, 2002).
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An incident laser at 488nm causes GFP to emit green light with a peak at 508nm. This 
can be detected on the FACS machine through the FL-1 channel (530/30 nm) or less 
strongly in the FL-2 channel (585/42 nm). FACS analysis of HEK293 cells (Fig. 3.3) 
shows that over 99% of cells transfected with GFP plasmid are emitting light in the FL- 
1 channel (b) compared to less than 1% of cells treated with lipofectamine alone (a). 
GFP is therefore expressed in at least 98% of GFP plasmid transfected cells. In contrast 
when cells are simultaneously transfected with GFP expressing plasmid and T7 dsRNA 
III less than 5% of cells express GFP (c). Treatment with irrelevant T7 dsRNA II caused 
a slight reduction in GFP expression with 97% of cells now showing expression of GFP
(d).
The suppression of GFP in this experiment shown by the results in Figures 3.2 and 3.3 
validate the technique. However, it would have been preferable to suppress an 
endogenously expressed protein. A cell line stably expressing GFP could have been 
used for this purpose, however, such a line was not available in the laboratory and since 
the final aim was to suppress ERp57 it did not seem worth investing the time and 
resources into the development of a stable line expressing GFP.
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Figure 3.2. GFP detected by microscopy in transfected 293 cells can be 
silenced by both commercial and T7 preparation of dsRNA.
Cells were grown to 90 % confluence and then transfected with a) 1pg GFP 
plasmid, b) 1pg GFP plasmid and 2pg commercial dsRNA against GFP or c) 
1pg GFP plasmid and 2pi (22 pg) T7 dsRNA sequence III against GFP using 
lipofectamine 2000. 24 hours later GFP expression was detected by light 
microscopy using UV light excitation. Phase contrast pictures and UV light 
images are shown for purposes of comparison; the microscope magnification of 
images is x100.
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Figure 3.3. GFP expression detected by FACS is silenced by specific 
dsRNA.
HEK293 cells at 90% confluence were transfected using lipofectamine 2000 
and assessed for expression of GFP by FACS using the FL-1 channel. GFP 
can also be detected in the FL-2 channel as can be seen from the data, a) 
Lipofectamine alone, b) 1pg GFP plasmid, c) 1pg GFP plasmid and 2pl of anti 
GFP T7 dsRNA (III), d) 1pg GFP plasmid and 2pl of irrelevant T7 dsRNA (II).
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3.3.3 RNA interference silences GFP expression in NIH 3T3 cells.
To test the effectiveness of the T7 dsRNA produced against mouse ERp57 it was 
necessary to move into a mouse cell line. The mouse fibroblast cell line NIH 3T3 was 
chosen as a suitable line. When transfection of GFP plasmid and dsRNA against GFP 
were assessed in this cell line, cells transfected with GFP plasmid were found to express
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GFP. However there was no detectable fluorescence in cells transfected simultaneously 
with GFP plasmid and T7 dsRNA (Fig. 3.4), showing good silencing by dsRNA.
Figure 3.4. Transfection efficiency is low but T7 dsRNA silences GFP 
expression in NIH 3T3 cells.
a) NIH 3T3 cells were transfected with GFP alone and assessed by microscopy. 
Image shows both phase contrast and UV light excitation of GFP. b) NIH 3T3 
cells were transfected with GFP and T7 dsRNA against GFP. 24 hours later 
cells were observed by microscopy. Left -  Phase contrast image. Right -  UV 
light excitation of GFP (none detected).
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Although T7 dsRNA still effectively silenced GFP expression, the transfection 
efficiency of NIH 3T3 cells was considerably poorer than in 293 cells. In order to assess 
the effectiveness of dsRNA against T7 RNA it was felt that higher transfection 
efficiency was needed. Optimisation of conditions was performed by varying the 
lipofectamine concentration (Fig. 3.5) and the confluence of cells (Table 3.2).
Figure 3.5. NIH3T3 cells were transfected most effectively with 5|j| 
lipofectamine/ ‘6 well’.
Transfection efficiency of GFP plasmid, in 3T3 cells grown to 20% confluence in 
a 6-well plate, was optimised for lipofectamine concentration and analysed by 
FACS, a) No lipofectamine, 1pg GFP plasmid, b) 2.5pl lipofectamine, 1pg GFP 
plasmid, c) 5pl lipofectamine, 1pg GFP plasmid, d) 10pl lipofectamine, 1pg 
GFP plasmid.
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Table 3.2. NIH 3T3 cells were transfected more effectively at low 
confluence.
Cell confluence on day of 
transfection
Amount of GFP 
plasmid used
Percentage GFP positive 
cells by flow cytometry
100% None 3.19
100% lug 19.62
90% lug 26.00
60% lug 31.55
30% lug 43.53
20% .... 1.M................. 43.69
Based on these results the optimised conditions for transfection of NIH3T3 cells were: 
cells at 20-30% confluence on day of transfection and 5pl of lipofectamine per well in a 
six well plate. Transfection efficiency under these conditions was typically between 38 
and 45%.
Although efficiency of plasmid DNA transfection does not necessarily correlate exactly 
with the efficiency of dsRNA transfection, in these experiments RNA interference with 
T7 RNA III invariably suppressed GFP expression to levels undetectable by blue light 
microscopy. It is reasonable to assume then that the transfection efficiency of the 
dsRNA must be at least as good as that for plasmid DNA since dsRNA is suppressing 
expression of GFP in every cell which has received plasmid.
3.3.4 The sequences chosen for RNA interference do not silence 
expression of ERp57 effectively.
In order to assess the suppression of ERp57 by RNA interference, the ERp57 protein 
level was measured by western blot against the housekeeping gene calnexin (Fig. 3.6). 
By western blot it was not possible to detect a significant change in the expression of 
ERp57 protein.
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Figure 3.6. ERp57 expression is not silenced by any of the three dsRNA 
sequences tested.
NIH3T3 cells at 20% confluence in a 6-well plate were transfected with 2pl of T7 
dsRNA specific for ERp57 or GFP and 5pl lipofectamine. 48 hours later 
expression of ERp57 and the housekeeping gene calnexin was assessed by 
western blot
dsRNA
target
Calnexin
ERp57
ERp57 levels were also measured by intracellular FACS. It can be seen that the 
expression of ERp57 as measured by intracellular FACS, is not normally distributed 
after treatment with either RNA I or RNA II (Fig. 3.7 a and b). The presence of a small, 
low expressing population of cells in figure 3.7b, suggests some suppression of ERp57 
protein levels in these cells. However, these results were not consistent, and when the 
data are overlaid with the irrelevant dsRNA the suppression is cast into doubt (Fig. 
3.7c). The expression of ERp57 in cells transfected with irrelevant dsRNA is normally 
distributed, which shows that the population of low expressing cells in figure 3.7b is not 
purely an artefact of the intracellular staining. However, the peak of ERp57 expression 
in these cells lies between the high and the low expressing cells transfected with RNA I 
or RNA II.
Suppression o f ERp57 by transfection of dsRNA II, produces at best a 75% reduction in 
ERp57 expression in 30% of the population (Fig. 3.7b -  M l), which is consistent with 
the transfection efficiency of 30-40%. However, unlike GFP expression, which is 
suppressed to below detectable levels by dsRNA, expression of ERp57 remains 
significant even in the putative population o f RNAi suppressed cells.
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Figure 3.7. DsRNA sequences I and II may cause low level suppression of 
ERp57.
NIH3T3 cells at 20% confluence in a 6-well plate were transfected with 2pl of T7 
dsRNA and 5pl lipofectamine. 48 hours later expression of ERp57 was 
assessed by intracellular FACS, a) RNA sequence II - target ERp57, b) RNA 
sequence I - target ERp57, c) RNA sequence I (black), RNA sequence III - 
target GFP (grey).
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3.4 Discussion
Although this level of suppression may be enough to affect the function of some 
proteins it was felt that it was unlikely to be sufficient for a high expressing 
housekeeping gene like ERp57. Indeed analysis of cell surface expression of mouse 
class I in dsRNA treated cells showed no change in expression (data not shown). Other 
researchers have also commented that after 90% suppression of ERp57 there is no 
change in phenotype with respect to cell surface class I and peptide loading (Williams, 
2006) and that ERp57 can still be found in associated with the PLC (Cresswell personal 
communication).
It would have been possible to try and stably transduce cells to express dsRNAs against 
ERp57 or to use RNAi libraries to suppress ERp57. However, RNAi library technology 
is expensive and since the results of this preliminary work were not promising and the 
fact that other eminent researchers had also found the approach of RNAi unsuccessful 
for ERp57 it was decided not to pursue this further.
Since this work was undertaken, mice have been created with ERp57 knockout in the B 
cell compartment (Garbi et al., 2006). 2 loxP sites were directed to flank exons 2 and 3 
of the ERp57 gene and ‘floxed’ mice were produced Pdiam . When Crossed with Cre 
deleter mice no homozygous ERp57 negative offspring were obtained in the F2 
progeny, showing that ERp57 is essential for in utero development. However, using 
tissue specific Cdl9-Cre mice it was possible to produce mice with ERp57 knockout in 
the B cell compartment. ERp57 deficient fibroblasts were also produced by in vitro 
recombination of SV40 T antigen immortalised Pdiam  fibroblasts. Characterisation of 
both ERp57 deficient B cells and the fibroblast cell line showed that there is a 50% 
reduction in the expression of Kb in these cells by both western blot and by flow 
cytometry. This phenotype is explained by poor incorporation of heavy chain into the 
peptide-loading complex and rapid trafficking of Kb molecules resulting in instability 
and reduced half life at the cell surface. A smaller effect is also seen on the expression 
of Db. Most interestingly the absence of ERp57 leads to the loss of almost all heavy 
chain from both TAP and tapasin immunoprecipitates. Given this fact it is surprising 
that the phenotype is so mild, since incorporation into the peptide-loading complex (Tan 
et al., 2002) and association with tapasin (Williams et al., 2002) has previously been 
shown to be very important for peptide loading. However, ERp57 is clearly important 
for stabilising the interaction of heavy chain with the peptide-loading complex and it 
may be that like dependence on tapasin, the extent to which ERp57 is needed for class I
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loading is allele specific. Previously it had been thought that tapasin was sufficient to 
form a bridge between TAP and heavy chain but this work shows that ERp57 is also 
important for this interaction. ERp57 may strengthen the interaction between heavy 
chain and tapasin either by disulfide bonding with tapasin, altering its conformation and 
allowing it to bind heavy chain or ERp57 may bind to both heavy chain and tapasin 
thereby stabilising the interaction between the two. Whether the only requirement for 
ERp57 is in the stabilisation of the peptide-loading complex in unclear and a full 
discussion of the other possible roles of ERp57 is made in chapter 7. Briefly, since 
ERp57 is a member of the protein disulfide isomerase family it is thought likely that its 
function in the peptide-loading complex may be to ensure that the disulfide bond in the 
(X2 domain of the class I heavy chain remains oxidised. By transfection of a mutant 
tapasin, which fails to associate with ERp57, into tapasin deficient cells it has been 
shown that ERp57 does have a role in the oxidation of HLA-B44 (Dick et al., 2002). 
However, in ERp57 knockout cells no difference was detected in the redox state of 
MHC class I molecules isolated from the peptide-loading complex (Garbi et al., 2006).
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4 Expression of linked chain MHC class I constructs 
as a tool for dissecting the assem bly pathway
4.1 Introduction
As discussed in section 1.3 there is now a large body of knowledge about the molecular 
processes behind successful MHC class I antigen presentation (Villadangos et al., 
2005;Flutter and Gao, 2004). Antigenic peptides are mainly produced by proteasome by 
the turnover of cytosolic proteins and the breakdown of DRiPs (Defective Ribosomal 
Proteins) (Reits et al., 2000;Khan et al., 2001). TAP then transports peptides from the 
cytosol to the ER (Trowsdale et al., 1990;Deverson et al., 1990;Spies et al., 1990) 
(Anderson et al., 1991), where they are trimmed to size by the aminopeptidase ERAAP 
(Serwold et al., 2002;Saric et al., 2002;York et al., 2002). Meanwhile, newly 
synthesised MHC class I heavy chain molecules associate with calnexin in the ‘early 
complex’ of class I folding (Degen and Williams, 1991;David et al., 1993). 
Subsequently heavy chain pairs with and calnexin is dropped in favour of 
calreticulin (Farmery et al., 2000;Sadasivan et al., 1996). The class I p2m-HC 
heterodimer and antigenic peptide are thought to come together in the peptide-loading 
complex, and failure of class I molecules to associate with the peptide-loading complex 
generally leads to poor antigen presentation (Lewis et al., 1996;Ortmann et al., 1997).
However, there are a number of unanswered questions surrounding the details of class I 
assembly and peptide loading. It is clear that calnexin, calreticulin, tapasin and ERp57 
all associate with class I molecules during the process of class I folding (Farmery et al., 
2000;Sadasivan et al., 1996). However, the role of each of these molecules in antigen 
processing is not well characterised. The mechanisms of p2m recruitment to heavy 
chain, peptide loading and release of loaded class I molecules from the peptide-loading 
complex also remain unclear.
In order to investigate the folding mechanisms of MHC class I molecules, fusion 
proteins have been constructed, creating class I molecules, which after synthesis are 
effectively partially assembled. Fully folded MHC class I molecules consist of three 
different components - heavy chain, p2in and antigenic peptide. In total five different 
constructs, containing one or more of these three components have been made. Each of 
the constructs contains P2in and they are designed as follows (information repeated from 
section 1.4 for the reader’s convenience):
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p2m: (human) ‘P2m ’.
PB: ‘peptide - linker 1 - p2fli\
BA: ‘P2IH - linker 2 - HLA-A*0201\
BB: ‘p2m’-‘linker 2’-‘HLA-B*4402\
PBA: ‘peptide - linker 1 - p2m - linker 2 - HLA-A*0201\
Where ‘linker 1’ codes for GGGGGGSGGSGGSGG, ‘linker T  codes for 
GGGGSGGGGSGGGGS and ‘peptide’ codes for the HLA-A2 binding peptide 
GILGFVFTL derived from influenza virus matrix protein (Fig. 4.1). The BA construct 
was provided by Prof. W Bodmer (Oxford University, UK). Dr. Bin Gao (UCL, UK) 
created the fusion constructs PB and PBA, and engineered the BB construct from BA 
by replacing HLA-A2 with HLA-B*4402 (provided by Dr. C Peh. Oxford University, 
UK).
Figure 4.1. Schematic representation of MHC class I fusion proteins, (see 
also Figure 1.4b)
L1 -  Linker 1 
L2 -  Linker 2
Leader
LeaderpCMV
L2Leader
Leader L2
L2Leader
pCMV
Pept.
Pept.
HLA-A2
HLA-A2
HLA-B44
Use of these partially assembled class I molecules provides a new approach to studying 
the different mechanisms of class I antigen processing. By expressing fusion proteins in 
different deficient cell lines, and by examining their intermolecular interactions with 
other proteins and their rate of trafficking, it is possible to address issues such as: the 
role of calreticulin in (32m recruitment and the importance of peptide binding on the 
release of class I molecules from the peptide loading complex. These ideas are
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discussed further in sections 5.1 and 6.1. In order to validate the use of fusion constructs 
in the study of class I folding, they were first assessed for their ability to express at the 
cell surface and present antigen to T cells. In the work presented in this chapter, P2m,
BB and PB have been cloned into a lentiviral vector pLenti6-V5-D-TOPO (Invitrogen) 
and high titre virus produced. Lentivirus was used to express (bm in the human fbm 
deficient colon carcinoma cell line HCT (Dexter et al., 1979) and Dr. Bin Gao (UCL, 
UK) expressed the fusion proteins PB, BA and PBA in HCT cells. Since HCT cells 
express no cell surface class I, it is easy to assess the ability of the introduced proteins 
to restore cell surface expression of class I and to present antigen.
The advantage of using a viral system to stably express MHC class I constructs, is that 
the viruses can be used to infect several cell lines and this is useful in the study of 
different chaperones involved in class I antigen presentation.
4.1.1 Virapower lentivirus expression system (Invitrogen)
The Virapower lentivirus expression system allows production of a replication- 
incompetent HIV-based virus, capable of stably transducing most mammalian cells and 
allowing expression of the incorporated gene of interest. Virus is produced in the HEK 
293FT (fast growing 293 cells expressing SV40 large T antigen) cell line by 
simultaneous transfection of four plasmids encoding different vital components of the 
lentivirus.
The first plasmid pLenti-6-V5 is the pLenti-based expression vector into which the gene 
of interest is cloned (Appendix I). The gene of interest is amplified by blunt ended PCR 
and inserted into the plasmid by TOPO cloning. The forward primer is designed with a 
leader sequence CACC, which allows directional cloning (see Fig. 4.2) and the reverse 
primer may be designed such that there is no STOP codon at the end of the gene 
product causing the protein product to be tagged by a V5 epitope. The plasmid is 
supplied in an ‘open’ form which allows the gene to be cloned directly in front of the 
CMV promoter. An overhang complementary to the CACC forward primer leader 
sequence allows directional cloning catalysed by topoisomerase enzymes attached to 
each end of the open plasmid (Fig. 4.2).
Figure 4.2. The Topoisomerase reaction.
JpCC A3G MM 
—-'-'•frl'CCi T*C MM
ace Q
0w»hartg*iwri»* doubt*
QNA, depbdng ft« bosom **«and
PCRprodicI
m
.0i
T o p o b o m m t *
C*OC ASO MM MKX ,v*
Mill rs
(Taken from Invitrogen instruction manual ‘pLenti6/V5 Directional TOPO® Cloning Kit’ Version 
C. With kind permission from Invitrogen Eurotech.)
The pLenti vector contains modified 5’ and 3’ LTRs (Dull et al., 1998) and the \|/ 
packaging signal (Luciw, 1996), to allow packaging into virions, and also genes 
required for effective expression of the protein in mammalian cell lines such as the Rev 
Responsive element. The plasmid also contains a blasticidin resistance gene to allow 
selection of transduced cells, an ampicillin resistance gene for selection in E. coli and 
the pUC origin for high-copy replication.
The 3 other plasmids contain the genes required for production of virus in the packaging 
cell line. By separating the genes onto separate plasmids the safety of the virus system 
is greatly increased. The lack of these genes in the pLenti vector also makes the 
produced virus replication incompetent for infection of mammalian cells.
The vital genes expressed by the other plasmids include:
pL P l: Gag/pol fusion protein.
pLP2: HIV-1 Rev ORF, LTR polyadenylation signal.
pLP/VSV G glycoprotein, Human p-globin intron and polyadenylation signal.
(See Appendix I for plasmid maps.)
Viruses produced in 293FT cells are harvested from the supernatants and can 
theoretically be used to transduce any mammalian cell lines. A positive control virus 
expressing P-galactosidase (p-Gal), which can be easily detected by cell staining, is 
used to verify that the viral system is working. Cells can either be transduced to 
efficiently deliver transient protein expression to target cells or can be used to produce 
stable cell lines by selecting for transduced cells using the antibiotic blasticidin which is
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a protein synthesis inhibitor (TAKEUCHI et al., 1958). The blasticidin resistance gene 
contained within the pLenti6 vector codes for a blasticidin deaminase enzyme (bsd), 
which renders the blasticidin harmless to transduced cells (Kimura et al., 1994).
The lentivirus system developed in this chapter has several useful characteristics. The 
envelope of this virus expresses VSV-G (the glycoprotein of vesicular stomatosis virus), 
which means it is able to transduce with high efficiency a wide range of mammalian 
cells (Emi et al., 1991). Since some of the cells lines available with deficiencies in class 
I or class I antigen processing are of murine origin and others are of human origin, this 
is useful, because the same virus can be used transduce all of these cell lines. The CMV 
promoter drives powerful expression of the introduced genes in mammalian cells 
(Boshart et al., 1985) and because the plasmid integrates into the genome of the host 
cell this expression can be long lasting. The blasticidin resistance gene allows selection 
of transduced cells and facilitates production of stable cell lines where necessary.
Unlike some viral systems lentivirus is also largely non-toxic to the cells and since the 
titre of most preparations is about 106 virions/ml, it can also be used to transduce whole 
cell populations for transient expression.
4.1.2 Cell cytotoxicity assay
In order to test the ability of class I fusion proteins to present antigen to T cells a cell 
cytotoxicity assay was used. Because T cells can be difficult to grow and maintain, the 
assay was set up and optimised using a Natural Killer (NK) cell line NK92.
NK cells are a heterogenous lymphoid population capable of killing a wide variety of 
target cells that have been transformed or infected with virus. Target cell killing often 
negatively correlates with the expression of MHC class I and this led to the ‘missing 
self hypothesis of NK cell recognition (Ljunggren and Karre, 1990). The decision to 
kill is determined by a balance between activating and inhibitory signals received by the 
NK cell. KIRs (Killer Inhibitory Receptors) and ILTs (Immunoglobulin Like 
Transcripts) mainly interact with either classical or non-classical MHC class I 
molecules and are important in the control of killing. KIRs differ in their reactivity to a 
range of class I and can either promote or inhibit NK killing upon interaction with the 
appropriate class I. KIRs containing an ITIM (Immunoreceptor Tyrosine-based 
Inhibition Motif) sequence in their cytoplasmic tail inhibit killing, whereas KIRs that do 
not contain ITIMs promote killing (Moretta and Moretta, 1997). A number of other 
activating and inhibitory receptors also play a role in the control of target cell lysis.
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NK92 cells are a human cell line with a phenotype similar to activated NK cells and 
capable of killing the chronic myelogenous leukaemia cell line K562 (Gong et al.,
1994). The killing activity of NK92 cells is generally acknowledged to be high and 
most tumour cells, including those displaying class I molecules are susceptible to lysis 
(Komatsu and Kajiwara, 1998). K562 cells (Lozzio and Lozzio, 1975) are known to be 
sensitive to NK killing and have been used to determine the relative natural cytotoxicity 
of human lymphocytes (West et al., 1977). Conversely the CEM.NKR cells were 
generated by screening CEM cells for survival of NK killing (Howell et al., 1985). 
CEM.NKR cells are calnexin deficient and it is hypothesised that this deficiency leads 
to a failure of trafficking of cells surface markers that normally activate NK cell killing 
(Malyguine et al., 1998).
HCT cells have not been characterised for their susceptibility to NK92 killing. The use 
of K562, NKR and HCT cell lines should allow an assessment of the susceptibility of 
HCT cells to NK92 cell killing. A comparison between killing of HCT cells and HCT 
cells expressing class I fusion proteins will indicate the importance of class I expression 
in the susceptibility of a target cell to killing by NK92 cells.
4.1.3 Objectives
In this chapter, class I fusion proteins will be cloned into a lentivirus and viruses will be 
produced, which may be used to transduce any mammalian cells.
Using prepared lentivirus the linked chain construct P2m-B44 (BB) will be introduced 
into murine K41 cells and the calreticulin deficient cell line K42 and cell lines stably 
expressing p2m-B44 will be established.
Stable expression of different class I fusion proteins will also be established in the p2m 
deficient human HCT cell line. Together the resulting cell lines, HCT, HCT p2m, HCT 
PB (peptide linked P2m), HCT BA (p2m linked to HLA-A2) and HCT PBA (peptide 
linked to P2m and HLA-A2) provide a panel of cell lines each expressing class I 
molecules at different stages of assembly. It is hypothesised that each of the constructs 
will recover cell surface expression of MHC class I in HCT cells. Additionally, the 
peptide of the PB and PBA constructs will allow HCT cells expressing these constructs 
to stimulate the GILGFVFTL (influenza matrix protein derived peptide) specific T cell 
clone C T L flu- HCT p2m and and HCT BA cells will be also be able to stimulate
91
CTLflu, when provided with either flu peptide or when endogenously expressing whole 
flu matrix protein.
The effect that class I expression has on the susceptibility of HCT cells to NK92 cell 
killing will also be assessed.
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4.2 Methods
4.2.1 Lentivirus production
4.2.1.1 TOPO cloning
The gene sequences to be incorporated into lentiviral constructs (see table 4.2) were 
amplified using blunt ended PCR with the DNA Polymerase PfU (Stratagene). PCR was 
performed as laid out in section 2.4.4 using the primers in table 4.1.
Table 4.1. Primers for PCR
Primer Sequence Tm (°C) Features
B44 F TOPO CACCATGCGGGT 56 Start B44. CACC
CACGGCGC leader
B44R AGCT GT GAG AG A 58 End of B44 without
CACATCAG STOP codon
T7 TOPO (T7- RNA CACCTAATACGA 52 CACC leader
Polymerase promoter site) CT C ACT AT AGG
BGH (Bovine Growth T AGAAGGCACAG 52.5 Common reverse
Hormone polyadenylation TCGAGG primer site.
site)
M l3 TOPO (M 13- C ACCGT A AAACG 44 CACC Leader
Common primer site from ACGGCCAGT
the N-terminus of p-
Galactosidase gene)
Table 4.2. Characteristics of Lentiviral constructs
Construct Description Primers used to amplify gene
hp2m Human p2m T7TOPO, BGH. From 
pcDNA3.1-p2m.
B44-V5 HLA-B44 with V5 epitope tag. B44 F TOPO, B44 R. 
From pUC13-B*4402.
p2m-B44-V5 As p2m-B44 with a V5 epitope tag T7TOPO, B44R.
From pcDNA3.1-p2m-B44.
Lac Z p-galactosidase gene expressed Provided with TOPO vector 
(Invitrogen)
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PCR products were run on a 1% agarose gel and purified before use in the TOPO
cloning reaction as below:
lpl pLenti TOPO vector (Invitrogen)
4pl gel purified PCR product
lpl salt solution (1.2M NaCl, 0.06M MgCb)
The reaction was gently mixed and allowed to proceed for 5-10 mins at room 
temperature.
4.2.1.2 Transformation and DNA production
2pl of product from the TOPO cloning reaction was used to transform TOP 10 
competent E.coli (Invitrogen). Transformation products were plated onto LB agar plates 
with 50pg/ml blasticidin and 50pg/ml ampicillin and incubated for 12-18 hours at 37°C. 
2-5ml LB broth with 50pg/ml ampicillin was inoculated with a single colony from the 
plate and incubated in a 37°C shaker overnight. Bacterial broth was then used to 
miniprep the plasmid and DNA was digested with restriction enzymes to confirm the 
presence of the inserted gene. Once analysed a successfully cloned plasmid was 
amplified by Qiagen Maxiprep. The plasmid product was quantified by 
spectrophotometry and sent to the Wolfson Institute of Biomedical Research (WIBR) at 
University College London for sequencing.
4.2.1.3 Virus Production
The day before transfection, 293FT cells were trypsinised and counted, and 5 x 106 cells 
plated on a 10cm diameter plate in 10ml of normal medium (see Table 2.1). On the day 
of transfection, medium was removed and the cells washed with PBS. 5ml Opti-MEM® 
I medium was added to the cells. 3pg of pLenti expression vector, and 9pl of the 
optimised packaging mix (Invitrogen) containing pLPl, pLP2 and pLP/VSVG (see 
section 4.1.1) were diluted in 1.5ml of Opti-MEM® I medium. Lipofectamine 2000 was 
mixed gently and 36pl was diluted in 1.5ml of Opti-MEM® I medium. After 5 minutes 
the diluted DNA was mixed with the diluted Lipofectamine and the mixture was 
incubated for 20 minutes at room temperature.
The DNA and lipofectamine mixture was then added dropwise to the 293FT cells and 
the plate was rocked gently before returning to the incubator. After overnight incubation 
the medium was gently removed and the cells washed in PBS. 10ml of normal culture 
medium was added, and the cells were incubated for a further 48 hours. Following
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incubation supernatant containing produced virus was removed and centrifuged at 300g 
for five minutes to remove cell debris.
Virus containing medium was then dispensed into cryovials in 1 ml aliquots and stored 
at - 80°C. ‘Freeze -  thawing’ of virus was avoided as much as possible and was 
performed a maximum of three times as it can reduce the efficacy of viral infection.
4.2.1.4 Determining blasticidin sensitivity
Since transduced cells are to be selected using blasticidin it is necessary to determine 
the drug sensitivity of the cell line to be transduced.
Cells were plated at around 25% confluence on a 6-well plate. Medium at various 
concentrations of blasticidin from 0 -  lOpg/ml was added to the cells. Fresh blasticidin 
containing medium was added to the cells every 2-3 days or as necessary. Cells were 
grown for up to ten days, or until there were no surviving cells.
The lowest concentration of blasticidin at which no cells survived after 10 days of 
culture was subsequently used to select transduced cells.
4.2.1.5 Titering lentiviral Stock
Virus can be titred using any mammalian cell line. The human fibrosarcoma HT1080 
cells are most easily transduced and generally give a titre about 10-fold greater than 
NIH 3T3 cells, which were used here. (Invitrogen, 2005)
0.005 -  1 pi of virus stock was used to infect 25% confluent NIH 3T3 cells in a six well 
plate. After 10 days of drug selection medium was removed and cells were washed with 
PBS and then stained with 1ml 1% crystal violet, which stains live cells, in 10% ethanol 
for 10 mins. Crystal violet was removed and cells washed twice in PBS and stained 
colonies were counted.
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4.2.2 Stable transduction of mammalian cell lines
4.2.2.1 Cell transduction
Cells were plated in 6-well plates at about 25% confluence (~ 200,000 cells) 1 day prior 
to transduction. On day of transduction virus was thawed and 0.5ml fresh medium 
containing polybrene at a concentration of 12pg/ml (final concentration after 1 in 2 
dilution was 6pg/ml) was added to each well of the 6-well plate.
Viral stock was diluted into medium at various concentrations (Multiplicity of Infection, 
(MOI) from 0.001 - 2) and 500pl was added to each well of the 6-well plate. After 24 
hours, medium was removed and replaced with fresh medium. After a further 24 hours, 
medium was removed and fresh medium containing blasticidin was added. Drug 
selection was carried out for at least 10 days and colonies of transduced drug resistant 
cells formed.
4.2.2.2 Expansion of virally transduced clones
During blasticidin treatment distinct cell colonies formed from each transduced cell. 8 
colonies were selected with an inoculation loop and transferred to separate wells of a 24 
well plate containing normal medium (see Table 2.1) supplemented with blasticidin. 
Clones were subsequently screened for expression of protein by flow cytometry or 
western blot.
4.2.2.3 Expression of p-galacosidase
Expression of P-galactosidase in Lac Z transduced cells was assessed by the breakdown 
of X-gal substrate.
Stock ferrous solution - 5mM KFerricyanide, 5mM KFerrocyanide, 2mM MgCE was 
made up in PBS and stored at 4°C.
Cells were washed x2 in cold PBS, fixed for 5mins in 4% paraformaldehyde and 
washed again x2 in cold PBS. X-Gal (5-bromo-4-chloro-3indoly-p-D- 
galactopyranoside) was diluted 1 in 20 into the stock ferrous solution and added 
dropwise to cells to cover. Cells were incubated at 37°C for at up to 16 hours or until 
blue staining appeared.
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4.3 Results
4.3.1 Production of lentivirus to express class I constructs
4.3.1.1 Molecular cloning
Genes were successfully amplified from plasmid DNA as outlined in Table 4.2 by PCR. 
Amplification products were run on 1% Agarose gels and stained with EtBr. 
Amplification products were used for TOPO cloning, and miniprep DNA from the 
resulting colonies was analysed by restriction digestion to release the cloned insert. In 
each case the size o f the bands for the PCR product and the released insert of the chosen 
clones were verified.
The P2 m gene is 360bp and distance between the primer sites in the original pcDNA3.1 
vector is 18 lbp. The PCR amplification product should therefore be 541 bp long. PCR 
yield was poorer with the T7 TOPO primer, which incorporates the CACC leader 
sequence to allow directional cloning, than with the normal T7 primer and a weaker 
second band of larger molecular weight is seen. However, the smaller PCR product is of 
the correct size (Fig. 4.3) and the yield obtained with the T7 TOPO primer in 
conjunction with BGH primer was sufficient to successfully clone the gene into the 
TOPO vector (Fig. 4.4).
Figure 4.3. PCR amplification from pcDNA 3.1 -  p2m yields band of 541 bp.
j32m was amplified from pcDNA 3.1 - /32m plasmid with BGH reverse primer and 
either T7 or T7 TOPO primer, by 30 rounds of PCR using PfU DNA 
Polymerase. Denaturing, 30 secs at 94°C. Annealing, 60 secs at indicated 
temperature. Polymerisation, 60 secs at 72°C.
6.0 Kb
4.0 Kb
2.0 Kb
1.0 Kb
O.SKb
A nneal merit 4 0  4 2  4 7  50  4 0  4 2  47 50
temp.
T7 + BGH T7 TOPO + BGH
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Figure 4.4. pLenti 6-p2m contains inserted gene. Miniprep DNA from a 
colony formed after p2m TOPO cloning was cut with the indicated restriction 
enzymes to linearise the plasmid or to release the cloned gene.
500 bp
Enzym e None Spe /  Xho 1 Spe f
X h o i
The B44 gene was amplified using B44F TOPO and B44R primers (table 4.1) yielding 
a product consistent with the predicted size of 1086bp (Fig. 4.5). The PCR amplification 
product was used for TOPO cloning and resulting pL-B44 plasmids were digested to 
confirm incorporation of the gene (Fig. 4.6).
Figure 4.5. PCR amplification from pUC13 -  B*4402 yields a product of 
1086bp. HLA-B*4402 was amplified from pUC13 - B*4402 with B44F TOPO 
forward primer and B44R reverse primer by 30 rounds of PCR using Pfil DNA 
polymerase. Denaturing 30 secs at 94°C. Annealing 60 secs at indicated 
temperature. Polymerisation 60 secs at 72°C.
500 bp
1,5 Kb 
1Kb
42 45 47 50 Annealm ent
temperature
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Figure 4.6. pLenti 6-B44 contains inserted gene. Miniprep DNA from a 
colony formed after B44 TOPO cloning was cut with the indicated restriction 
enzymes to linearise the plasmid or to release the cloned gene.
1.5 Kb 
1 Kb
500 bp
N one BamHI Xho t Bam HI N one Bam HI Xho I Bam HI f j j z y i u e  
Xho I Xho I
pL B44 m ini 1 pL B44 m ini 2
The linked chain construct p2m-B44 (BB) was amplified for TOPO cloning using the 
T7TOPO forward primer and the B44R reverse primer. The gene for p2in-B44 is 
1419bp. Amplification yielded a product of the appropriate size and was used for TOPO 
cloning (Fig. 4.7). Resulting pLenti - p2m-B44, when cut with Spe I and Xho I also 
released a band of the expected size (Fig. 4.8).
Figure 4.7. p2m-B44 (BB) was amplified by PCR from pcDNA 3.0 - p2m- 
B44. (32m-B44 was amplified from pcDNA 3.0 - (32m-B44 with the indicated 
primers by 30 rounds of PCR using Pfil DNA Polymerase. Denaturing, 30 secs 
at 94°C. Annealing, 60 secs at indicated temperature. Polymerisation, 90 secs 
at 72°C.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Annealment 45 46.3 49.2 53.9 57.7 60.0 45 46.3 49.2 53.9 57.7 60.0 45 46.3 49.2 53.9 57.7
temperature
Primers T7 TOPO ♦ BGH T7 TOPO *  B44R J7 ♦ BGH
Lanes 2-7: PCR product from the T7 TOPO, BGH primer pair.
Lanes 9-14: PCR product from the T7 TOPO, B44R primer pair used to make 
‘pLenti (32m -B44-V5’.
Lanes 15-19: PCR product from the T7, BGH primer pair.
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PCR reaction performed with the T7 TOPO primer w'as again less efficient than with 
the T7 primer but the products obtained with T7 TOPO and B44R primers at an 
annealing temperature of 45°C were sufficient for the purposes of TOPO cloning (Fig.
Figure 4.8. pLenti 6-p2m-B44 and pLenti 6- p2m-B44-V5 plasmids contain 
the inserted genes. Miniprep DNA from colonies formed after f32m-B44 and 
fi2m-B44-V5 TOPO cloning was cut with the indicated restriction enzymes to 
linearise the plasmid or to release the cloned gene. ‘pLenti /S2m-B44’ (Lanes 9- 
11) and ‘pLenti [32m-B44-V5’ Lane (6-8). (Lanes 2-5 unsuccessful cloning 
product).
4.7).
1 2  3 4 5 6  7 8 9  10 11
1Kb
2Kb
Enzyme none S S+Xnone S S+X
Key:
S - Spe I 
X - Xho I
pLenti - B44 pLenti B44 
- V5. M iniprep 3 
M iniprep 4
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4.3.1.2 Blasticidin resistance
To establish the blasticidin sensitivity of cell lines for subsequent selection of 
transduced cells, a range of blasticidin concentrations was tested. K41 cells treated with 
10|ig/ml blasticidin were killed within 2 days. Blasticidin at 2gg/ml killed K41 cells 
effectively after 10 days, however when treated with 0.5gg/ml blasticidin some cells 
survived for more than 10 days (Fig. 4.9a).
NIH3T3 cells were a little more resistant to blasticidin, with a few live cells still visible 
after 10 days of treatment with blasticidin at 2|ig/ml. However, at 5|ig/ml cells were all 
killed within 10 days of treatment (Fig. 4.9b). HCT cells were also killed effectively at a 
blasticidin concentration of 5qg/ml (data not shown).
Figure 4.9. Blasticidin resistance determined for different cell lines.
K41 cells (a) and NIH3T3 cells (b) were tested for survival at a range of 
blasticidin concentrations. Results show a 200x magnification of cells grown in 
the indicated concentration of blasticidin for 7 days.
a) i) 0.5ijg/m l iii) No blasticidin
iii) No blasticidin
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4.3.1.3 Infectivity of virus and Lac Z expression in transduced cells
The infectivity of the produced virus was assessed by the transduction of NIH3T3 cells. 
These cells transduce relatively easily, although the titre is around 10-fold lower than 
that typically obtained in HT1080 cells (Invitrogen, 2005). After 10 days of selection 
with blasticidin at 5pg/ml, cells that have not been transduced will have been killed. 
The colonies formed correspond to live cells transduced with virus encoding the 
blasticidin resistance gene. These cells were stained with crystal violet. Estimated titres 
in HT1080 of around 105 — 106 virion/ml were obtained for each virus produced (Table 
4.3)
Table 4.3. Titre of lentivirus preparations. Lentivirus preparations were used 
to transduce NIH3T3 cells. Cells were selected for 10 days with for 5pg/ml 
blasticidin and surviving cell colonies stained with crystal blue.
Virus Crystal violet Volume Titre in NIH3T3 Estimated titre in
colonies of virus cells HT1080
Lac Z 24 1pl 2.4 x 104 virion/ml 2 x 105 virion/ml
10 0.5pl 2.0 x 104 virion/ml
2 0.1 pi 2.0 x 104 virion/ml
fom 45 10pl 4.5 x 103 virion/ml 9 x 104 virion/ml
36 2pl 1.8 x 104 virion/ml
10 1pl 1.0 x 104 virion/ml
B2m-B44 100 0.5pl 2.0 x 105 virion/ml 106 virion/ml
10 0.1pl 1.0 x 105 virion/ml
B44-V5 83 1 pi 8.3 x 104 virion/ml 8 x 105 virion/ml
38 0.5(jl 7.6 x 104 virion/ml
13 0.1pl 13 x 104 virion/ml
p2m-B44-V5 60 2fjl 3.0 x 104 virion/ml 3 x 105 virion/ml
31 1pl 3.1 x 104 virion/ml
17 0.5pl 3.4 x 104 virion/ml
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Expression of p-galactosidase was assessed in NIH3T3 cells transduced with Lac Z 
virus (Fig. 4 .10a). After blasticidin selection about half of the surviving colonies 
expressed p-gal. Most of these colonies were homogeneous, such that either all or none 
of the cells within the colony expressed P-gal. In some regions it appeared that colonies 
were mixed (Fig. 4.10b).
Figure 4.10. Lac Z expression in NIH3T3 cells.
NIH 3T3 cells were transduced with Lac Z virus and selected for 10 days with 
blasticidin. Resulting colonies were stained for P-gal expression and viewed by 
microscopy, a) Lac Z expressing colony (x100) b) Mixed expression colony 
(x200).
a) b)
103
4.3.2 Expression of p2m-B44-V5 in K41 and K42 cells.
Murine K41 fibroblast cells and calreticulin deficient K42 cells (Mesaeli et al., 1999) 
were transduced with p2in-B44-V5 (BB) virus and treated with blasticidin. Clones were 
assessed for production of P2m-B44-V5 protein by western blot using BBM.l antibody 
specific for human P2m (Fig. 4.11). Positive clones were obtained in both K41 cells and 
K42 cells transduced with virus; as expected no protein was detected in normal K 41 and 
K42 cells, since these are murine cells and BBM. 1 does not bind murine P2m.
Figure 4.11. p2m-B44 is expressed in transduced K41 and K42 cells.
K41 and K42 cells were transduced with lentivirus expressing /32m-B44-V5, 
cells were selected by addition of blasticidin and clones screened for 
expression of protein by western blot. Samples were loaded at 2 x 105 cells per 
lane. Membrane was probed with BBM. 1 and a-mouse - HRP. Film was 
exposed for 1 minute. * The human cell line HEK293 was used as a positive 
control expressing human f$2m.
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A western blot for calreticulin was also performed on these cells. K41 cells and all K41 
clones transduced with P2m-B44-V5 were confirmed as calreticulin positive, but K42 
cells and K42 p2m-B44-V5 clone 5 were confirmed as calreticulin deficient (Fig. 4.12).
Figure 4.12. Calreticulin is expressed in K41 but not K42 cells.
Samples of 4 x 105 cells were separated by SDS PAGE and analysed by 
Western Blot using a-calreticulin rabbit serum and a-rabbit - HRP. Film was 
exposed for 1 minute.
Construct: §§
Cell line: ^
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The creation of K 41 and K42 subclones expressing P2m-B44 by transduction with 
lentivirus, provides a tool for investigating the role of calreticulin and possibly also of 
human tapasin in p2 m recruitment to heavy chain and surface expression of class I. This 
will be explored further in chapter 6. Lentivirus expressing P2m-B44 has also been 
confirmed to be proficient in transduction and expression of P2m-B44 protein and 
having confirmed this, p2m-B44 virus and other viruses can be used in other cell lines 
such as tapasin or TAP deficient cell lines (see section 5.3.3).
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4.3.3 Functional characterisation of various class I linked chain 
proteins in HCT cells
HCT cells are derived from a human colon carcinoma cell line, which is p2in deficient 
and hence displays no surface MHC class I (Dexter et al., 1979). This HCT cell line was 
chosen for this study, because it is deficient in P2m, but endogenously expresses heavy 
chain alleles including HLA-A2 (Bicknell et al., 1994). The p2m deficiency is useful 
because it means that the introduced constructs can easily be detected using antibody 
against P2m and also, because the HCT cell displays no cell surface MHC class I there 
is no interference from native class I in the results. The presence of HLA-A2 is 
necessary for the study of the PB construct whose peptide is derived from flu matrix 
peptide and is a natural binding epitope of HLA-A2.
HCT cell lines expressing PB, BA and PBA were provided by Dr. Bin Gao and to 
complement these an HCT line expressing P2111 was produced using the lentivirus pL- 
p2m. HCT cells were transduced with lentivirus and stably selected for 10 days using 
blasticidin at 5pg/ml. 6 surviving colonies were successfully expanded for further 
analysis. (For details of constructs see Fig. 4.1).
4.3.3.1 Class I constructs were successfully expressed in HCT cells.
HCT, HCT PB, HCT BA and HCT PBA cells obtained from Dr. Bin Gao and HCT 
cells transduced with p2m and selected with blasticidin were analysed by western blot 
for expression of the introduced protein using BBM.l antibody (Fig. 4.13).
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Figure 4.13. The four class I constructs can be detected in HCT cell lines.
.174 cells or HCT cells stably expressing the construct indicated were lysed, 
separated by SDS-PAGE and analysed by western blot with BBM. 1 antibody. 
Except HCT BA, cells were loaded at 4 x 105 cells per lane. HCT BA cells were 
loaded with 1x105 cells. Membrane was probed with BBM. 1 and a-mouse HRP. 
Film (a) was exposed for 10 minutes, film (b) was exposed for 1 minute.
* Indicates native expression of protein.
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The western blots show successful expression of all four constructs in HCT cells. Lane 
2 of Fig. 4.13a shows HCT cells in which normal p2 m has been restored. It can be seen 
from the other lanes, that wild type (32m is absent in the other HCT cell lines, but is 
expressed strongly in the B cell line .174. The PB construct is 24 amino acids longer 
and can be seen as a band of slightly larger size than wild type p2 m. The BA construct 
consisting o f both p2 m and the heavy chain allele HLA-A2 is seen as a band of 
significantly higher molecular weight (~50kDa), and the PBA construct is a similar size 
(Fig. 4.13b). The PBA construct is 24 amino acids longer than BA but because of the 
larger molecular weight of these molecules compared to P2 m and PB, this difference is 
not significant enough to see a clear difference in the size o f the bands by separation 
using 12% SDS PAGE. The level of BA protein detected is significantly higher than the 
expression o f the smaller proteins PB and p2 m in HCT cells, despite loading 4 times 
fewer cells and exposing the film for less time. This was repeatedly the case in western 
blots and shows that the expression level of BA is very high. All the constructs are 
under the control of the CMV promoter, so there is no reason to expect that the 
transcription rate for the BA protein is higher than the other constructs. It is more likely 
that the greater level of expression reflects high stability of the BA construct in HCT
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cells. However, the copy number of the integrated plamids within each cell line is not 
known line and this cannot be ruled out as a possible influence on the protein 
expression level.
4.3.3.2 Cell surface MHC class I expression in HCT cells is restored by p2m, PB 
and BA.
Each of the HCT cell lines was analysed by flow cytometry and drug selected or 
subcloned where necessary to obtain a uniform population. Several different antibody 
stains were then used to determine whether the different class I constructs were able to 
restore expression of cell surface class I expression and to check the folding status of 
the constructs.
4.3.3.2.1 Selection o f HCT p 2 nt clone
FACS was used to screen clones for fbm expression in HCT cells transduced with the 
lentivirus expressing human P2in. After transduction of HCT cells with hp2in virus and 
expansion of individual blasticidin resistant colonies cells were stained with W6.32 
antibody (recognising folded human class I molecules) and analysed by flow cytometry. 
Three “clones” (clones 2,3 and 4) showed clear cell surface expression of class I in 
40%, 20% and 60% of cells respectively but appeared to have a mixed population of 
high and low expressers (Fig. 4 .14a i). The other clones seemed to have only a slight 
increase in surface class I expression (Fig. 4.14a ii). Since good expression of p2m in 
the HCT cell line should fully restore surface class I, the high expressers were thought 
to be those successfully transduced with p2m virus. To obtain a pure population of high 
expressers, a cell sort was performed by flow cytometry. Clone 4 was sorted on a gate 
to include only the top 20% cells expressing class I. Cells were plated in a 96 well plate 
at an average of 0.5 cells per well to carry out limited dilution cloning. New subclones 
were grown up from single cells and screened for their surface expression of class I. 
From the single cell sort of clone 4 the high expressing clone ‘4.2’ was chosen for use 
in future experiments as it expressed high levels of cell surface class I (Fig. 4.14b).
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Figure 4.14. A population within HCT 02m clones 2,3 and 4 expressed 
surface class I, and subclone 4.2 displays good expression of class I.
HCT cells (shaded), HEK 293 cells (light grey) and HCT (S2m clones were 
stained with W6.32 antibody and a-mouse PE and analysed by flow cytometry, 
a) i) HCTp2m clone 2 (dark grey -*2), clone 3 (thin black -*3) and clone 4 (thick 
black -*4) ii) HCT p2m clones 1,5 and 6 (*1, *5 and *6). b) Further subclones of 
clone 4. Clone 4.1 (thick black - *4.1), 4.2 (dark grey - *4.2), 4.3 (black - *4.3)
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4.3.3.2.2 PB cells were selected to obtain a pure population
The HCT PB cell line obtained from Dr. Bin Gao was thawed and allowed to recover. 
The PB construct had been introduced into the HCT cell line using a plasmid encoding 
a zeocin resistance gene. Cells were assessed for expression of the PB construct by 
staining with W6.32 and analysing by flow cytometry. However, expression of class I in 
the HCT PB cell line was found to be unstable when grown in zeocin free medium. 
About 20% of cells expressed p2m at the cell surface when thawed from stock the HCT 
PB cell line. However, this expression was rapidly lost within 10 days if grown in 
zeocin free medium. When grown in medium containing 50pg/ml zeocin, initially most 
of the cells died and growth of surviving cells was slow. However, after maintenance in 
zeocin for 6 weeks, cells were dividing at a rate typical for HCT cells (about 1 division 
every 24 hours) and cell death was low (less than 5%). When assessed by flow 
cytometry using W6.32 antibody a high level of expression was detected at the cell 
surface of all zeocin treated cells indicating that the cells expressing PB had been 
positively selected (Fig. 4.15).
Figure 4.15. A uniform population of HCT PB cells expressing surface 
class I was obtained by treating cells with zeocin.
HCT PB stock cells were thawed and grown in: zeocin free medium and 
assessed 24 hours later (thick black), zeocin free medium for 10 days (thin 
black) or grown for six weeks in medium containing zeocin at 50pg/ml (thick 
grey). HCT cells -  shaded. Cells were stained with W6.32 and a-mouse PE and 
analysed by flow cytometry.
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4.3.3.2.3 Stable expression at the surface o f HCT p 2 m, HCT PB and HCT BA is 
confirmed by staining with a panel o f class I  specific antibodies.
The expression of human MHC class I on the surface of the 5 HCT cell lines was 
assessed by flow cytometry using purified polyclonal a-hp2m (DAKO), the monoclonal 
a-hp2m antibody BBM.l, the monoclonal antibody W6.32, which recognises folded 
p2m-HC heterodimer (Fig. 4.16 a-c) and the monoclonal antibody BB7.2, which 
recognises HLA-A2 (data not shown). The antibodies all show a similar staining 
pattern, with p2m, PB and BA all restoring expression of MHC class I, but PBA 
showing little or no expression. The linked chain constructs PB and BA both express at 
high levels, and consistent with western blot results BA was consistently found at a 
level at least 10-fold higher than HCT cells expressing p2m.
The staining of HCT PBA cells is weak with all antibodies. A marginal shift in cell 
surface expression was typically observed with all antibodies but it is hard to be sure 
that such a small shift reflects genuine cell surface expression of the PBA construct. 
Intracellular staining with BBM. 1 and flow cytometry also fails to detect a significant 
shift in PBA expression (Fig. 4.16d) despite the fact that it is detectable by western blot 
using BBM.l (Fig. 4.13b). It is surprising that PBA cannot be recognised by 
intracellular staining given that BBM. 1 recognises a linear epitope within P2m and the 
other constructs can all be stained with BBM. 1. However, it may be that the true 
intracellular staining with BBM. 1 is weak and that the shift observed for intracellular 
staining of HCT BA and other cell lines is a reflection only of the surface class I and is 
not actually intracellular staining.
i n
Figure 4.16. A panel of antibodies confirms expression and folding of class I constructs on the surface of 
HCT cell lines, a-c) HCT cells and HCT cells expressing j82m, PB, BA or PBA were stained with polyclonal a-hj32m 
(DAKO) (a), conformation dependent o-class I mAh W6.32 (b), or a-hj32m mAb antibody BBM. 7 (c) and analysed by 
flow cytometry, d) Cells as in (a) were permeabalised and stained with BBM. 1 antibody and analysed by flow 
cytometry. HCT- HCT, HCT PBA - PBA, HCT J32m - p2m, HCT PB - PB, HCT BA - BA.
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4.3.3.3 Class I fusion proteins PB and BA are functional in terms of antigen 
presentation to T cells.
Expression of either PB or BA in HCT cells recovered the defect in cell surface 
expression of class I in HCT cells, showing that both PB and BA constructs are able to 
express at the cell surface. However, the function of class I molecules is to present 
antigens to T cells, and although recovery of class I expression is important, it does not 
prove that these constructs are able to present antigen. Using a CTL clone specific for 
flu matrix peptide GILGFTFVL in association with HLA-A2 (C T L flu) (kindly provided 
by Dr. Xiaoning Xu, Institute of Molecular Medicine, Oxford), it is possible to assess 
how effectively each of the MHC class I constructs presents antigen to T cells. The PB 
and PBA constructs include the flu matrix peptide in their sequence and recognition by 
C T L flu would show that these constructs are able to fold normally and that the peptide 
sits correctly in the HLA-A2 peptide binding groove. The other constructs can be 
assessed for their ability to present antigen by pulsing the cells with flu peptide prior to 
incubation with the C T L flu-
Upon activation, T cells produce cytokines such as IFNy and by using the ELISpot 
assay to measure IFNy production, it is possible to determine the number of cells 
stimulated by the antigen presenting cells (see section 2.5.2). To determine whether 
class I constructs were able to present antigen to T cells, HCT cells expressing fusion 
proteins were tested for their ability to stimulate IFNy production by in C T L flu- 
Antigen presenting cells (HCT cell lines) were pulsed with either flu matrix peptide or 
the irrelevant ovalbumin derived peptide SIINFEKL, at lOOpM for 1 hour at 37°C, 
washed 3 times to remove free peptide and then 50,000 cells were used to stimulate 0, 
1000, 3000 or 9000 C T L flu cells.
As expected, untransfected HCT cells were unable to stimulate additional IFNy 
production by C T L flu even when pulsed with flu peptide (Fig. 4.17). HCT PB cells 
stimulated strongly regardless of the peptide provided indicating that the peptide 
attached to the PB construct sits in the peptide groove and can present effectively to T 
cells. HCT p2m and BA cells were both able to stimulate C T L flu when pulsed with flu 
peptide GILGFVFTL but not when pulsed with irrelevant peptide. The IFNy response 
of C T L flu to HCT P2in pulsed with GILGFVFTL and HCT PB cells is similar 
indicating that cells expressing PB are able to present specific antigen as efficiently as 
cells expressing normal class I molecules. The antigen specific response of C T L flu to
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HCT BA cells is enhanced nearly 2-fold over HCT cells indicating that BA may be 
able to present antigen more efficiently than wild type class I. This may be influenced 
by the higher level of cell surface expression of class I in HCT BA cells.
Figure 4.17. PB can stimulate T cells as effectively as normal class I and 
BA can stimulate a stronger response.
HCT cells (HCT) and HCT cells expressing p2m (B2m), or the class I fusion 
proteins PB (PB), BA (BA) or PBA (PBA) were pulsed with either 100gM flu 
matrix peptide GILGFVFTL (GILG) or 100pM irrelevant peptide SIINFEKL (SIIN) 
for 1 hour at 37°C. 5 x 104 targets were then incubated with C T L flu overnight. 
IFNy producing cells were measured by ELISpot. Data shown is the mean and 
standard deviation of 4 wells in one of 3 similar experiments. (Limitations of the 
experiment mean that a maximum of 250 spots may be counted per well.)
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4.3.3.4 NK92 Cell killing is not significantly changed by the expression of class I 
constructs on HCT cells.
The NK like cell line, NK92 was used primarily to optimise the Cr51 cell killing assay, 
since unlike specific T cells, which can be difficult to maintain, NK92 cells are easy to 
grow. Additionally, it was interesting to test whether HCT cells were particularly 
susceptible to NK92 killing because of their deficiency in p2m and whether restoring 
class I expression either with normal 02m or with linked chain constructs affected the 
rate of killing. NK92 susceptible K562 cells were used as a positive control and the 
resistant CEM.NKR cells (NKR) as a negative control. Target cells were assessed for 
susceptibility to killing by analysing the induced chromium release after a 4 hour
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incubation with NK92 cells (Fig. 4.18). As expected K562 cells were killed effectively 
by NK92 cells, with chromium release of over 65% even at a NK92 to target cell ratio 
of 3:1. At this NK92 to target cell ratio, killing of NKR cells is only 12% and rises only 
to 30% at a ratio of 30:1. Killing of HCT cells by NK92 was significantly lower than 
killing of K562 cells but significantly higher than killing of NKR cells. Killing of HCT 
cells expressing BA or PB constructs (where cell surface class I expression is restored) 
was slightly reduced in two of three experiments performed, but the difference was not 
found to be significant. Killing of HCT p2m and HCT P2m-B44 cells was very similar to 
HCT cells. Overall the results indicate that although HCT cells are susceptible to NK92 
cell killing, surface class I expression in HCT target cells does not have a significant 
influence on their susceptibility to NK92 killing.
Figure 4.18. Expression of fem or class I fusion proteins in HCT cells has 
no effect on susceptibility to NK92 killing.
K562, NKR, HCT cells and HCT cells expressing p2m (B2m) or the class I 
fusion proteins PB, BA or BB were labelled for 1 hour with Cr51, washed 
thoroughly and incubated for 4 hours with NK92 cells at the ratio indicated. 
Target cell death was estimated from the % Chromium release, normalised to 
take into account spontaneous release. Triplicate data are pooled from 3 
independent experiments and are shown as mean and 95% confidence 
intervals.
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4.3.3.5 BA and PB constructs can be specifically recognised and killed by 
CTLflu*
Once the conditions of chromium loading and incubation had been established in 
killing assays with NK92 cells, C T L flu were assessed for their ability to kill HCT cells 
expressing the different class I constructs. As expected when the p2m-/- HCT cell line 
was pulsed with flu peptide it was not killed by C T L flu as measured by Chromium 
release (Fig. 4.19a). However, expression of either 02m or BA not only restored cell 
surface expression of class I but also allowed cells to present specific peptide to 
C T L flu- hi the chromium release assay when these cells were pulsed with flu peptide 
up to 80% of them were killed by C T L flu, whereas irrelevant peptide induced no 
increase in killing (Fig. 4.19a). This confirms that not only is the BA construct able to 
fold and reach the surface, but also that peptide is able to bind to the binding groove in 
the usual conformation for recognition by T cells.
The PB construct shows similarly positive results, here there is no need to pulse the 
cells with peptide because the construct contains both (32m and flu matrix peptide, in the 
experiment shown in figure 4.19b HCT PB cells were pulsed with an irrelevant peptide, 
but C T L flu could be stimulated equally efficiently without addition of any peptide 
(Fig. 5.4). In the chromium release assay C T L flu is able to kill HCT PB cells as 
efficiently as HCT p2m cells pulsed with flu peptide (Fig. 4.19b). These results show 
that the PB construct is functional, in other words that it can pair up correctly with 
HLA-A2 and fold into a mature class I molecule with the peptide lying correctly in the 
binding groove of the heavy chain.
In contrast cells expressing PBA are unable to elicit any response from C T L flu presumably 
reflecting the failure of this construct to reach the cell surface (Fig. 4.19b).
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Figure 4.19. HCT cells expressing class I fusion proteins can be 
specifically killed by C T L f lu -
Cells were labelled with Cr51 and simultaneously pulsed with peptide. Cells 
were then incubated with C T L flu for 4  hours at the indicated T- cell to Target 
ratios. Target cell death was estimated from the % Chromium release 
normalised to take into account spontaneous release. Data shown are pooled 
from at least 3 independent experiments and show mean and 95% confidence 
intervals, a) HCT cells expressing p2m (B2m) or BA (BA) pulsed with flu peptide 
GILGFVFTL (GILG) or the irrelevant peptide SIINFEKL (SIIN) as indicated, b) 
HCT cells (HCT) or HCT cells expressing p2m (B2m), PB (PB) or PBA (PBA) 
pulsed with with flu peptide GILGFVFTL (GILG) or the irrelevant peptide 
SIINFEKL (SIIN) as indicated.
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4.3.3.6 Endogenously processed antigen can be presented as efficiently by the 
linked chain class I molecule ‘BA’ as native class I.
To allow an effective immune response to occur in vivo, cells must be able to process 
antigen from whole protein and then load the antigenic peptide on to the developing 
class I molecule in the ER. In order to check that the BA construct can present such 
endogenously processed antigen, cells were infected with vaccinia virus expressing full 
length flu matrix protein (V-MP). In order to be recognised by C T L flu, cells must now 
be able process whole protein into peptide antigens and load them on to developing 
class I molecules in the ER.
When infected with V-MP, HCT p2in cells but not HCT cells were able stimulate 
specific T cells resulting in recognition and killing (Fig. 4.20). HCT BA cells were also 
able to stimulate killing showing that they were able to process antigen correctly and 
present peptide derived from endogenously expressed flu matrix protein to specific T 
cells (Fig. 4.20). The presentation of endogenous antigen to T cells induces a less 
powerful response than cells pulsed with peptide. However, there is still a significant 
difference in the rate of killing of either HCT p2m or HCT BA cells infected with 
vaccinia virus expressing flu matrix protein compared to those infected with vaccinia 
virus expressing the irrelevant protein ovalbumin. The ability of BA to present 
endogenously processed antigen shows that peptide loading of BA can occur efficiently 
in the ER as well as at the cell surface.
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Figure 4.20. The BA construct can present endogenously processed 
antigen and induce T cell killing.
HCT cells (HCT) and HCT cells expressing fom (B2m) or the class I fusion 
protein BA (BA) were infected with vaccinia virus expressing either Flu matrix 
protein (MP) or the irrelevant protein ovalbumin (OVA). After infection cells were 
labelled with Cr51 and incubated with C T L flu for 4  hours at the indicated T- cell 
to Target ratios. Target cell death was estimated from the % Chromium release 
normalised to take into account spontaneous release. Data shown are pooled 
from at least 3 independent experiments and show mean and 95% confidence 
intervals.
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4.4 Discussion
In the work shown in this chapter, a viral system for delivery of class I fusion proteins 
has been developed and validated, and stable cell lines expressing fusion proteins have 
been created in both human and mouse cell systems. Furthermore, the class I fusion 
proteins PB and BA have been shown to express at the cell surface in human cells and 
to present antigen to an influenza specific CTL clone.
A 5 cell HCT system -  HCT, HCT 02m, HCT PB, HCT BA and HCT PBA has now 
been created and optimised. The three fusion proteins upon synthesis, are at different 
stages of folding into a fully assembled class I molecule containing peptide, heavy chain 
and p2tn, and represent an interesting prospect for research into class I folding and 
assembly. In this chapter P2111, PB, BA and PBA have been successfully expressed in 
HCT cells. Of these, p2in, PB and BA are able to express at the cell surface but PBA is 
not.
The PB construct restores expression of class I molecules at the surface of P2m deficient 
HCT cells. In order to do this it must pair up in the normal way with HLA-A2 heavy 
chain (to which the peptide binds) and traffic to the cell surface. The W6.32 antibody 
recognises folded class I p2m-HC heterodimer and positive staining of HCT PB cells 
with W6.32 confirms that the PB construct is able to form a native structure when 
paired with endogenous heavy chain. Comparison of BBM.l and W6.32 staining 
indicates that the proportion of correctly to incorrectly folded p2m-HC heterodimer at 
the cell surface is similar in HCT PB cells to that in HCT p2m. The level of expression 
is found to be higher for HCT PB than HCT p2m and together these findings imply that 
expression and folding of PB with heavy chain is stable. In order to present its peptide 
correctly to T cells, PB must not only fold with HLA-A2, but also the peptide must sit 
correctly in the peptide binding groove. T cell stimulation and T cell killing assays both 
show that the PB construct is able to effectively present to the T cell clone C T L flu 
without provision of peptide, proving that the peptide of the PB construct does indeed 
sit in the peptide groove of HLA-A2.
There are several possible applications for PB both in dissecting the mechanisms of 
class I antigen processing and in T cell stimulation. To date there has been a large 
amount of interest in the mechanisms of peptide binding and optimisation and of the
120
chaperones involved (Howarth et al., 2004;Zarling et al., 2003;Paquet et al., 2004). The 
quality control mechanism of class I loading is thought to allow trafficking of properly 
loaded class I molecules, whilst retaining those that are empty or loaded with low 
affinity peptide. There is some evidence that this may be achieved by peptide triggered 
release of class I molecules from the peptide loading complex (Knittler et al., 1999;Suh 
et al., 1994). The PB construct provides a valuable tool for analysing this theory and 
this is explored further in chapter 5.
Since it has been shown to stimulate specific CTL, PB or similar constructs could be 
used to expand T cells in vitro. This could have a distinct advantage over normal 
peptide stimulation, since the stimulation could be more powerful and longer lasting, 
although in this work stimulation was comparable in strength to p2m expressing HCT 
cells pulsed with specific peptide. However, the stimulation of T cells with peptide 
pulsed feeder cells relies on the class I molecules of the feeder cells swapping the 
endogenously processed peptide for the exogenously administered peptide at the cell 
surface. Although this does seem to occur, the proportion of class I molecules 
expressing the desired peptide may be low and may be dependent on the peptide used. 
Furthermore, as class I molecules are turned over at the cell surface, the expression of 
molecules carrying the desired peptide will fall. In contrast, expression of PB in the 
antigen presenting cells should persist, resulting in steady cell surface expression of 
class I molecules carrying the desired peptide. In the case of HCT cells it is probable 
that all class I molecules will display the incorporated peptide since there is no 
competition by wild type P2111. However, HCT may not be the cell line of choice for 
such work since it displays relatively low levels of class I compared with B cells or 
other professional antigen presenting cells.
Since, it has been shown in this chapter that expression of PB is stable at the cell 
surface, it could therefore provide more prolonged stimulation of T cells than peptide 
pulsed cells. The obvious disadvantage of such a system is that the peptide incorporated 
in PB must be changed for each peptide of interest and of course the correct class I 
allele must be carried by the antigen presenting cell. Nevertheless, PB constructs could 
be useful for the expansion of known peptide specific CTL or to detect peptide specific 
CTL within a PBMC or other mixed cell population.
Taking this idea one step further PB like constructs could be used for vaccination. The 
mechanisms of DNA vaccination remain poorly understood, but presumably involve
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protein synthesis within cells. After DNA vaccination with PB, antigen presenting cells 
would be able to fold PB with the appropriate endogenously expressed heavy chain 
allele and present the peptide at the cell surface. Unlike presentation of traditional 
antigens this would not require any processing within the cell. This may increase the 
antigen presentation efficiency and boost T cell stimulation leading to a powerful 
immune response. Limited work has been carried out on such a vaccine strategy but this 
deserves further study (Uger et al., 1999).
FACS staining with W6.32 shows that the BA construct (P2m linked to HLA-A2) is also 
able to fold correctly and traffic to the cell surface. It is highly expressed at the cell 
surface in HCT cells as shown by staining with a panel of class I antibodies. This 10- 
fold increase in surface expression may reflect a slower cell surface turnover rate of BA 
compared with normal MHC class I molecules. Previous work has shown that loss of 
peptide from class I destabilises the interaction between p2m and heavy chain and 
results in internalisation of MHC class I (Ljunggren et al., 1990). Since heavy chain and 
P2m are covalently linked in the BA construct, it is possible that it retains peptide more 
effectively or that class I remains more stable at the cell surface even after loss of 
peptide. This would lead to a lower turnover rate, a higher level of cell surface 
expression (as shown by flow cytometry) and a higher level of total expression (as 
shown by western blot).
The BA construct is able to fold correctly and become loaded with peptide, which it can 
present to T cells as efficiently or more efficiently that native MHC class I in p2m 
expressing HCT cells. The slightly increased level of C T L flu stimulation and killing 
induced by BA may reflect the higher level of class I at the cell surface. Like normal 
class I molecules BA is able to present endogenously processed antigen as well as 
exogenously provided peptide. Although the rate of killing is fairly low (30%) in HCT 
BA cells when they are provided with whole flu matrix protein it is significantly higher 
than killing of cells expressing irrelevant ovalbumin protein. HCT BA cells appear to be 
slightly more susceptible to specififc T cell killing than HCT p2m cells although the 
difference is not statistically significant. However, it demonstrates that antigen can be 
loaded onto the BA fusion protein in the ER at least as efficiently as native class I. The 
low level of killing in these experiments may reflect either incomplete infection of cells 
by vaccinia virus expressing flu matrix protein, or the fact that HCT cells express 
relatively low levels of chaperones and MHC class I and are therefore relatively poor
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targets for T cell killing. B cell lines or PBMCs which are often used as targets in this 
type of work express much higher levels of these molecules and would therefore be 
more susceptible to T cell killing.
Linked chain constructs of P2111 and heavy chain may also provide useful tools in the 
future for detection of specific T cell receptors. Current tetramer technology requires 
production and in vitro refolding of P2m heavy chain and peptide. This is a laborious 
process and conditions must often be optimised for each peptide or heavy chain allele 
required. The covalent linkage of P2m and heavy chain could simplify refolding 
allowing tetramers to be synthesised more cheaply and easily. Single chain trimers such 
as PBA would potentially also be useful for this kind of work. Although the desired 
peptide would have to be cloned into the construct for each tetramer required the whole 
molecule could then be produced in bacterial or yeast systems. If the protein correctly 
folded in these systems, it would greatly reduce the cost and labour involved in the 
production of tetramer as no in vitro refolding would be required.
The fact that both the BA and the PB constructs are functional makes it surprising that 
the PBA construct (containing all three components of the folded class I molecule) is 
unable to traffic to the cell surface and present antigen. Intracellular staining with 
BBM. 1 antibody also fails to detect the PBA complex although it is shown to be present 
by western blot. One possible explanation for this is that it folds incorrectly in the ER 
causing chaperone molecules to bind it and hiding the epitope normally recognised by 
BBM. 1 antibody. Detection by western blotting is still possible because as the proteins 
are denatured, chaperone interactions are disrupted and the epitope becomes available.
It is not clear why PBA fails to traffic to the cell surface, but it is possible that there is 
some steric problem in folding the molecule in its current form. It may be that 
expressing the fragments in a different order or with different linkers would allow 
expression of a complete single chain MHC class I molecule (Yu et al., 2002).
By introducing p2m-B44 (BB) into the murine cell line K41 and its calreticulin deficient 
counterpart K42 using lentivirus, a model has been created to assess the function of 
calreticulin and other species specific components in the trafficking of class I 
molecules. It is widely accepted, that when class I heavy chain is newly synthesized, it 
associates with calnexin, which maintains it in a p2m receptive state (David et al.,
1993). When p2m is recruited to associate with class I heavy chain, this is accompanied
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by the replacement of calnexin with calreticulin (Sadasivan et al., 1996). Although the 
mechanism of the association of f^m and heavy chain and the simultaneous replacement 
of calnexin with calreticulin is not known, given the sequence of protein interactions it 
is possible that calreticulin may be responsible either for promoting the assembly of 
class I heavy chain with or for the recruitment of p2m. If calreticulin plays an 
important role in the formation of the p2m-HC heterodimer, then this might explain the 
reduced cell surface expression of class I in the K42 (crt -/-) cell line. By linking p2m 
and heavy chain together the requirement for recruitment would be lost and class I 
expression might be restored in K42 cells. Similarly the BA construct might be useful in 
the study of the recruitment of p2m to heavy chain. A comparison of BB (p2m linked to 
HLA-B44) and BA might also reveal allele specific differences in regards to p2m 
recruitment; these ideas are explored further in chapter 6.
HLA-B44 virus was also created in this chapter, primarily for use as a control for the 
linked chain molecule p2m-B44 (BB) as this was expected to be useful in an assessment 
of the importance of chaperone molecules in the recruitment of p2m to heavy chain. 
Because alleles of class I are known to vary in respect of peptide loading especially in 
their dependency on tapasin, the choice of class I allele is important. HLA-B*4402 is 
known to be particularly dependent on tapasin for its expression (Peh et al., 1998). This 
has been attributed to the presence of an aspartic acid at residue 116 located in the 
peptide groove; HLA-B*4405 in which this residue is replaced with tyrosine, is known 
to traffic more independently of tapasin (Williams et al., 2002). For the purpose of this 
study it is useful to study HLA-B*4402, since its high dependency on tapasin and the 
PLC may mean that any enhancement of expression by linking to heavy chain is 
more noticeable for HLA-B44 than for other alleles.
The work in this chapter provides the basis for further experimentation. By showing that 
the fusion proteins PB and BA express and fold correctly and that they are fully 
functional it is reasonable to use such constructs to investigate their interactions with 
molecular chaperones. The generation of both murine and human cells stably expressing 
fusion proteins will facilitate this study and the versatility of the lentivirus system 
allows transduction of other cells when necessary.
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5 Fusion proteins indicate a default pathway for class I 
maturation unaffected by peptide binding and fem 
recruitment.
5.1 Introduction
In human cells, the generally the accepted model of MHC class I trafficking is that 
heavy chain (HC) binds to calnexin during and shortly after synthesis in what is 
commonly known as the ‘early complex’ (Degen and Williams, 1991;David et al.,
1993). Following binding of p2m to heavy chain, calnexin is dropped in favour of 
calreticulin (Sadasivan et al., 1996). After the fbm-HC class I heterodimer has formed, 
it associates with the peptide-loading complex, which facilitates binding of high affinity 
peptide (Ortmann et al., 1994;Sadasivan et al., 1996;Zarling et al., 2003). Once high 
affinity peptide is bound to class I, it is released from the peptide-loading complex (Suh 
et al., 1994). Because release of class I is conditional on the binding of high affinity 
peptide this provides a mechanism for quality control of class I peptide loading.
In this chapter, partially preassembled class I molecules ‘peptide linked p2m’ (PB) and 
‘p2m linked heavy chain’ molecules p2m-A2 (BA) and p2m-B44 (BB) (see Fig. 1.4) are 
used to investigate this pathway. The theory that peptide binding triggers the release of 
class I from the peptide-loading complex is investigated, by studying the interaction of 
PB with tapasin and TAP. The trafficking rate of PB and BA constructs is examined by 
pulse chase to determine whether the fact that they are partially preassembled allows 
them to fold and leave the ER faster than normal class I molecules. The dependence of 
class I p2m-HC heterodimers on the peptide-loading complex is then investigated, by 
examining their interaction with tapasin and TAP and by expression in tapasin and TAP 
deficient cell lines. Finally, the release of class I from the ‘early complex’ is examined 
by investigating the interaction of calnexin with normal heavy chain and with the linked 
chain construct BA.
Numerous approaches have previously been used to investigate the processes involved 
class I folding, from the synthesis of MHC class I in the ER to the presentation of 
antigenic peptide at the cell surface. These approaches fall broadly into three categories, 
which may be used on their own or in concert. Firstly, the study of associations between 
proteins involved in class I loading and antigen processing, typically using the 
technique of immunoprecipitation. Secondly, the study of cells, which display an 
abnormal phenotype with respect to MHC class I antigen processing, because of a
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deficiency in one of the proteins involved. Thirdly, modification of heavy chain, or 
other components of class I loading, resulting in a change in its interactions with other 
proteins and an altered phenotype (e.g. HLA-A2 mutant T134K (Lewis et al., 1996)). 
Here a novel approach is presented: MHC class I fusion proteins that are partially 
assembled upon synthesis are examined in terms of their trafficking and peptide 
loading. By linking together the three different pieces of a mature MHC class I trimeric 
complex consisting of HLA-A2, p2m and the flu matrix protein derived peptide 
GILGFVFTL (Fig. 1.4), it is possible to investigate the interactions between MHC class 
I and different chaperone molecules along the process of maturation.
The human HCT cell line, which is deficient in P2in and therefore displays no cell 
surface MHC class I, is a good model cell line to use in this work. The p2in deficiency 
is convenient as it allows easy antibody detection and isolation of the introduced 
constructs without interference from native p2m. Additionally, in the absence of P2111, 
heavy chain does not associate with the peptide-loading complex, but is instead 
degraded before leaving the ER (Williams et al., 1989). Therefore, it can be deduced 
that any class I entering the peptide-loading complex is doing so as a consequence of 
the introduced class I construct. The genotype of the HCT cell line includes HLA-A2 
(Bicknell et al., 1994), which is required for the study of the PB construct whose 
peptide is derived from flu matrix protein and is a natural binding epitope of HLA-A2.
The technique of immunoprecipitation (IP) can be used to isolate proteins and under the 
correct conditions to study interactions between proteins. In this work 
immunoprecipitation is used to analyse interactions between different molecules 
involved in MHC class I antigen processing. However, most common detergents disrupt 
the interactions between class I and members of the peptide-loading complex, so care 
must be taken with the conditions of lysis to maintain protein associations. One of the 
most significant investigations of the interactions between class I and its associated 
chaperones was carried out by Sadasivan et al (Sadasivan et al., 1996), in which they 
showed that not only is p2in-HC heterodimer bound by calreticulin, but also identified 
“a novel uncharacterized 48 kDa glycoprotein, tapasin, which can bind independently to 
both TAP and class I-p2m-calreticulin complexes.”. In this and other studies 1% 
digitonin is used as lysis buffer and so a similar protocol has been followed in the work 
presented here.
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Cell lysates are then incubated with antibody or antiserum against the target protein; the 
choice of antibody is important since the interaction must be of high affinity and the 
epitope must be available to the antibody when the protein is itself complexed with 
other proteins. In this work polyclonal rabbit serum has generally been used, which can 
be more reliable since it is not dependent on any one particular epitope of the protein in 
interest. Antibody -  protein complexes are then purified using protein G or protein A 
beads, which bind to the antibody. Protein A and protein G are structural polypeptides 
of bacterial cell walls. Protein A was identified first and was isolated from 
Staphylococcus aureus and was shown to bind to antibody molecules (Forsgren and 
Sjoquist, 1966), hence it can be used to purify antibody from solution. Protein G was 
subsequently purified from group G Streptococci and protein A and protein G were 
shown to have distinct but overlapping binding properties for the Fc portion of 
antibodies(Langone et al., 1978;Kronvall et al., 1970).
Once the target protein has been ‘immunoprecipitated’ the complex is washed 
extensively and the proteins of interest are eluted, usually by low pH or SDS. Detection 
of eluted proteins may be done specifically by immunoblotting (using an antibody or 
antiserum of a different species from the IP antibody), or cells can be labelled with 
radioactive amino acids prior to lysis and detected using photographic film, following 
SDS PAGE or two-dimensional electrophoresis (O'Farrell et al., 1977).
In this work, immunoprecipitation is used to identify the interactions occurring between 
class I fusion proteins and other proteins of the class I processing pathway. These 
interactions can then be compared with those made in cells expressing wild type class I 
molecules.
In order to examine the rate of class I export from the ER, the technique of pulse chase 
has been used. In this technique, proteins are radioactively labelled during synthesis and 
then immunoprecipitated at various time intervals to follow their trafficking. Cells are 
starved of methionine (met) and cysteine (cys) for 60 minutes and then incubated for 15
t c
minutes with met and cys labelled with S for 15 minutes. During this time proteins 
synthesised incorporate the S label allowing them to be ‘chased’ for a period of time 
afterwards. The target protein, in this case heavy chain, is isolated from lysates at 
various time points after labelling using immunoprecipitation with specific antibody and 
protein G purification. By treating the isolated heavy chain with endoglycosidase H 
(endo H), it is possible to detect whether it has exited the ER and passed through the 
trans-Golgi network.
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This technique relies on the fact that proteins such as class I heavy chain, which are N- 
glycosylated in the ER, are susceptible to sugar cleavage by endo H enzyme. As a result 
when treated with endo H the molecular weight is decreased and the protein has higher 
mobility on SDS separation than untreated or endo H resistant proteins. However, in the 
Golgi network, the sensitive high mannose sugar residues are modified to complex 
forms and susceptibility to endo H is lost. By analysing the proportion of endo H 
sensitive to endo H resistant labelled protein at different time points, it is possible to 
estimate the average length of time that the protein spends in the ER before trafficking 
through the Golgi body.
In this chapter, class I fusion proteins will be used to examine the processes of class I 
loading. The process of class I loading may be thought of like an assembly line. After 
synthesis heavy chain heavy chain interacts with calnexin in the ‘early complex’, once it 
has assembled into the P2U1-HC heterodimer it progresses to the peptide-loading 
complex. After high affinity peptide is bound, the trimeric class I molecule is complete 
and can be released from the peptide-loading complex and can traffic to the cell surface. 
Since class I fusion proteins are partially assembled their full assembly may no longer 
require every stage of the ‘assembly line’. The BA construct for instance may no longer 
interact with calnexin since the heavy chain allele HLA-A2 is covalently linked to p2m 
in this construct. On the other hand since no peptide is present it would still be expected 
to travel via the peptide-loading complex. In contrast the PB construct in which peptide 
is covalently linked to p2in would be expected to have no requirement for the peptide- 
loading complex. Once PB associates with HLA-A2 it already contains all three 
components of the complete class I molecule and so it may be able to traffic directly to 
the cell surface.
These ideas are tested in this chapter using pulse chase, immunoprecipitation, and by 
expression of fusion constructs in cell lines deficient in different components of the 
class I loading pathway. The objectives of this work are: to determine whether folding 
of the P2m-HC heterodimer precludes binding of calnexin, to see if tapasin and TAP are 
important for the recruitment of fcm to heavy chain and for the expression of stable 
p2m-HC heterodimers, and to show whether peptide binding to class I triggers release 
from the peptide-loading complex.
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5.2 Methods
The methods used in this chapter are all detailed in chapter 2 and include: 
immunoprecipitation, western blotting (section 2.3), flow cytometry (section 2.2) and T 
cell killing assays (section 2.5.3).
5.3 Results
5.3.1 Peptide binding does not automatically release class I from 
the PLC.
The main function of the peptide-loading complex is thought to be binding and 
optimisation of peptide to the maturing MHC class I molecule (Howarth et al, 
2004;Zarling et al., 2003). Reports have been made that import of peptides into the ER 
by TAP (Knittler et al., 1999) or provision of high affinity peptide, cause the 
dissociation of class I from the peptide-loading complex (Suh et al., 1994). This would 
provide a quality control mechanism for peptide loading, in which it is envisaged that 
class I molecules are retained by the peptide-loading complex only until high affinity 
peptide is bound. In this model, the action of tapasin is somewhat similar to the role of 
HLA-DM in class II maturation.
To try and clarify whether provision of high affinity peptide causes dissociation of 
human class I from the peptide-loading complex, two different approaches were taken. 
Firstly, cells were permeabalised with 0.003% digitonin, provided with ATP and HLA- 
A2 binding peptide (as in Suh et al., 1994) and then immunoprecipitated with RB4 
(anti-TAP). Secondly, cell lysates were incubated with peptide prior to 
immunoprecipitation (as in Knittler et al., 1999). However, neither method of peptide 
provision had any detectable affect on the association of p2ni, PB or BA with TAP, 
indicating that high affinity peptide did not lead to rapid dissociation of class I from 
TAP (Fig. 5.1).
130
Figure 5.1. Provision of high affinity peptide does not significantly alter 
the association between class I and the peptide-loading complex.
a) 5x106 BM9 T cells or HCT cells expressing class I fusion proteins were 
permeabalised by incubation on ice with 50pi 0.003% digitonin for 7 minutes. 
Digitonin was diluted out with 450u! of cold PBS and permeabalised cells were 
incubated with ATP and HLA-A2 binding peptide GILGFVFTL for 20 minutes at 
37°C. Cells were washed three times in cold PBS, lysed in 1% digitonin and 
immunoprecipitated with anti-TAP (RB4) or control (RS) rabbit serum. Eluted 
proteins were analysed by western blot with BBM. 1 antibody, b) Cells were 
lysed in 1 % digitonin and incubated with peptide for 1 hour at 4 °C. 
Immunoprecipitation and western blot were performed as in (a). * Indicates 
native expression of protein
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Although HLA-A2 binding peptide failed to trigger the release of class I from the 
peptide-loading complex in both these peptide release assays, care should be taken in 
drawing conclusions from these ‘negative' results. The peptide release assay in figure 
5.1a suffers from the fact that it is difficult to prove that the cells have been successfully 
permeabalised by treatment with 0.003% digitonin. One possible way to test this would 
be to incubate the permeabalised cells with fluorescently labelled peptide and then to 
analyse loading by flow cytometry. The experiment in figure 5.1b does not involve 
permeabalisation and the peptide must therefore have access to class I molecules in
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the peptide-loading complex. However, since peptide provision occurs in the cell lysate 
the conditions are somewhat artificial. Because of the technical difficulties of the 
peptide release assays shown in figure 5.1 the PB fusion protein is a useful tool in 
dissecting the problem. Since the PB (peptide linked fbm) construct already contains 
peptide, immunoprecipitation was used to check whether PB still traffics via the 
peptide-loading complex. In this assay the peptide must have access to the groove of the 
heavy chain of class I since it is covalently linked to p2 m. Interestingly it was found that 
the PB construct immunoprecipitated with both anti tapasin rabbit serum (Giles) and 
anti TAP 1 rabbit serum (RB4), showing that the PB construct is in association with 
tapasin and TAP and hence, presumably the peptide-loading complex (Fig. 5.2). This 
implies that either the peptide-loading complex plays an active role in binding the 
peptide of the PB construct to the groove of the class I molecule, or that the interaction 
between the developing class I and the peptide-loading complex is can be maintained 
even when peptide is bound.
|32m can also immunoprecipitated by both anti tapasin and anti TAP antibodies (Fig.
5.2), supporting the model that developing native class I molecules traffic via the 
peptide-loading complex. Expression of p2 in in HCT cells was consistently low and 
immunoprecipitation using this cell line proved difficult. However, P2m could be 
consistently immunoprecipitated from B cell lines such as BM9.
Figure 5.2. PB c o n s tru c t  is found in a s so c ia t io n  with the  PLC. Digitonin 
lysates from 107 BM9 cells or HCT cells expressing the class I fusion protein PB 
were immunoprecipitated with anti-TAP (RB4), anti-tapasin (Tap A) or control 
(RS) rabbit serum as indicated. Proteins were eluted with 2xSDS loading buffer 
separated by SDS-PAGE and immunoblotted with BBM. 1 (mAb specific for 
human P2IT1).
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It was shown in figure 5.2 that the peptide of the PB construct did not stop it from 
incorporating into the peptide-loading complex. However, it remains possible that the 
PB construct is found in the peptide-loading complex either because it interacts with 
other alleles of class I to which the flu peptide cannot bind, or because even once 
associated with PB, HLA-A2 traffics to the peptide-loading complex to load with 
another peptide. In order to try and exclude these possibilities two further experiments 
were performed. To test the interaction of the PB construct with other class I alleles, PB 
was introduced into the Daudi cell line, whose genotype like HCT is deficient in P2in 
but in contrast to HCT does not contain HLA-A2 (Browning et al., 1995). Daudi cells 
were transduced with lentivirus expressing PB and protein expression was confirmed by 
western blot (Fig. 5.3a). Cell surface expression of class I was then assessed in 
transduced Daudi cells. However, there was no recovery of human class I expression in 
Daudi cells after introduction of PB (Fig. 5.3b), implying that it does not fold properly 
with the alleles of class I present in these cells.
Use of the HCT cell line transduced with PB provides a positive control for the virus, 
however, it does not prove the competency of the Daudi cell for class I expression. 
Although this has been demonstrated previously in the literature, it would have been 
beneficial to demonstrate recovery of class I expression in the Daudi cell by provision 
of p2m alone.
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Figure 5.3. PB c a n n o t  pair up with c la s s  I alleles o ther  than  HLA-A2. Daudi 
(fi2m -/-, HLA-A2 -/-) cells were transduced with lentivirus expressing PB. a) 
HCT p2m cells, Daudi cells and Daudi cells transduced with PB virus, were 
analysed by western blot with BBM. 1 antibody, b) HCT cells, HCT PB cells, 
Daudi cells and Daudi cells transduced with PB virus were analysed for cell 
surface expression of class I by flow cytometry, using W6.32 antibody.
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To test whether HLA-A2 can become loaded with an alternative peptide when 
associated with PB, HCT PB cells were pulsed with different peptides, and incubated 
with specific T cells. Whether HCT PB cells were provided with no peptide, flu peptide 
GILGFVFTL (GILG) or the MART-1 derived HLA-A2 restricted peptide AAGIGILTV 
(AAGI) (Coulie et al., 1994), they were killed effectively by flu specific T cells (Fig. 
5.4a). Conversely, even when specific peptide AAGIGILTV was provided, HCT PB 
cells could not be killed by MART-1 specific T cells (Fig. 5.4b). As expected HCT 
cells were killed by specific T cells only when pulsed with the relevant peptide (Fig. 5.4 
a and b). The fact that HCT PB cells cannot present AAGIGILTV, to specific T cells 
indicates that the flu peptide of PB is blocking the binding of other peptides and implies 
that other peptides cannot be loaded onto HLA-A2 molecules when it is in association 
with PB.
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Figure 5.4. HLA-A2 cannot bind free peptide when associated with PB.
Target cells (HCT cells or HCT cells expressing fom or PB) were labelled with 
Cr51 and pulsed with flu peptide (GILG) or MART-1 peptide (AAGI) for 1 hour. 
After washing thoroughly target cells were mixed with flu specific T cells (a) or 
MART-1 specific T cells (b). Experiments were performed in triplicate and 
repeated 3 times. Data shown is mean and standard deviation of a 
representative experiment.
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5.3.2 The trafficking rate of the partially assembled class I 
constructs PB and BA is unaltered
Since the fusion proteins PB and BA are already effectively partially assembled class I 
molecules, their trafficking rate may be faster than normal class I molecules. To test 
this, pulse chase was performed by Dr. B Gao (Institute of Molecular Medicine, Oxford 
University) to measure the rate of ER export of these constructs. The results are 
included here as it is highly relevant to this work (Fig. 5.5). It was shown that the 
trafficking rate of neither the PB nor the BA construct to the Golgi body was 
accelerated. For heavy chain molecules in both HCT and HCT PB and for the 
linked chain molecule in HCT BA cells, 50% of molecules were Endo H resistant 60 
mins after labelling and almost all detectable molecules were endo H resistant after 160 
mins. In contrast the PBA construct did not become endo H resistant and by 160 
minutes after labelling it had largely disappeared.
Figure 5.5. The export rate of class I molecules is similar in HCT cells 
expressing fS2m, PB and BA constructs. HCT cells expressing p2m, PB, BA 
or PBA were labelled with S35 met and cys for 10 minutes. Cells were ‘chased’ 
for up to 160 minutes lysed with Triton X-100 and immunoprecipitated with 
BBM. 1 (mAb anti- p2m). Proteins were treated with endo H enzyme, separated 
by SDS-PAGE and transferred onto nitrocellulose membrane. Photographic film 
was exposed to the membrane for 4 days, allowing detection of radioactive 
proteins. The proteins shown are wild type heavy chain (a) and (b), or linked 
chain molecules BA (c) or PBA (d). (Upper band - endo H resistant, lower band 
endo H sensitive.)
Chase time (mins) 
a) HCT |32m
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137
5.3.3 Tapasin and TAP do not play a crucial role in the formation of 
the class I p2m-HC heterodimer.
The fusion proteins p2m-A2 (BA) and p2m-B44 (BB) provide a tool for investigating 
the importance o f p2m recruitment in class I folding. It is thought that tapasin and TAP 
do not interact with class I molecules until heavy chain has folded with p2m. If this is 
correct, then it is unlikely that either tapasin or TAP plays a role in the recruitment of 
p2m to heavy chain.
Since p2m-A2 (BA) and p2m-B44 (BB) have a covalent link between p2m and heavy 
chain, they may be more stable than wild type p2m-HC heterodimers. Wild type p2m- 
HC heterodimers are known to become more stable when assembled with peptide and 
this may act as a trigger for the release o f class I from the peptide-loading complex. If 
peptide free p2m-HC linked chain constructs are more stable than their wild type 
counterparts, then this might influence their binding of tapasin or other molecules 
involved in class I folding.
To assess the interactions made by the BA construct, lysates of HCT BA cells were 
immunoprecipitated with rabbit serum against either tapasin or TAP. After recovery 
with protein G, samples were washed thoroughly and eluted in 2xSDS loading buffer 
and analysed by SDS PAGE and immunoblotting with mouse mAb BBM .l. Both TAP 
and tapasin strongly immunoprecipitated BA, indicating that it interacts not only with 
calnexin immediately after synthesis, but also follows the normal route of class I 
trafficking via the peptide-loading complex (Fig. 5.6).
Figure 5.6. BA construct interacts with both tapasin and TAP during 
maturation. Digitonin lysates of HCT cells expressing the class I fusion protein 
BA, were immunoprecipitated with anti-TAP (RB4), anti-tapasin (Tap A) or 
control (RS) rabbit serum. Proteins were eluted in 2xSDS loading buffer and 
separated by SDS PAGE. BA was detected by immunoblot with BBM. 1 (mAb 
specific for human (32m).
<
IP Antibody S §-
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To assess the importance of the observed interaction between the peptide-loading 
complex and linked chain p2m-heavy chain construct BA, lentivirus expressing the 
similar p2m-B44 (BB) (see section 4.2) fusion construct was used to transduce tapasin 
deficient (.220) (Grandea, III et al., 1995) and TAP deficient (.174) (Cerundolo et al., 
1990) human cell lines. As a control, lentivirus expressing HLA-B44 was also used to 
transduce these cells. HLA-B44 is a useful allele to use to assess the possible rescue of 
class I expression in these cells, since it is known to be particularly dependent on 
tapasin and the peptide-loading complex (Peh et al., 1998). In contrast HLA-A2 can be 
expressed well even in the absence of tapasin.
Expression of human class I is reduced in .174 and .220 cells in comparison to normal B 
or T cells and this can clearly be seen in a comparison of W6.32 staining of these cell 
lines (Fig. 5.7a). After transduction of .174 and .220 cells with lentivirus expressing 
BB, protein expression was confirmed by western blot using BBM. 1 antibody (Fig. 
5.7b). Detection of HLA-B44 by western blot is not possible since the cells already 
express other heavy chain alleles, which would interfere with the detection of the 
introduced protein. However virus preparations were tested for colony forming units in 
murine NIH.3T3 cells by selection with blasticidin and the titre of the 2 types of virus 
was shown to be similar (Table 4.3). Expression of p2m-B44 did not enhance expression 
of surface class I on either .174 or .220 cells to a greater extent than HLA-B44 (Fig. 5.7 
c and d). This indicates that not only do p2m-HC molecules interact with and tapasin 
and the PLC, but also that this interaction is necessary for proper peptide loading and 
stable cell surface expression.
It can also be confirmed that neither tapasin of TAP is essential for the assembly of the 
p2m-HC heterodimer, since linkage of p2m to heavy chain fails to improve class I 
expression in either tapasin or TAP deficient cell lines.
A significant shift is seen when either HLA-B44 alone or the linked chain construct is 
expressed in .174 cells. This may reflect the fact that large parts of the MHC are 
missing in this cell line and consequently endogenously expressed levels of class I 
heavy chain are relatively low (Salter et al., 1985). Introduction of any heavy chain 
therefore increases the surface expression of class I. Alternatively, it is possible that the 
lentivirus itself has somehow caused a shift in the surface level of class I, although there 
is no reason to expect that the virus would cause a shift in class I expression.
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Figure 5.7. Linkage with p2m does not enhance expression of HLA-B44 in 
the absence of tapasin or TAP.
a) Expression of class I on .174, .220 and BM9 cells was assessed by flow 
cytometry with W6.32 antibody, b) .174 and .220 cells were transduced with 
lentivirus expressing p2m-B44 (BB). Expression of BB was analysed by 
immunoblot with BBM. 1 antibody, c and d) .174 cells (c) and .220 cells (d) 
transduced with lentivirus expressing either HLA-B44 or BB, were analysed by 
flow cytometry as in (a).
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5.3.4 Calnexin can associate with heavy chain alone or p2m linked 
heavy chain (BA).
In human cells it has been shown that heavy chain binds to calnexin early after 
synthesis (Degen and Williams, 1991). However, when heavy chain is bound to p2 m, 
calnexin is thought to be replaced by calreticulin (Sadasivan et al., 1996). If the trigger 
for the release o f heavy chain from calnexin was binding of (hm, then the BA construct 
(in which p2in is already linked to heavy chain allele HLA-A2) would not be expected 
to bind to calnexin, or at least only briefly during synthesis. To test this digitonin 
lysates from HCT cells and from HCT BA cells were immunoprecipitated with rabbit 
antiserum specific for calnexin. After immunoprecipitation, samples were washed 
thoroughly, eluted with 2xSDS loading buffer at 95°C for 5 mins and separated by SDS 
PAGE. By immunoblotting with BBM.l (mAb specific for human p2m) and HC10 
(mAb specific for MHC class I heavy chain) not only native heavy chain, but also high 
levels of the BA construct were shown to associate with calnexin (Fig. 5.8). This 
suggests that (Em binding does not result in immediate release o f heavy chain from 
calnexin, but rather that the interaction can continue after P2 U1 binding. Although it is 
also possible that the BA construct does not fold into a native conformation 
immediately, resulting in a more prolonged interaction with calnexin.
Figure 5.8. Calnexin binds to linked chain BA as well as free heavy chain.
3x106 HCT cells expressing class I fusion proteins were immunoprecipitated 
(IP) with rabbit antiserum against calnexin (CX) or control rabbit serum (RS). 
Proteins were eluted with 2x SDS loading buffer, separated by SDS PAGE and 
then analysed by western blot (WB). Loaded samples represent protein 
immunoprecipitated from 106 cells/lane. The first lane of each blot shows a 
positive control cell lysate and is loaded at 105 cells/lane.
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5.3.5 Immunoprecipitation using BBM.1 is not sensitive enough to 
verify the interactions made by fusion proteins in HCT cells.
In order to try and verify the interactions made by fusion proteins, immunoprecipitation 
of cells lysates was performed using BBM. 1 (mouse mAb specific for human p2m). 
Immunoprecipitates were analysed by immunoblotting with rabbit antisera specific for 
calreticulin, tapasin and ERp57. Unfortunately, it was not possible to detect any of these 
proteins by immunoblotting following BBM. 1 immunoprecipitation of HCT cell lysates 
(Fig. 5.9a). However, it was possible to detect both calreticulin and tapasin in BBM.l 
immunoprecipitates of BM9 B cells. This difference may reflect the fact that HCT cells 
are not immune cells and hence may express lower levels of class I heavy chain and 
class I machinery than BM9 cells. This hypothesis is supported by the fact that, 
calreticulin can also be detected in RB4 (anti-TAP) immunoprecipitates of BM9 cells 
but not those of HCT cells (Fig 5.9b). Since it was not possible to detect chaperone 
proteins in the BBM. 1 immunoprecipitates any of the HCT cell lines it was not possible 
to double check the interactions so far indentified in this chapter using aCX, aTAP and 
atapasin immunoprecipitation.
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Figure 5.9. Calreticulin and tapasin can be detected in BBM.1 
immunoprecipitates of BM9 cells but not HCT cell lines.
a) Digitonin lysates of BM9 (B cells) or HCT cells expressing class I fusion 
proteins, were immunoprecipitated with BBM. 1 (mAb specific for human fS2m) 
and purified by protein G beads. Proteins were eluted with 2xSDS loading 
buffer and separated by SDS PAGE. Calreticulin (Crt) and tapasin (Tpn) were 
detected by immunoblotting with the appropriate rabbit serum, b) 
Immunoprecipitation was performed with rabbit serum against TAP (RB4) or 
control rabbit serum (RS) as in (a) and calreticulin was detected by 
immunoblotting with Stressgene mouse anti-calreticulin mAb. *lndicates native 
expression of protein.
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5.4 Discussion
Antigen presentation to T cells involves a complex process of class I folding and 
peptide loading in the endoplasmic reticulum. MHC class I fusion proteins provide a 
unique way to investigate this process. Most existing work investigating MHC class I 
antigen processing, has inferred function to various chaperones through phenotypic 
variation in the ability of cells to process normal MHC class I molecules. In this way it 
has been possible to show that heavy chain, fLm and TAP are vital to class I 
presentation, that other chaperones such as tapasin, ERp57 and calreticulin play 
important functional roles in the presentation of many peptide antigens, and that other 
proteins such as calnexin and BiP associate with MHC class I during the folding 
process. However, apart from TAP, which has a clear role in peptide provision to the 
ER it remains difficult to assign a particular function, such as recruitment of P2in, 
peptide selection or release of correctly loaded MHC class I, to other chaperones within 
the complex.
In this chapter the PB construct was studied by immunoprecipitation to examine its 
interactions with chaperone molecules. Like normal p2m, PB was not found to interact 
with calnexin, but did appear to traffic via the peptide-loading complex, showing 
association with both TAP and tapasin. Given that the PB construct already contains 
high affinity peptide, it is interesting that it is still traffics via the peptide-loading 
complex. The mechanism for class I release from the peptide-loading complex is not 
known. However, peptide editing or facilitating of peptide loading have been suggested 
as functions of tapasin; a proposed mechanism for this is the retention of empty class I 
molecules in the peptide-loading complex, followed by release upon binding of high 
affinity peptide. This would suggest that efficiently loaded class I molecules are 
generally not in contact with the peptide-loading complex. The fact that PB traffics via 
the peptide-loading complex does not support this model, but suggests that the 
interaction of class I and the peptide-loading complex occurs by default during 
processing and that the mechanism of release may be more subtle. Other evidence also 
suggests that a peptide-triggered release model may be too simplistic. Zarling et al. find 
that tapasin enhances the presentation of peptides whose binding affinity for class I is 
lower than those which bind in tapasin negative cells (Zarling et al., 2003). If binding of 
high affinity peptide causes release from the peptide-loading complex it seems unlikely 
that tapasin could enhance the loading of low affinity peptide in this way. Furthermore, 
Li et al. were able to isolate peptide loaded HLA-A2 class I molecules, which are
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clearly still stably associated with both tapasin and TAP (Li et al., 2000). It seems likely 
then, that although there may be a mechanism for retaining empty class I molecules, 
this mechanism does not exclude the interaction of loaded class I molecules with the 
peptide-loading complex. The duration of this interaction may then be governed by the 
‘off rate’ of class I from the complex and this may be affected by the nature of the 
peptide bound to class I. Peptides of much lower affinity would then have an 
opportunity to dissociate from class I before release from the PLC, allowing another 
round of peptide binding and resulting in the optimisation of peptide binding to class I 
molecules.
Others have proposed that the peptide-loading complex may act by holding class I 
molecules in a peptide receptive state and it is possible that the peptide-loading 
complex still acts on HLA-A2 in association with PB facilitating the binding of the 
peptide of the PB construct to the groove of HLA-A2. However, the failure of the 
MART-1 peptide to bind to HLA-A2 when it is associated with PB, shows that the 
binding of the peptide of the PB construct is highly dominant and suggests that it may 
bind to the groove of HLA-A2 before it reaches the peptide-loading complex where 
other peptides might be loaded.
Interestingly PB is unable to rescue class I expression in Daudi cells, which implies that 
the presence of the peptide prevents p2ni from interacting correctly with heavy chain 
alleles other than HLA-A2. Since the flu peptide is unlikely to bind the groove of other 
class I alleles it is possible that the free peptide is recognised as an ‘unfolded protein’ 
and the protein is degraded in the ER. If PB is unable to pair up with heavy chain alleles 
other than HLA-A2, and other peptides are unable to bind to HLA-A2 when it is in 
association with HLA-A2, this suggests that the peptide of PB is always resident in the 
peptide groove of HLA-A2 at the cell surface and that the relationship between HLA- 
A2 and PB is exclusive. Combined with evidence which shows that PB associates with 
both TAP and tapasin, this suggests that class I peptide loading does not automatically 
trigger release from the peptide-loading complex. This is furether supported by peptide 
release assays in which high affinity peptide fails to release class I molecules from the 
peptide-loading complex.
Immunoprecipitation with calnexin antibody provides a way of examining the ‘early 
complex’, which forms after protein synthesis. Interestingly the BA construct still 
associates with the chaperone calnexin, which is generally thought only to interact with 
free human heavy chain and not with p2m-HC heterodimer. While some calnexin may
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be bound to BA before it has folded into its native heterodimer conformation, the level 
of BA protein found in association with calnexin is surprisingly high. It is possible that 
BA does not fold efficiently into a heterodimer, and is therefore bound to calnexin for 
longer than expected, or that calnexin is involved in catalysing the formation of the 
heterodimer, and so is bound to BA just as it is bound to free heavy chain. In any case it 
is interesting that calnexin, which would not be expected to play any role in folding of 
the BA construct is found bound to it at high levels. A prolonged interaction of calnexin 
with class I is not unprecedented since in mouse cells calnexin is known to be 
associated with heavy chain in all stages of class I maturation in the ER (Suh et al., 
1996). However, it is generally considered that mouse heavy chain alleles are able to 
maintain interactions with calnexin through extra N-glucosylation sites (Zhang and 
Salter, 1998). These sites are not present on human alleles or therefore the BA 
construct, so calnexin would not be expected to be able to interact with class I once it is 
bound to calreticulin and the peptide-loading complex. The role of calnexin in antigen 
processing remains obscure, since calnexin knockout cells exhibit an unaltered 
phenotype with respect to MHC class I (Scott and Dawson, 1995). In any case, the fact 
that BA traffics at the same rate as normal class I molecules suggests that its interaction 
with calnexin is not hindering processing.
The normal trafficking rate, coupled with the association of BA with calnexin and also 
tapasin and TAP, implies that the pathway for processing BA is similar to the 
processing of normal class I molecules. To test the reliance of linked chain p2m-HC 
molecules on interactions with tapasin and TAP the BB construct was used since HLA- 
B*4402 is known to be particularly dependent on tapasin. However, it was shown that 
BB does not express at the cell surface any more strongly than HLA-B44 in these 
deficient cell lines implying that its expression is equally dependent on tapasin and 
TAP. Empty heterodimer molecules at the cell surface are common in tapasin deficient 
cells (Grandea, III et al., 2000) and the fact that p2m-B44 is not expressed more highly 
at the cell surface of .220 cells than HLA-B44 implies that empty linked chain molecule 
is no more stable at the cell surface than wild type class I. Therefore, the mechanism for 
turnover of empty class I at the cell surface may not only be reliant on the dissociation 
of p2m from heavy chain, but may also be sensitive to the peptide state of the class I 
heterodimer.
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In this chapter it has been shown that calnexin binds to a preformed fem-HC class I 
heterodimer (BA) as well as to free heavy chain. This may be because the BA construct 
is slow to fold into its native conformation, but could also indicate that wild type heavy 
chain during synthesis and early folding and then dissociate spontaneously from 
calnexin. Once released from calnexin heavy chain may rapidly bind to calreticulin and 
p2m, explaining the observed patterns of binding previously observed (Farmery et al., 
2000;Sadasivan et al., 1996). Under this model the linked chain would be found to 
interact with calnexin after synthesis in the same way as free heavy chain, consistent 
with the findings in this chapter.
Work presented in this chapter has also shown that preformed f^m-HC class I 
molecules interact with and are dependent on the peptide-loading complex. This implies 
that tapasin and TAP are not key to the recruitment of p2m to heavy chain. If either 
component was crucial to the formation of the p2in-HC heterodimer, then the linked 
chain molecule P2in-B44 might be expected to express more effectively than separately 
expressed HLA-B44 and native p2m in .174 (TAP deficient) or .220 (tapasin deficient) 
cells. Such a phenomenon was not observed. However, some caution should be taken 
when interpreting this negative result, since it is possible that TAP and tapasin facilitate 
class I antigen processing by more than one mechanism. Although linking p2m to heavy 
chain removes one step in the folding class I, it would not compensate for other possible 
functions of tapasin or TAP. Since TAP is known to be crucial in peptide supply and 
tapasin is thought to play an important role in peptide loading, it is perhaps not 
surprising that linkage of to heavy chain does not rescue class I expression in these 
deficient cell lines.
Most interestingly it has been shown that peptide binding to class I does not necessarily 
trigger its release from the peptide-loading complex. This contradicts models of peptide 
loading which rely on peptide mediated release of class I from the peptide-loading 
complex. Instead the results support a role for the peptide-loading complex in the 
facilitating of class I loading, by providing a suitable environment for loading to take 
place.
In conclusion, it is found that partially preformed class I molecules interact with the 
same chaperone molecules as wild type class I. Supporting the hypothesis that the 
interactions of the developing class I molecule follow a ‘default’ pathway involving 
calnexin and the peptide-loading complex. Although it is possible that some 
components of processing may become redundant in the process of folding linked chain 
molecules, the basic pathway for class I maturation remains the same. Chaperones
molecules should therefore be seen as ‘passive catalysts’ in the process of class I 
folding.
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6 An allele specific molecule is implicated in the 
surface expression of fem linked HLA-B*4402
6.1 Introduction
It is well documented that although expression of mouse MHC class I Heavy Chain 
(HC) in human cells results in cell surface expression of mouse class I (Alexander et al., 
1989), heavy chain alleles of human MHC class I often express poorly in murine cells 
(Peh et al., 1998). Although, HLA-A2 is able to express stably in normal murine cells 
(Irwin et al., 1989) or in Daudi (human B cells, that are deficient for (32m) cells provided 
with mouse p2in (Seong et al., 1988), expression of alleles such as HLA-B8 and HLA- 
A25 is enhanced by the provision of human p2m (Wang et al., 1993). For other alleles, 
such as HLA-B*4402, cell surface expression in mouse cell lines remains reduced even 
in the presence of human p2m and full recovery requires co-expression of human 
tapasin (Peh et al., 1998). It is possible to exploit this species incompatibility to study 
antigen processing; effectively with respect to HLA-B44 the K42 (crt -/-) murine cell 
line represents a doubly deficient cell line, lacking both calreticulin and human tapasin. 
The K41 cell line on the other hand is a proficient in calreticulin but still lacking human 
tapasin. It is widely believed that chaperone molecules of MHC class I antigen 
processing work cooperatively; in other words a combination of interactions between 
proteins stabilises the peptide-loading complex for efficient peptide loading. Because of 
the high dependence of HLA-B44 on human tapasin the cooperative effects of 
chaperones in class I antigen processing can be investigated by expression in mouse 
K41 and K42 cells.
For the purposes of this work the linked chain molecule p2m-B44 has been expressed in 
both K41 and K42 (crt -/-) cells using a lentivirus system (section 4.3.2). The rationale 
for the use of this linked chain molecule is two-fold. Firstly, it provides human p2in to 
the cells, which is required for the expression of HLA-B44 in murine cells. Secondly, 
because p2in is covalently linked to HLA-B44 the P2ih-B44 heterodimer it is already 
partially assembled and may have altered requirements for either human tapasin or for 
the chaperone calreticulin. It is known from the murine RMA-S (TAP -/-) cell line, that 
empty or Tow affinity peptide’ bound class I molecules can traffic to the cell surface if 
their stability is increased by cooling the cells to 20-26°C (Ljunggren et al., 1990;De 
Silva et al., 1999). A similar situation could be envisaged for the linked chain 
constructs; if they are more stable than separately expressed class I molecules they may 
traffic to the cell surface better without optimisation of peptide by tapasin. For purposes
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of comparison viruses expressing HLA-B44 and p2in were also created (section 4.3) and 
a linked chain protein for the allele HLA-A2 (P2m-A2) has also been used. Although the 
usual trafficking of the MHC class I allele HLA-A2 involves interactions with TAP and 
tapasin, it is widely documented to be able to traffic independently of this pathway 
(Lewis et al., 1998). As a result it expresses stably in tapasin deficient human cell lines 
and also in mouse cells. One would therefore expect HLA-A2 to express well in K41 
cells, but since its calreticulin dependence is not known, how it will express in K42 
cells is not clear.
K42 is an immortalised calreticulin deficient mouse fibroblast cell line (Mesaeli et al., 
1999), which displays decreased surface expression of MHC class I in comparison to 
the calreticulin proficient equivalent cell line K41 (Gao et al., 2002). The calreticulin 
dependent expression level of class I, and the simultaneous association of calreticulin 
and p2m with heavy chain, has led to speculation that calreticulin may be crucially 
involved in the formation and maintenance of the P2m-HC heterodimer. Since linked 
chain molecules already express both components of the p2m-HC heterodimer, there 
should be no requirement for p2m recruitment. By comparing the expression level of 
both p2in-B44 and P2m-A2 in K41 cells with the level in K42 (crt -/-) cells an 
assessment of the importance of calreticulin in p2m recruitment may be possible. The 
expression of human class I constructs in murine cell lines will also add to the body of 
knowledge of species specific differences in class I processing between mice and 
humans.
6.2 Methods
Cell lines K41 p2m-B44 and K42 P2m-B44 were used as established in section 4.3.2. 
K41 P2m-B44 was further subcloned by limited dilution cloning to obtain a pure 
population. Other methods used in this chapter are all detailed in chapter 2 and include: 
western blotting (section 2.3), transfection (section 2.1.10), flow cytometry (section 2.2) 
and T cell killing assays (section 2.5.3).
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6.3 Results
6.3.1 p2m-B44 fails to express at the cell surface of murine K41 and 
K42 cells.
K41 and K42 cells were transduced with virus expressing p2m-B44 and selected with 
blasticidin. Surviving colonies were expanded and assessed for expression of p2m-B44 
by western blot and positive clones were chosen (section 4.3.3). The phenotype of these 
cells was assessed by flow cytometry using BBM. 1 or W6.32 antibody, which recognise 
human p2in and folded human class I respectively and do not cross react with mouse 
class I. Expression of HLA-B44 in murine L cells also expressing human p2m has 
previously been shown to produce a 10-fold increase in surface staining using W6.32 
antibody (Peh et al., 1998). Therefore, it was expected that murine K41 cells 
endogenously expressing p2m-B44 would stain with W6.32 and that K42 (calreticulin 
deficient murine) cells expressing P2m-B44 might stain somewhat less strongly. 
However, as shown in figure 6.1, endogenous expression of p2in-B44 caused no 
detectable shift in W6.32 staining in either K42 or K41 cells. To confirm the absence of 
cell surface expression of P2m-B44 in transduced cell lines, cells were stained with 
BBM. 1 antibody, which recognises human p2m regardless of the folding status of class 
I. However, like W6.32 antibody, BBM.l did not stain K41 or K42 cells expressing 
p2m-B44, providing further evidence that despite strong expression of protein, detected 
by western blot using BBM.l antibody (Fig. 4.11), there is no cell surface expression of 
the linked chain construct in these cells (Fig. 6.1).
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Figure 6.1. p2m-B44 fails to express at the cell surface of K41 and K42 
cells.
K41 cells (a) and K42 cells (b) transduced with ‘pLenti p2m-B44-V5’, and stably 
selected with blasticidin, were stained for 1 hour with primary antibody W6.32 
(black line), BBM. 1 (grey line) or isotype control (shaded histogram). Cells were 
washed and stained for 1 hour with PE labelled secondary antibody and 
analysed by flow cytometry.
a)
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b)
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6.3.2 BA construct is able to express normally in K41 cells and at a 
reduced level in K42 cells.
To check that there is no other defect in K41 and K42 cells which inhibits expression of 
human class I, a linked chain construct for HLA-A2 was expressed in these cells. P2111- 
A2 was introduced by transfection, and cells were selected using zeocin (50pg/ml). 
Expression of p2m-A2 was detected by western blot and cell surface expression by flow 
cytometry using W6.32 antibody (Fig. 6.2). Unlike the P2m-B44 construct, p2m-A2 was 
highly expressed at the cell surface in K41 cells, causing a 2-log shift in W6.32 
staining. P2in-A2 also expressed at the surface of K42 cells and interestingly this shift 
was about 8-fold lower than in K41 cells. This shows that calreticulin plays an 
important role in the expression of HLA-A2 and furthermore indicates that the 
requirement for calreticulin cannot be overcome by linkage of HLA-A2 to p2in. K42 
cells expressing P2m-A2 were able to present peptide to CTL in a killing assay, 
indicating that p2in-A2 is folded in a normal conformation at the cell surface of these 
murine cells (Fig. 6.2c). Unfortunately, expression of p2m-A2 in the K41 cell line was 
lost after 2-3 passages, so it was not possible to compare the susceptibility of K41 and 
K42 cell lines expressing p2m-A2 to T cell killing.
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Figure 6.2. p2m-A2 e x p re s s e s  in K41 and K42 cells and can p re sen t  
an tigen  to  CTL. K41 and K42 cells were transfected with (32m-A2 and stably 
selected with zeocin. a) Cells were assessed by western blot for expression of 
/32m-A2 using mAb BBM. 1. b) K41 cells (thin black line) and K41 /32m-A2 cells 
(thick black line) and K42 f32m-A2 cells (thick grey line), were assessed for 
surface human MHC class I by flow cytometry using mAb W6.32. (shaded 
histogram shows isotope control) c) K42 cells or K42 /32m-A2 cells were pulsed 
with influenza matrix protein derived peptide (GILGFVFTL) and labelled with 
Cr51 for 1 hour. Cells were washed and incubated for 4 hours with CTLflu, a T 
cell clone recognising GILGFVFTL presented by HLA-A2. Cell killing was 
calculated from the release of chromium from labelled target cells, normalised 
using values for detergent mediated and spontaneous release.
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6.3.3 p2m-B44 is able to fold into a native heterodimer structure 
inside murine cells and expresses normally on the surface of 
human cells.
To confirm that the p2m-B44 molecule is able to fold correctly and that it can be 
recognised by both and W6.32 and BBM. 1 antibodies two further experiments were 
performed. Firstly the p2m-B44 construct was expressed in the human colon carcinoma 
cell line HCT, which is deficient in P2m (Dexter et al., 1979), and secondly K41 and 
K42 cells transduced with p2m-B44 were stained for intracellular protein expression 
and analysed by flow cytometry. Flow cytometry shows that transient expression of 
P2m-B44 by transduction of HCT cells with lentivirus causes a significant shift in 
staining by W6.32 in more than 50% of cells (Fig. 6.3a). This shows that in human cells 
P2in-B44 is not only able to come to the surface, but that it is also forms a normal 
heterodimer structure. Similarly transduced HCT cells can also be stained by BBM. 1 
(data not shown).
Intracellular staining of K41 and K42 cells transduced cells with W6.32 confirmed that 
transduction had been successful and that the P2m-B44 construct was folding correctly 
inside the cell. Although there was some background using W6.32 antibody, there was 
a clear shift in a proportion of both K41 and K42 transduced cells, indicating the 
endogenous expression of P2m-B44 (Fig. 6.3b). However, staining of K41 p2m-B44 
clones indicated the presence of 2 subpopulations within transduced cells. Using 
BBM. 1 antibody, cleaner staining was obtained and it was confirmed that although 
around 50% of K41 cells were expressing p2m-B44, the clones were not pure (Fig.
6.3c). In order to obtain a clonal population expressing p2in-B44 in all cells, limited 
dilution cloning was performed. Expression was then checked by intracellular BBM. 1 
cloning and pure clones were chosen for further work (Fig. 6.3d).
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Figure 6.3. The p2m-B44 construct is able to express at the cell surface in 
human cells and is able to fold inside murine cells, a) HCT cells (grey line) 
and HCT cells transduced with p2m-B44 virus (black line) were stained for 
surface expression of human class I (mAb W6.32). M 1=54.8 %. b and c) K41 
p2m-B44 (black line) and K42 p2m-B44 (grey line) were permeabalised with 
0.1% saponin and stained for intracellular expression of folded human class I 
(mAb W6.32) (b), or human p2m (mAb BBM.1) (c). d) K41 p2m-B44 cells were 
subcloned to obtain a pure population. Cells were then stained for intracellular 
human p2m, as in (c). All shaded histograms show non transduced K41 cells.
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6.3.4 Absence of cell surface p2m-B44 does not result from 
accelerated trafficking or instability of the construct.
Two main mechanisms have been reported that can explain impaired surface expression 
of MHC class I. Either class I molecules fail to traffic to the cell surface and instead are 
retained in the ER and degraded (Paulsson et al., 2001), or trafficking is accelerated and 
suboptimally loaded or unstable MHC class I is rapidly lost from the cell surface (Lewis 
et al., 1996).
Class I molecules that traffic at an accelerated rate, in a peptide receptive state, can be 
stabilised by incubating with exogenous class I binding peptide. To determine whether 
this was the mechanism leading to the failure of expression of P2m-B44 in murine cells, 
either MEVDPIGHLY, an HLA-B44 binding peptide derived from the melanoma 
associated protein MAGE-3 (Herman et al., 1996), or the irrelevant ovalbumin peptide 
SIINFEKL was incubated with transduced K41 and K42 cells. The addition of HLA- 
B44 binding peptide had no effect on cell surface expression of p2m-B44 as assessed by 
FACS (Fig. 6.4 a and b), suggesting that the lack of cell surface expression does not 
result from accelerated trafficking to the cell surface in a peptide free state, followed by 
rapid turnover from the cell surface. It therefore seems likely that the p2m-B44 construct 
is not leaving the ER at all.
MHC class I heterodimers that are peptide free or bound to low affinity peptide are 
unstable, for example, when HLA-B44 is processed in the presence of mouse rather than 
human tapasin. As a result they are normally retained in the ER. However, trafficking of 
unstable class I molecules can sometimes be enhanced significantly by incubating the 
cells at 26°C (Peh et al., 1998). To test whether this may be true for the p2m-B44 
construct expressed in K41 and K42, cells were stained with W6.32 antibody after 
overnight incubation of cells at 26°C (Fig. 6.4 c and d). However, expression of p2m- 
B44 could not be detected after overnight incubation at 26°C, suggesting that the lack of 
cell surface expression does not result from low stability of the p2m-B44 structure and 
inability to load peptide in the ER.
A positive control using a cell line such as T2 would have been beneficial here to 
demonstrate that under certain conditions class I expression can be enhanced by 
provision of class I binding peptide or by incubating the cells at 26°C.
157
Figure 6.4. Incubation at 26°C or provision of peptide cannot restore cell 
surface expression of p2m-B44. a) and b), K41 and K42 cells stably 
expressing ($2m-B44, were incubated for 1 hour with HLA-B44 binding peptide 
MEVDPIGHLY or an irrelevant peptide SIINFEKL. c) and d) the same cells were 
incubated overnight at either 37°C or 26°C. All cells were stained for expression 
of human class I with W6.32 antibody. Bottom panel - staining of HEK 293 cells 
was used as a positive control and isotope contol staining is also shown 
(shaded).
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6.3.5 Provision of human tapasin does not facilitate surface 
expression of p2m-B44
Since p2m-A2 was able to express in murine K41 and K42 cells, the failure of p2m-B44 
to express must be an allele specific phenomenon. In light of previous studies showing 
a high dependency of HLA-B44 on human tapasin (Peh et al., 1998), K41 and K42 
cells transduced with P2H1-B44 were transfected with plasmid expressing either native 
human tapasin or a soluble human tapasin molecule shown previously to be able to 
facilitate class I loading (Gao et a l, 2004). 48 hours after transfection using 
lipofectamine 2000, cells were assessed for human tapasin expression by western 
blotting and for cell surface human MHC class I expression by flow cytometry. Cells 
transfected with tapasin, expressed a protein that could be detected by western blot 
using Giles anti-tapasin rabbit serum; however, the protein detected was larger than 
expected, around lOOkDa rather than 48kDa (Fig. 6.5a). This band was only detectable 
in cells transfected with human tapasin and not in untransfected cells. Control human 
HCT cells expressed a protein, which stained with Giles and was of the expected size. 
The exact nature of the lower mobility band in transfected cells is not clear although it 
may represent a dimer of tapasin or alternatively, a stable complex of tapasin with 
Erp57. A stable disulfide bridge has been identified between ERp57 and tapasin 
(Peaper et al., 2005) and it may be that at this fairly low level of tapasin expression all 
the tapasin is associated with Erp57. GFP transfection indicated that around 50% of 
K41 and K42 cells were transfected by using lipofectamine 2000 (Fig. 6.5b).
However, transfection with either tapasin or soluble tapasin did not increase the cell 
surface expression of human class I in either K41 or K42 cells endogenously expressing 
p2m-B44 (Fig. 6.5c).
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Figure 6.5. Transfection of human tapasin into K41/K42 p2m-B44 cells has 
no effect on cell surface human MHC class I. a) K41 p2m-B44 (BB) and K42 
($2m-B44 (BB) cells were transfected with wild type tapasin (Tpn) using 
lipofectamine 2000. Expression of tapasin was detected by western blot using 
anti-tapasin rabbit serum Giles, b) K41 /32m-B44 cells (grey line) and K41 (S2m- 
B44 cells transfected with GFP (black line) were analysed by flow cytometry for 
fluorescence in the FL-1 channel (GFP). M1=58%. c) Surface expression of 
human MHC class I on positive control HEK 293 cells (thin black), and on K41 
($2m-B44 cells transfected with tapasin (thick black) or soluble tapasin (thick 
grey) was assessed by flow cytometry using W6.32 antibody. Shaded histogram 
shows non transfected cells.
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Since the transfected tapasin detected by western blot was not of the expected size, 
tapasin was also introduced into these cells using vaccinia virus, containing a human 
tapasin expression cassette. Vaccinia virus was titrated by intracellular FACS staining 
using Giles anti tapasin rabbit serum, and a vaccinia virus containing ovalbumin was 
used as a control. Over 90% of K41 cells expressed tapasin after transduction with 2ul 
of the human tapasin vaccinia virus preparation (Fig. 6.6a) and cell death assessed by 
trypan blue staining was less than 15% (data not shown). Increasing the viral load did 
not improve the efficiency of transduction and resulted in significant cell death. 
Western blot confirmed that tapasin was being expressed by cells transduced with 
tapasin vaccinia virus, and unlike when tapasin was introduced by transfection, the 
major protein detected was of the expected size of 48kDa, although a larger band 
could also be detected at about lOOkDa (Fig. 6.6b). Despite high levels of human 
tapasin in these cells, there was still no cell surface expression of p2m"B44 on K41 or 
K42 cells as assessed by FACS using W6.32 antibody (Fig. 6.6c), showing that the 
failure of P2m-B44 expression in these cells does not result from the absence of human 
tapasin.
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Figure 6.6. Expression of human tapasin by vaccinia virus does not allow 
expression of p2m-B44 on K41 cells, a) K41 (32m-B44 cells transduced with 
2f.il (thick grey) or 10id (thick black) of vaccinia virus expressing human 
tapasin (Tpn), or 10/ul of vaccinia expressing irrelevant ovalbumin (OVA) 
protein (thin black), were analysed for intracellular expression of tapasin by 
permeabalisation with 0.1% saponin and staining with rabbit antiserum Giles 
specific for human tapasin. b) Human .174 B cells or cells as in (a) were 
analysed by western blot for expression of human tapasin using Giles 
antiserum, c) K41 /32m-B44 cells transduced with 2pi of vaccinia virus 
expressing human tapasin (black) or ovalbumin (grey) were assessed by 
FACS for expression of human class I by staining with W6.32 Ab. Shaded 
FACS histograms show non transduced K41 f$2m-B44 cells.
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6.3.6 B2m-B44 blocks processing of native class I in K41 cells.
Given that p2m-B44 is expressed at high levels in transfected cells but does not appear 
to leave the ER, it was reasoned that ER machinery might be affected in its ability to 
process other class I molecules. In order to test this, the level of mouse MHC class I 
on K41 cells expressing p2m-B44 was measured by flow cytometry using mAb Y3. 
The expression of p2m-B44 in K41 cells was found to lower the level of expression of 
native MHC class I by around 8-10 fold (Fig. 6.7a). K42 cells display a similar 10-fold 
reduction in class I expression in comparison to K41 cells because of the absence of 
calreticulin (Gao et al., 2002) but the reduction in surface class I in K42 cells can be 
rescued by pulsing the cells with class I binding peptide (Fu et al., 2006 under review). 
Rescue of cell surface expression of mouse class I in K41 p2m-B44 cells by pulsing 
with peptide would indicate a similar phenotype and suggest that maybe calreticulin is 
being sequestered by the p2m-B44 construct in the ER. To test this K41 cells, K42 
cells and K41 p2m-B44 cells were pulsed for 1 hour with H2-Kb binding peptide 
SIINFEKL or the irrelevant peptide GILGFVFTL and cells were stained for cell 
surface expression of K (mAb Y3). Unlike the reduction in surface expression of 
mouse class I in K42 (calreticulin -/-) cells, the reduction in Kb expression in K41 
p2m-B44 cells could not be rescued by addition of peptide (Fig. 6.7 b and c). This 
implies that not only is p2m-B44 unable to leave the ER of the cell but that it binds to 
and blocks the antigen processing machinery, and in so doing reduces native class I 
loading and export. Conversely, the expression of p2m-A2 in K41 cells does not 
downregulate native class I molecules supporting the view that it is the accumulation 
of p2m-B44 in the ER that is inhibiting the expression of murine class I (Fig. 6.7a).
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Figure 6.7. p2m-B44 but not p2m-A2 blocks the export of native class I to 
the cell surface. All cells were assessed for surface expression of K? by 
FACS using mAb Y3 (shaded histograms show isotype controls). Where 
indicated cells were incubated at 37 °C for 1 hour with the irrelevant peptide 
GILGFVFTL or the K? binding peptide SIINFEKL. a) K41 cells (thick grey) and 
K41 p2m-B44 cells (thin black *) or K41 p2m-A2 cells (thick black), b) K41 cells 
(thick grey), K42 cells with GILGFVFTL peptide (thick black) or SIINFEKL 
peptide (thin black *). c) K41 cells (thick grey), K41 fi2m-B44 with GILGFVFTL 
peptide (thick black) or SIINFEKL peptide (thin black *).
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6.4 Discussion
A detailed basic phenotype for the calreticulin deficient cell line K42 was first 
published in 2002 by Gao et al. and showed that class I expression was reduced, and 
that certain peptides were not properly presented to T cells in the absence of calreticulin 
(Gao et al., 2002). This was an important step to understanding the role of calreticulin in 
class I assembly, since as a general ER chaperone its interactions with class I, like those 
of calnexin (Scott and Dawson, 1995) could have proved to be redundant. However, the 
observed phenotype of the K42 (crt -/-) cell line for mouse class I molecules, highlights 
the importance of calreticulin in antigen processing.
Since it is known that the binding of calreticulin to heavy chain coincides with the 
binding of heavy chain to p2m (Sadasivan et al., 1996), it has been suggested that the 
role of calreticulin might be to promote the binding of p2m to heavy chain and 
subsequently to hold the p2m-HC heterodimer in a peptide-receptive state. p2m-HC 
linked chain molecules provide a powerful tool to investigate this theory, since they are 
synthesised as preformed heterodimer and as a result have no requirement for 
recruitment of P2m to heavy chain and might therefore have decreased dependency on 
calreticulin. For this purpose, the p2m-B44 construct did not prove useful since it did 
not reach the cell surface in either K41 or K42 cells. However, the P2in-A2 construct 
was able to express in these cells and it was interesting to find that, as with mouse class 
I molecules this human linked chain molecule still suffered an 8-10 fold reduction in 
expression in the absence of calreticulin, indicating that low class I expression in 
calreticulin deficient cells does not result from a defect in the recruitment of p2m to 
heavy chain. These findings have formed part of a larger investigation of calreticulin 
deficiency in class I antigen processing, which has taken place in the rheumatology unit 
of the Institute of Child Health in London, and has contributed towards a paper, which 
has been submitted for publication (Fu et al., 2006 under review). The work presented 
in this chapter has shown that calreticulin deficiency does not lead to a failure in the 
assembly of P2m with HC, since preassembled p2m-A2 heterodimer is still expressed 
approximately 10-fold less efficiently in calreticulin defcient 42 cells than in ‘wild type’ 
K41 cells. Further to this, other work has shown that K42 cells behave somewhat like 
TAP deficient RMA-S cells (Ljunggren et al., 1990) in that the majority of class I 
molecules reaching the cell surface are unstable, but can be stabilised by incubation at 
26°C. However, in calreticulin deficient cells this phenotype does not result from poor 
peptide supply since the level of TAP and its efficiency of peptide transport was found
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to be unaffected. In fact, the major defect in these cells seems to be an inability to load 
with peptide when antigen concentration is low. In other words calreticulin is important 
in lowering the peptide concentration threshold, at which class I molecules will become 
efficiently loaded. This is shown, by the ability of calreticulin deficient cells to present 
H2-Kb/SIINFEKL at the cell surface when provided with high levels of full length 
ovalbumin or ER targeted peptide, but an inability to present antigen provided at lower 
concentration where presentation by wild type cells is still possible.
There are several possible ways in which calreticulin may enhance the presentation of 
scarce antigen. Firstly, it may be important in the stabilisation and maintenance of 
peptide receptive p2m-HC heterodimer. Although the data presented here suggest that 
calreticulin is not required for recruitment to heavy chain, its interaction with the 
heterodimer may still be important. It may be that calreticulin holds the heterodimer in a 
conformation that is favourable for peptide binding or that its association with heavy 
chain stabilises other interactions with the peptide-loading complex and thus indirectly 
helps in the catalysis of peptide loading. Such a model is attractive, since class I has 
been shown to traffic at an accelerated rate in K42 cells (Gao et al., 2002), a phenotype 
that has been shown before to correlate with poor association of class I with the peptide- 
loading complex (Lewis et al., 1996). However, class I does still associate with the 
peptide-loading complex in calreticulin deficient cells, suggesting that calreticulin is not 
crucial for this interaction (Gao et al., 2002). A second possible role for calreticulin lies 
in its close cooperation with the glucosylation quality control pathway. Calreticulin 
binds only to N-glucosylated class I molecules. When class I molecules (and other 
glycopreteins) are correctly folded, the terminal glucose residue of the N-linked glycan, 
is removed by glucosidase II, disrupting the interaction between class I and calreticulin. 
This is a generalised pathway for quality control of protein folding in the ER, and like 
other glycoproteins that are not fully folded, it is possible that peptide-free class I 
molecules are sensed by UDP-Glucose glycoprotein glucosyltransferase (GT) resulting 
in the replacement of the terminal glucose residue. Calreticulin binding would then be 
restored and might therefore promote another round of peptide loading in the peptide- 
loading complex. The third possible function of calreticulin is that it could promote 
peptide loading through its association with free peptides. Calreticulin has been shown 
to bind to peptides in vitro (Spee and Neeljes, 1997) and to be able to promote specific 
immunity against bound peptides (Basu and Srivastava, 1999). Since calreticulin can 
both bind to peptides and to the developing class I molecule a role in peptide
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recruitment could be played by calreticulin, which might allow it to promote the loading 
of peptides that are at low concentrations in the ER.
It has been previously reported that certain human alleles of MHC class I express poorly 
in mouse cells because of species differences in tapasin (Peh et al., 1998) and also that 
even alleles which are supposedly ‘tapasin independent’ such as HLA-B27 present a 
quantitavely and qualitatively different repertoire of peptides in the absence of human 
tapasin (Sesma et al., 2005). Consistent with these problems the expression of P2H1-B44 
in murine K41 and K42 cells seems to be impaired. However, expression of human 
tapasin either by transfection or by transduction with vaccinia virus expressing human 
tapasin, failed to facilitate cell surface expression of p2m-B44 in murine K41 cells. p2m- 
B44 has been shown to express well in human HCT cells (Fig. 6.3) and in the tapasin 
deficient human B cell line (Fig. 5.5) demonstrating that the linked chain construct is 
able to fold normally. K41 cells can therefore be said to suffer from a human tapasin 
and p2m independent inability to present certain human MHC class I alleles including 
HLA-B44.
It has previously been shown that low cell surface class I can be a consequence either of 
accelerated trafficking of suboptimally loaded MHC class I from the ER to the cell 
surface or of retention of class I molecules in the ER. The HLA-A2 mutant T134K is a 
classic example of accelerated trafficking (Lewis et al., 1996). Because of a single 
amino acid change, this mutant class I allele is unable to interact with tapasin and the 
peptide-loading complex and as a result exits the ER rapidly after synthesis. However, 
because they have not been through the normal processing pathway, T134K molecules 
are not properly loaded with peptide and as a result are unstable at the cell surface and 
turnover rapidly. Accelerated trafficking to the cell surface therefore leads to a decrease 
in the steady state level of cell surface class I. This phenomenon is also observed for 
class I molecules in K42 (calreticulin -/-) cells (Gao et al., 2002), and consistent with 
this it has been shown here that the reduction in native cell surface class I expression in 
K42 cells can be recovered by providing the cells with allele specific exogenous class I 
binding peptide (Fig. 6.7b). However, addition of exogenous HLA-B44 binding peptide 
failed to enhance expression of P2iu-B44 in K41 cells (Fig. 6.4), indicating that the 
observed impairment of p2m-B44 expression in these cells is not a consequence of 
accelerated trafficking to the cell surface.
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Reduced cell surface expression of class I as a result of retention in the ER, seems to 
occur when class I molecules cannot be properly loaded with peptides. This occurs in 
Daudi (human p2in -/-) cells in which a peptide receptive P2111-HC heterodimer cannot 
be formed (Williams et al., 1989), and also in TAP deficient cells such as T2 (Paulsson 
et al., 2001). When class I heterodimer (p2m-HC) is unable to load with high affinity 
peptide it is usually retained in the ER, but incubation at lower temperature may allow 
cell surface expression of these poorly loaded class I molecules. Whereas at 37°C, 
peptide free or low affinity peptide bound heterodimer would not be stable enough to 
traffic first to the Golgi body and then on to the cell surface, at 26°C it is more stable 
and is able to reach the cell surface. The expression of p2m-B44 is unaffected by 
incubation at 26°C indicating that it is not forming an unstable peptide-free heterodimer 
in the ER.
It is interesting to note that with the exception of P2m deficient cell lines, most reports 
of poor expression of class I have usually referred to a reduction rather than an absence 
in cell surface expression of class I. For instance in murine cells even when human p2m 
is not provided there is substantial expression of many alleles of human class I (Irwin et 
al., 1989), and when HLA-B44 is expressed with human p2m in murine L-cells not 
expressing human tapasin, there is around a 10-fold increase in surface staining by 
W6.32 antibody (Peh et al., 1998). It is said that HLA-B44 expresses at the cell surface 
at ‘reduced’ levels in this scenario, in that provision of human tapasin will facilitate a 
higher level of expression. However, this is fundamentally different from the situation 
shown here, where surface expression of p2m-B44 in K41 and K42 cells is completely 
lacking. It is perhaps less surprising then that it is found that co-expression of human 
tapasin, provision of exogenous peptide and cooling the cells to 26°C all fail to enhance 
expression of p2in-B44. Yet the p2m-B44 construct is able to fold correctly inside K41 
and K42 cells, as evidenced by intracellular W6.32 staining and it is also able to express 
at the cell surface of human cells transduced with the same virus.
The failure of p2m-B44 to express at the surface of K41 cells despite the fact that it 
expresses well in human cells implies that there is another component necessary for 
antigen presentation by HLA-B44, which is present in human HCT cells but not in the 
mouse cell line K41. A report of a similar phenomenon was made in a recent 
publication using a mutant cell line 4S8.12 derived from African green monkey COS7 
kidney cells (York et al., 2005). In this mutant monkey cell line, transfection with 
mouse class I alleles allowed cell surface expression of murine class I. Furthermore 
ovalbumin protein could be processed into suitable peptide, loaded onto Kb and
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presented to T cells. However, transfected human and primate class I molecules were 
unable to traffic to the cell surface. The explanation proposed for this deficit was the 
failure of P2111 to assemble with heavy chain; however it is interesting that the deficiency 
was still present when a covalently linked p2m-HLA-A3 protein was expressed in these 
cells. This would imply that it is not recruitment of P2m to heavy chain that is deficient 
in these cells, but rather that there is a defect at a later stage of processing which 
prohibits the trafficking of class I. It is interesting that both in the work of York et al. 
and in the work presented here, the cells are proficient in surface expression of mouse 
class I molecules but fail to express at least some human class I alleles. The failed 
surface expression of human class I cannot be rescued in either situation by provision of 
suitable binding peptide, and there is no evidence that the defect is due to tapasin. Both 
findings point towards an as yet unidentified component required for folding and 
subsequent trafficking of at least some alleles of human and primate class I molecules, 
which is not necessary for mouse class I trafficking.
However, some differences do exist between the results reported here and those of York 
et al.. Firstly the 4S8.12 cell line if anything exhibits enhanced cell surface expression 
of mouse MHC class I, even in the presence of primate heavy chains which are unable 
to appear on the surface. In contrast, expression of the p2m-B44 construct in K41 causes 
a downregulation of mouse MHC class I. Secondly the 4S8.12 mutant displays a 
biphasic phenotype in relation to primate class I expression in which a minority of cells 
display normal levels of class I; such a population is not seen in K41 cells endogenously 
expressing p2m-B44 which unanimously fail to express this construct at the cell surface. 
It is possible that the two similar phenotypes discussed here have different causes or 
that other species differences between the monkey COS7 cell and the mouse K41 cell 
cause the more subtle differences in phenotype. It is also possible that the a greater 
stability of the linked chain P2m-B44 causes it to remain in the ER for a long period of 
time and to occupy proteins of the class I machinery, whereas the monkey or human 
heavy chain in COS7 cells may be more rapidly degraded if it fails to fold correctly for 
peptide binding. Despite these differences there is a striking similarity between the 
phenotype shown by the 4S8.12 mutant and by K41 cells transfected with p2m-B44.
It is interesting to note that the p2m-A2 construct expresses at the surface of K41 cells, 
since it shows that the requirement of this unknown component for surface expression 
of HLA-B44 is an allele specific phenomenon with relation to human class I molecules. 
The reduction in mouse class I expression of cells expressing p2m-B44 as compared to 
P2m-A2 , implies that when unable fold in such a way as to receive peptide in these cells,
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the P2in-B44  construct impedes mouse class I molecules loading with peptide. Rather 
than the explanation suggested by Rock et al. (York et al., 2005), that the defect results 
from a failure of heavy chain and P2m fail to associate, the model proposed here is that 
the P2m-HC heterodimer must be chaperoned in such as way that it can bind to available 
peptide. If this does not occur the molecule will fail to load with peptide and instead 
will remain associated with other components of class I processing, such as the peptide- 
loading complex, hence the reduction in mouse class I in K41 cells expressing p2m-B44 
but not in those expressing p2m-A2.
In conclusion, data presented in this chapter have shown that calreticulin does not play a 
crucial role in P2111 recruitment to class I heavy chain. This has formed part of a larger 
project, the data from which points to a role for calreticulin in lowering the peptide 
concentration threshold at which class I molecules can become efficiently loaded. Other 
data presented in this chapter suggest, that at least for some human heavy chain alleles, 
a hitherto unidentified component of class I folding may exist which is required for 
presentation of class I at the cell’s surface.
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7 Discussion
MHC class I antigen presentation is central to the cellular arm of the immune system. It 
is vital for the clearance of many pathogens and may play an important role in the 
prevention of cancer. Increasing our understanding of MHC class I antigen processing 
and the production of effective cellular immunity could be instrumental in the 
development of future treatments for infectious diseases, cancer and autoimmunity.
The work presented in this thesis has focused on the mechanisms that occur in the ER to 
allow the successful presentation of antigen by MHC class I molecules. This process 
requires the pairing of class I heavy chain with p2i*i, followed by the loading of peptide 
onto the binding groove of the heavy chain and the export of class I molecules to the 
cell surface. A number of chaperones are required for this process to take place 
efficiently and despite, or perhaps because of, the numerous different approaches used 
to determine the roles of these chaperones, their functions remain unclear.
What is generally accepted is that in normal cells, heavy chain interacts first with 
calnexin and then later with the peptide-loading complex. Expression of linked chain 
class I constructs in different cell lines in this work has allowed an examination of these 
processes and the chaperones involved.
Although clear functions for individual chaperones remain illusive, several lines of 
evidence suggest that for most alleles the peptide-loading complex is the key player in 
ensuring that class I molecules are efficiently loaded with peptide when they leave the 
ER. Knockout cell lines for tapasin (Ortmann et al., 1997), calreticulin (Gao et al.,
2002) and most recently ERp57 (Garbi et al., 2006) all show reduced efficiency in 
peptide loading and in each case at least some alleles of class I dissociate from the 
peptide-loading complex and traffic to the cell surface at accelerated rate. Similarly the 
HLA-A2 mutant class I molecule T134K does not interact with tapasin or the peptide- 
loading complex, traffics quickly to the cell surface and is found to poorly optimise its 
peptide cargo (Peace-Brewer et al., 1996). Conversely the mutant HLA-A2 heavy chain 
allele S132C, which is shown to make a prolonged interaction with the peptide-loading 
complex and becomes endo H resistant more slowly than its wild type counterpart, is 
found to be very stable at the cell surface and the peptide groove is found to be bound at 
high occupancy (Lewis et al., 1996). Apart from its role in the provision of peptides the 
requirement of a functional TAP in the peptide-loading complex is controversial. Some 
researchers find that surface class I expression can be restored in tapasin deficient cells
172
by transfection of soluble form of tapasin, which interacts normally with class I 
molecules but does not interact with TAP (Lehner et al., 1998). This suggests that the 
crucial interaction for peptide loading is made between class I and tapasin, and that 
TAP itself is not a required component of the peptide-loading complex. Other 
researchers have shown that the presence of TAP in the peptide loading-complex is 
important to class I peptide loading (Tan et al., 2002) and further to this, it has been 
reported that both nucleotide binding by TAP (Knittler et al., 1999) and the peptide 
occupancy of TAP (Owen and Pease, 2001)(regardless of actual peptide transport) may 
be important in the release of class I molecules from the peptide-loading complex.
These differences may partly be explained by the observation that the absence of tapasin 
can cause a decrease in the rate of peptide transport by TAP. This occurs either because 
TAP is unstable and expressed at lower levels in the absence of tapasin (Garbi et al.,
2003) or is impaired in its function by reduced peptide binding efficiency (Li et al., 
2000). Since this effect seems to be dependent on cell type (Grandea, III et al., 2000) 
and since different alleles display different dependencies on tapasin and TAP (Peh et 
al., 1998) variations in results from different groups may also partly result from 
differences in the experimental system used.
Regardless of the exact role of each component of the peptide-loading complex the 
overall function is to facilitate or optimise peptide binding to class I in the ER. Two 
different simple models can be envisaged that would allow the peptide-loading complex 
to carry out this function. In the first ‘sensing’ model, class I molecules are released 
from the peptide-loading complex only when they have become efficiently bound to 
high affinity peptide. This model might allow a peptide editing function, but would 
require a sensing mechanism, which retained empty class I while releasing peptide 
loaded class I. In the second ‘automatic’ model, class I molecules progress to the 
peptide-loading complex by default and are retained there for a period of time defined 
by their binding affinity for tapasin and other members of the complex. During this 
period of time, proteins of the peptide-loading complex would provide an environment 
favourable for binding of available peptides to class I heavy chain. Because class I 
molecules are not immediately released from the peptide-loading complex there would 
then be an opportunity for low affinity peptides to dissociate from class I and for 
another round of peptide binding to occur.
The sensing model is supported by several key findings, most importantly that provision 
of high affinity peptide leads to allele specific dissociation of class I from the peptide- 
loading complex (Suh et al., 1994). Conversely, in TAP mutant T2 cells, which cannot
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import peptide into the ER from the cytoplasm, the interaction between tapasin and 
class I is found to be prolonged, resulting in the retention of class I molecules in the ER 
(Paulsson et al., 2001). The conformation of class I molecules changes upon binding of 
peptide, as evidenced by specific antibodies able to distinguish between peptide loaded 
and peptide free class I molecules (Lie et al., 1991). This change in conformation could 
be sensed by tapasin (Hansen et al., 2005) or other members of the peptide-loading 
complex, allowing release of peptide loaded class I molecules (Elliott, 1997).
In chapter 5, this sensing model was tested using the PB construct, which consists of an 
HLA-A2 binding peptide from flu matrix protein linked to p2in. PB was shown to fold 
express efficiently at the cell surface with HLA-A2, and was shown to elicit a powerful 
T cell response from flu specific T cells, showing that the peptide binds efficiently to 
the groove of the heavy chain. Furthermore, the peptide groove of HLA-A2 was 
unavailable to bind other peptides at the cell surface as indicated by the failure of HCT 
PB cells to present another HLA-A2 restricted peptide AAGIGILTV to specific CTL. 
PB was also shown to be unable to pair up and express with heavy chain molecules 
other than HLA-A2 when expressed endogenously in Daudi cells. These data suggest 
that PB pairs with only HLA-A2 in the ER and that the peptide is bound to the binding 
groove of HLA-A2. Interestingly despite this evidence that the high affinity peptide of 
PB is bound to the groove of HLA-A2, PB is still found to traffic via the peptide- 
loading complex as shown by immunoprecipitation with both TAP and tapasin. This 
finding implies that class I molecules bound to high affinity peptide can be retained by 
the peptide-loading complex.
Immunoprecipitation of TAP and tapasin from Daudi cells expressing PB would 
provide stronger evidence that PB is not present in the peptide-loading complex with 
heavy chain alleles other than HLA-A2. However, since immunoprecipitation requires a 
large number of cells it would only be practical to do this using a stable cell line 
expressing PB. Time constraints have not yet allowed for production of this stable cell 
line. However, other research has also isolated high levels of class I molecules bound to 
radioactive peptide from tapasin immunoprecipitates in both murine and human cells 
(Li et al., 1999;Li et al., 2000). Since the vast majority of tapasin is found in association 
with TAP in normal cells (Diedrich et al., 2001) it seems these tapasin associated, 
peptide loaded class I molecules have also been retained by the peptide-loading 
complex. These findings support the automatic model, where class I molecules traffic to 
the peptide-loading complex by default and dissociate from it in a peptide independent 
fashion.
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Neither simple model is entirely satisfactory, but either can be modified to explain the 
experimental data. The sensor model could incorporate the idea of retaining loaded class 
I molecules. If the conformational change in class I upon peptide binding did not trigger 
immediate release from the peptide-loading complex but merely a lowering in affinity 
between the peptide-loading complex and class I then this would allow for the recovery 
of some loaded class I molecules from the peptide-loading complex as shown in this 
work and by Li et al., and would also allow peptide binding in vitro to catalyse the 
release of class I from TAP. This modified model would also ensure that class I 
molecules that become loaded with low affinity peptide are not released immediately 
and might have another opportunity to be reloaded with high affinity peptide. 
Alternatively, the automatic model could be modified by adding a further quality 
control step. Class I molecules would still leave the peptide-loading complex according 
to a fixed half-life related to their affinity for the peptide-loading complex but poorly 
loaded class I molecules that dissociated from the peptide-loading complex would be 
somehow retained in the ER and returned to the peptide-loading complex. This would 
allow for the retention of class I molecules in TAP deficient cells and explain why the 
allele specific recovery of class I from the peptide-loading complex gradually falls 
during incubation with binding peptide. Calreticulin is one candidate, which could fulfil 
the role of ‘retaining and recycling’ unloaded class I since in cooperation with UDP 
Glucosyl transferase it is responsible for the retention of poorly folded glycoproteins. 
Alternatively the Bap31 (B cell associated protein 31) export system might exclude 
empty class I molecules from exit sites in the ER causing them to be retained in the ER 
and return to the peptide-loading complex. Although recycling doesn’t seem to occur in 
the case of the T134K HLA-A2 mutant or in tapasin deficient cell lines in which the 
majority of class I molecules that reach the cell surface are peptide free, it is possible 
that since these molecules are not incorporated into the default pathway for class I 
molecules, they leave the ER via the ‘bulk flow pathway’ rather than by Bap31 
controlled export.
The data presented in this thesis support a model for peptide optimisation in which class 
I molecules can be retained by the peptide-loading complex even after loading with 
high affinity peptide. This suggests that the peptide-loading complex does not optimise 
peptide binding by simply sensing the peptide occupancy of the class I molecule and 
releasing those molecules that are found to be peptide bound. Instead the mechanism for 
peptide loading is more subtle, involving automatic retention of peptide-free molecules 
by the peptide-loading complex and additionally mechanisms for retaining loaded class
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I molecules either in the peptide-loading complex or elsewhere in the ER to allow 
optimisation of their cargo.
Before incorporation into the peptide-loading complex heavy chain is known to interact 
with calnexin in the ‘early complex’ (Degen and Williams, 1991). Isolation of this 
complex using the monoclonal antibody HC10, which recognises heavy chain 
molecules free from p2m has indicated the presence of ERp57. In the presence of 
calnexin but not in its absence, ERp57 is found disulfide bonded to free heavy chain in 
the early complex (Lindquist et al., 2001;Antoniou et al., 2002), wheras in the peptide- 
loading complex ERp57 is found disulfide bonded to tapasin and not directly to heavy 
chain (Dick et al., 2002). An early study of ERp57, reported a disulfide linked 
intermediate containing ERp57 in the peptide-loading complex (Lindquist et al., 2001) 
and at the time was assumed to represent heavy chain linked to ERp57. However, in 
hindsight it seems more likely that the interaction is the same one reported subsequently 
between ERp57 and tapasin (Dick et al., 2002). The study of interactions between class 
I heavy chain and both calnexin and ERp57 in the ‘early complex’ is complicated by the 
fact that both proteins can also be detected in association with TAP and in some 
circumstances the peptide-loading complex (Suh et al., 1996;Diedrich et al., 
2001;Lindquist et al., 1998). Care must therefore be taken when analysing these data, 
but the main body of evidence suggests that for human class I alleles, which bear a 
single N-linked glycan, calnexin is not found in association with heavy chain once it has 
assembled with P2IX1 (Zhang et al., 1995;Diedrich et al., 2001). It is surprising then that 
in the work presented in this thesis, the linked chain molecule p2m-A2 (BA) was found 
in association with calnexin. Control experiments showed that free heavy chain also 
immunoprecipitates with calnexin but that p2m does not, supporting the accepted model 
that calnexin, does not normally bind to P2m-HC heterodimer. The most likely 
explanation for these apparently contradictory observations is that calnexin is 
interacting with BA before the protein has been properly folded into its tertiary 
structure. However, the association of BA with calnexin was strong, so it seems likely 
that this interaction is persisting beyond the initial stages of protein folding. This could 
be explained by poor folding of the BA construct in comparison to normal class I. It 
should be remembered that although the BA linked chain construct has been shown to 
be functional, it is still an artificial construct and especially given the failure of the PBA 
construct (peptide-P2m-A2 ) to fold, it is possible that the folding of BA is slow, and that 
it therefore maintains a prolonged interaction with calnexin for the purposes of quality
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control. It is also possible that the p2m of the BA construct somehow disrupts the 
interaction between HLA-A2 and ERp57. This could impair the formation of disulfide 
bonds, which are required before the exchange of calnexin for calreticulin can occur. 
Alternatively, it may be that release of heavy chain from calnexin is independent of p2m 
binding. Evidence that p2m binding causes release of heavy chain from calnexin in 
human cells is only circumstantial, and the work presented in chapter 5 contradicts such 
a model. Instead it is possible that both wild type heavy chain and the linked chain 
construct P2in-A2 bind calnexin during synthesis. This interaction may persist until 
initial folding of the heavy chain is complete, when class I molecules could dissociate 
from calnexin spontaneously. Wild type heavy chain would then associate with p2m, 
calreticulin and the peptide-loading complex in the normal way. This model is 
consistent with the finding that p2m-A2 seems to bind to calnexin as strongly as wild 
type heavy chain molecules.
Interestingly despite the numerous reports of interactions between calnexin and class I, 
no apparent defect in class I presentation has been identified in the absence of calnexin 
(Scott and Dawson, 1995;Sadasivan et al., 1995;Prasad et al., 1998). Chaperone 
redundancy has been cited as a possible explanation for this somewhat surprising 
finding, with the major candidates for replacing the function of calnexin being BiP and 
possibly calreticulin (Prasad et al., 1998;Balow, 1995). Although such ideas of 
redundancy have been fashionable in modelling mechanisms of evolution and 
Darwinian theory (Bruggeman et al., 2000;Miglino and Walker, 2002), other evidence 
suggests that the presence of proteins with redundant functions are not prolonged during 
this process of evolution (Ganfomina and Sanchez, 1999), and that duplicated genes, 
which are not functionally useful either become pseudogenes or ‘deteriorate’ (are lost 
from the genome) (Meyer, 1998). Indeed claims of chaperone redundancy between Skp, 
Sur A and Deg O of E. coli (Rizzitello et al., 2001) were later proved to be incorrect 
with specific functions later assigned to both Sur A (Justice et al., 2005) and Deg P 
(Castillo-Keller et al., 2006). In the latter case it was found that under normal conditions 
Deg P deficient cells appeared normal, but that when a mutant outer membrane protein 
was expressed it was lethal in the absence of Deg P. Although it is possible that 
calnexin is redundant for class I assembly it is more likely that it plays a role, which we 
do not fully understand. Calnexin, like Deg P, may not be important for class I 
molecules that fold correctly, but may be involved in the degradation of those that 
don’t. It has been shown that calnexin is necessary for the recruitment of ERp57 to free 
heavy chain (Lindquist et al., 2001) and independently that ERp57 is important in
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disulfide bond reduction of class I molecules that fail to fold properly (Antoniou et al., 
2002). Calnexin along with ERp57 might therefore play an important role in the 
unfolding of class I molecules that fail to mature, allowing them to be translocated into 
the cytoplasm for degradation (Hughes et al., 1997).
Further to its involvement in the ‘early complex’, ERp57 is also found in the peptide- 
loading complex (Lindquist et al., 1998;Dick et al., 2002). Data presented in chapter 3 
described attempts to inhibit the expression of ERp57 using RNA interference, with a 
view to exploring the various functions carried out by ERp57, first in the early complex, 
and then in the peptide-loading complex. Evidence that ERp57 is disulfide bonded to 
tapasin in the peptide-loading complex suggested that the two proteins might be 
cooperating in a system for peptide binding or optimisation (Dick et al., 2002). ERp57 
contains 2 thioredoxin domains each containing an active CXXC motif, capable of 
catalysing disulfide bond isomerisation (Hirano et al., 1995;Urade et al., 1997). ERp57 
is bonded to tapasin via Cys-57 of the 57CXXC60 motif and mutation of Cys-60 to 
alanine traps this intermediate. The site of binding on tapasin is Cys-95 and mutation of 
this residue leads to loss of ERp57 from the peptide-loading complex (Dick et al.,
2002). Despite the loss of interaction with ERp57, the Cys-95 mutant tapasin was able 
to restore cell surface expression of HLA-B44 in tapasin deficient cells and the 
interactions of HLA-B44 with tapasin and the pepide-loading complex were unaffected 
implying that ERp57 recruitment is not required for HLA-B44 expression. However, 
the phenotype was not entirely normal in these cells, since HLA-B44 displayed 
increased turnover at the cell surface suggesting a failure of efficient peptide loading. 
This inefficiency in peptide loading was confirmed by a radioactive peptide binding 
assay. These data suggest that the major functions of ERp57 in peptide binding and the 
folding of normal class I molecules occur in the peptide-loading complex, and this is 
supported by the fact that failure of ERp57 to associate with immature class I molecules 
in calnexin deficient cells does not affect class I expression. It was hypothesised that 
suppression of ERp57 might lead to a class I phenotype similar to that observed with 
the Cys-95 tapasin mutant, confirming the role of ERp57 in the peptide-loading 
complex. Unfortunately it was not possible to suppress ERp57 sufficiently to observe 
any change in surface class I expression using RNA interference, either in the work 
presented in chapter 3 or in attempts made by Cresswell et al. (personal communication) 
or Williams et al. (Williams, 2006). However, in 2006 data have been published using a 
mouse knockout for ERp57 (Garbi et al., 2006). The phenotype is found to be similar to
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tapasin deficient cells expressing Cys-95 mutant tapasin, in that class I turnover is 
increased at the cell surface. Both overall expression and cell surface expression of H- 
2Kb is reduced about 2-fold in ERp57 knockout cells but expression of H-2Db is only 
slightly affected. In contrast to work with the Cys-95 tapasin mutant, the interaction 
between heavy chain and the peptide-loading complex in ERp57 deficient cells was
bfound to be 10-fold reduced and the interaction was short lived. Furthermore, H-2K 
molecules exited the ER at an accelerated rate and could be stabilised at the cell surface 
by addition of H-2Kb binding peptide. These findings confirm that ERp57 like tapasin is 
important in the retention of some class I alleles in the ER for proper peptide loading. It 
seems that the dependence of different class I molecules on ERp57 does not necessarily
b bfollow the same pattern as tapasin dependence, since whereas both H-2D and H-2K 
are thought to be dependent on tapasin only H-2Kb expression was significantly altered 
by lack of tapasin. This finding is somewhat surprising given that H-2D was found to 
associate weakly with tapasin in ERp57 deficient cells but apparently displayed 
normally at the cell surface. It is possible that dependence on ERp57 is governed by the 
requirement of class I molecules for disulfide bond formation in the peptide-loading 
complex. Interestingly, it has been observed that in Cys-95 tapasin mutant cells, which 
fail to recruit ERp57 to the peptide-loading complex, HLA-B44 is incompletely 
oxidised in the peptide-loading complex. Cells expressing normal tapasin contain only 
fully oxidised class I molecules in the peptide-loading complex (Dick et al., 2002). 
ERp57 may therefore play a key role in maintaining or forming the disulfide bond of 
the a 2 domain of heavy chain, which is likely to be exposed in the absence of peptide. 
The persistence of the interaction of ERp57 and tapasin is unusual for members of the 
protein disulfide isomerase (PDI) family, since usually the function of the PDI is to 
catalyse folding and then dissociate from its substrate (Huppa and Ploegh, 1998). The 
persistence of this interaction ensures that ERp57 is always present in the peptide- 
loading complex and available to catalyse disulfide bond isomerisation of the heavy 
chain. When bound to tapasin via the 57CXXC60 motif the free 406CXXC409 motif of 
ERp57 is found in both reduced and oxidised states, confirming that it is available to 
undergo redox reactions in the peptide-loading complex and supporting the hypothesis 
that its role in class I folding involves the catalysis of disulfide bond isomerisation 
(Antoniou and Powis, 2003).
The various roles for tapasin, calreticulin and ERp57 in peptide loading, peptide 
optimisation and retention of unloaded class I molecules are still not fully elucidated.
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Assigning particular roles to each molecule is difficult, since each component is 
important in maintaining the stability of the peptide-loading complex and as a result 
knockout cell lines for each of the molecules show overlapping functions. But I will 
now attempt to summarise the current understanding of these molecules from the body 
of literature and the evidence provided in this thesis.
The possible roles of ERp57 in the complex were discussed to some extent earlier and a 
role in the isomerisation of the disulfide bond of the a 2 domain of the heavy chain is an 
attractive one since ERp57 is an oxidoreductase enzyme. However, the conundrum here 
remains that heavy chain molecules isolated from the peptide-loading complex of 
ERp57 deficient cells are reported to be fully oxidised just as they are in wild type cells 
(Garbi et al., 2006). In contrast, Dick et al. reported that HLA-B*4402 molecules 
recovered from peptide-loading complexes lacking ERp57 were partly reduced (Dick et 
al., 2002). It is possible that the requirement for ERp57 to fully oxidise class I 
molecules is an allele specific phenomenon and future work using a recently created 
ERp57 knockout cell line (Garbi et al., 2006) may help to clarify this. One likely 
approach for this would be to transfect into ERp57 knockout cells, mutant forms of 
ERp57, which retain their ability to bind tapasin through Cys-57 but are mutated at the 
C-terminal CXXC motif and are therefore unable to catalyse other redox reactions. This 
would allow separate assessment of the importance of ERp57 in stabilising the peptide- 
loading complex and in oxidation of class I.
Tapasin is the most likely candidate for a peptide editing function -  if indeed one exists 
at all. Unlike calreticulin and ERp57, tapasin is thought to be a dedicated molecule for 
class I processing (Diedrich et al., 2001) and as such may be more likely to be able to 
carry out a specialised function such as peptide editing. Moreover, tapasin is thought to 
bind to residues of the heavy chain in or surrounding the peptide groove (Yu et al., 
1999), giving it access to the crucial residues that are likely to shift upon peptide 
binding. Recently a study of peptide binding to class I has also implicated a role for 
tapasin in peptide selection (Howarth et al., 2004). In this study a range of similar 
peptides which, when bound to H2-K variably stabilise its expression at the cell 
surface, were assayed for peptide loading efficiency in several cell lines. In wild type 
cells the peptide SIINFEKL, which most efficiently stabilised H2-Kb expression was 
also found to be loaded most efficiently onto class I molecules in the ER; binding of the 
other peptides showed a similar pattern with a correlation between stability of the Kb- 
peptide complex at the cell surface and the efficiency of peptide loading. However, in 
tapasin deficient cells this hierarchy was lost so that the most stabilising peptide
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SIINFEKL was now bound to Kb at less than half the rate than the peptide SHNFEKM, 
which forms a relatively unstable complex with Kb. This experiment is unable to 
distinguish fully between the function of tapasin and that of the peptide-loading 
complex as a whole since the stability of the whole peptide-loading complex is 
compromised by the absence of tapasin. However, in calreticulin deficient cells or cells 
in which ERp57 is not recruited to the peptide-loading complex the hierarchy of peptide 
binding remains the same as in wild type cells. Tapasin therefore seems to specifically 
enhance the presentation of peptides that bind to class I with high affinity in preference 
to those with lower affinity. Peptide elution assays from class I molecules of normal and 
tapasin deficient cells have been able to confirm that the class I peptide repertoire of 
tapasin deficient cells is significantly different from that of wild-type cells, however the 
peptides eluted in the absence of tapasin were not found to be of lower affinity than in 
wild type cells (Zarling et al., 2003). However, elution assays take only a snapshot of 
the peptides bound at the cell surface and do not necessarily represent the distribution of 
peptides leaving the ER, since low affinity peptides would be turned over quickly at the 
cell surface and would be recovered at low frequency by elution.
The function of calreticulin in MHC class I antigen processing is an area of active 
research in the group of Dr. Gao with whom the work presented in this thesis has been 
carried out. Work from this thesis and from others in the group has led to a greater 
understanding of the role of calreticulin in peptide loading and class I expression. It has 
previously been shown that class I molecules traffic at an accelerated rate in calreticulin 
deficient cells (Gao et al., 2002); further to this it has now been possible to show that 
this accelerated trafficking leads to unstable expression of class I at the cell surface, 
which can be restored by addition of exogenous peptide (Fig. 6.7) or by incubating the 
cells at 26°C. This phenotype is somewhat analogous to that observed in TAP deficient 
RMA-S cells, which also express unstable class I molecules at the cell surface.
However, expression of tapasin and TAP by western blot and the function of TAP 
assessed using a peptide transport assay, are found to be unaffected in calreticulin 
deficient cells implying that calreticulin has a direct role in peptide loading. The fact 
that the peptide-loading complex forms and incorporates class I molecules in 
calreticulin cell lines along with reduced surface expression of class I supports this. 
Binding of heavy chain to P2m and exchange of calnexin for calreticulin are thought to 
occur simultaneously (Sadasivan et al., 1996) suggesting that calreticulin might be 
important in the recruitment of P2m to the heavy chain. This theory was tested in 
chapter 6 by expressing the linked chain molecule p2in-A2 in both calreticulin deficient
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(K42) and wild type (K41) cells, since P2m is already covalently linked to HLA-A2 
upon synthesis of the p2m-A2 construct. However, it was shown that the phenotype of 
P2m-A2  in calreticulin deficient cells was similar to that of wild type class I, displaying 
an 8-10 fold decrease in cell surface expression (Fig. 6.2). The deficiency in surface 
class I expression in calreticulin deficient cells does not therefore result from a failure to 
recruit P2m to heavy chain. Instead data produced by H. Fu indicate that in calreticulin 
cells the defect is in the ability of cells to present scarce peptide at the cell surface. In 
order to elicit a detectable response from a B3Z T cell hybridoma specific for the 
ovalbumin derived peptide SIINFEKL, calreticulin deficient cells had to be pulsed with 
4-fold higher concentration of ovalbumin than wild type cells. From these results, it is 
hypothesised that calreticulin lowers the concentration threshold for antigen to be 
loaded onto class I molecules and expressed at the cell surface. It is not clear how 
calreticulin facilitates the binding of scarce antigen to class I. However, possible 
mechanisms include: stabilisation of the p2m-HC heterodimer and/or the peptide- 
loading complex, cooperation with the UDP glucose system of quality control for ER 
proteins, and enrichment of peptides through the ability of calreticulin to bind to 
peptides and deliver them to the peptide-loading complex. These possible mechanisms 
were discussed extensively in section 6.4.
Evidence from the work of York et al. (York et al., 2005) and from chapter 6 suggests 
that some human alleles require another unidentified component in order to be properly 
processed. This component is not present in mouse fibroblast K41 cells or a mutant 
African Green Monkey COS7 cell line 4S8.12. HLA-A2 and mouse class I molecules 
do not seem to have any requirement for this component, conversely HLA-B44 and 
HLA-A3 cannot be presented in its absence. Data shown in chapter 6 confirmed that 
human tapasin could not recover cell surface expression of the linked chain molecule 
p2m-B44  in K41 cells showing that the required component was not a protein 
previously identified as being necessary for human class I processing in murine cells. 
Conversely, it was shown that p2m-B44 expresses normally in human HCT cells and 
that the similar linked chain molecule P2m-A2 is able to express in K41 cells. The 
expression of linked chain P2m-B44  in K41 cells could not be recovered by addition of 
exogenous HLA-B44 binding peptide. Class I molecules that traffic rapidly to the cell 
surface but are then quickly degraded are stabilised by adding exogenous peptide (Peh 
et al., 1998), so p2m-B44 is presumably not trafficking to the cell surface at all in K41 
cells. The defect in p2m-B44 presentation does not therefore arise from a failure to be
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efficiently recruited to the peptide-loading complex as seen in cells deficient in tapasin 
(Peh et al., 1998) or ERp57 (Garbi et al., 2006). These other deficiencies also allow 
some cell surface expression of class I although at a lower level than in wild type cells, 
in contrast the absence of this novel component leads to a complete failure of class I 
expression at the cell surface. The stage at which p2m-B44 is being retained in the ER in 
K41 cells is not clear but it is interesting that in COS7 cells, which display a similar 
phenotype, York et al. find that the formation of p2m-HC heterodimer is impaired (York 
et al., 2005), suggesting that the defect occurs early in the process of class I folding. 
However, it is clear that it is not a deficiency in the recruitment of that is inhibiting 
expression of (32H1-B44  in K41 cells since the HLA-B44 is already linked to p2m in this 
construct. Interestingly the expression of native mouse class I is reduced in K41 cells 
when p2m-B44  is introduced. This is perhaps not surprising since P2m-B44  is being 
expressed in the ER but is not progressing from it, and is therefore likely to be 
interacting with proteins which are usually involved in mouse class I folding. Inhibition 
of mouse class I folding by p2m-B44  at an early stage of assembly is consistent with 
other findings of competition between class I alleles at this stage of development 
(Tourdot et al., 2005). It is possible that expression of HLA-B44 might inhibit mouse 
class I even if it were processed normally, but it seems likely that the failure of p2m- 
B44 to leave the ER is exacerbating this effect, especially given the fact that the p2in-A2 
construct, which is expressed normally at the cell surface does not alter mouse class I 
expression. It is not clear whether the ‘missing’ component for p2m-B44  expression is 
absent in K41 cells or whether the murine protein expressed is unable to carry out the 
function that is performed by its human counterpart. It is possible that P2m-B44 
competes with mouse class I molecules for this component and since P2m-B44  cannot 
be correctly folded, mouse class I expression is inhibited by lack of access to this 
component. However, expression of HLA-B44 and other human alleles has been 
demonstrated successfully in other murine cells (Peh et al., 1998), so it is not clear why 
there would be a species compatibility issue for this component in K41 cells. It is 
possible that K41 cells express a mutated or unusual allele of this protein, which does 
not facilitate folding of HLA-B44 or that it is absent in these cells. Mouse class I 
molecules do not seem to have an absolute requirement for this component since 
expression of mouse class I is normal both in K41 cells and in the COS7 4S8.12 mutant 
cell line (York et al., 2005). It is formally possible that the nature of the p2m-B44 
construct is inhibiting its expression in these cells, however its successful expression in 
human cells and the successful expression of the similar p2tfi-A2  construct in K41 cells
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argues against this. It is therefore hypothesised that a hitherto unknown component is 
required for cell surface expression of HLA-B44 and some other primate alleles. This 
component is likely to be involved in the early processes of class I folding and cannot 
be compensated for by expression of human tapasin or provision of peptide.
From the body of information in the literature and the findings discussed here the 
following pathway is proposed for the processing of class I alleles such as HLA- 
B*4402 that are dependent early after synthesis for an unknown component of class I 
processing and then subsequently are also dependent on tapasin and ERp57 (Peh et al., 
1998). During and shortly after synthesis, heavy chain is bound to calnexin and is 
folded with the aid of disulfide bond formation in the a3 domain by ERp57 (Farmery et 
al., 2000). Subsequently, heavy chain dissociates from calnexin (human alleles) and 
binds to P2H1 and calreticulin (Sadasivan et al., 1996). A hitherto unknown component 
also assists in the development of class I at this early stage (York et al., 2005)(data 
presented here); different class I alleles show different requirements for this component 
and may also compete for it (Tourdot et al., 2005). By default class I molecules are then 
incorporated into the peptide-loading complex (data presented here). Meanwhile, TAP 
is transporting peptides into the ER from the cytoplasm (Spies et al., 1992) and ERAAP 
(Endoplamic Reticulum Aminopeptidase associated with Antigen Processing) trims 
amino acids one at a time from the N-terminus of imported peptides to produces 
sequences of 8-9 residues (Serwold et al., 2002;York et al., 2002).
Class I molecules are then held by the peptide loading complex in a state where they are 
able to bind peptides efficiently. If necessary ERp57 oxidises and then maintains the 
disulfide bond of the a l  domain of heavy chain (Dick et al., 2002), tapasin monitors 
peptide binding and optimises the cargo (Howarth et al., 2004), and calreticulin 
enhances the binding of scarce peptides to the groove of class I (work presented here 
and H Fu personal communication). Once bound by peptide, class I molecules may 
have lower affinity for the peptide-loading complex (Suh et al., 1994) but can remain 
associated with it (data presented here). The half-life of the continuing interaction is 
controlled by the off-rate of the loaded class I molecule or by deglucosylation of class I 
by glucosidase II enzyme (van Leeuwen and Kearse, 1996) or by recruitment of loaded 
class I molecules to ER exit sites by Bap29/31 (Paquet et al., 2004). Class I molecules 
that lose their peptide after dissociation from the peptide-loading complex may be 
recycled to the peptide-loading complex to optimise peptide loading (Paulsson et al.,
2002). Otherwise, peptide loaded class I molecules are transported out of the
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endoplasmic reticulum in coat protein complex II (COPII) vesicles and traffic via the 
Golgi body to the cell surface.
An understanding of MHC class I presentation is important for medical science, since 
stimulating or controlling cellular immunity is likely to provide powerful tools for 
fighting infectious disease and cancer, generating new vaccines, and controlling 
autoimmunity. In order for an effective CD8+ T cell response to be mounted several 
crucial encounters must occur between the T cell receptor (TCR) and MHC class I 
molecules. If any of these encounters is disrupted then cytotoxic T cell immunity will 
fail and the offending cells will not be destroyed.
In the thymus T cells are both positively and negatively selected according to the 
interaction between the TCR and self-antigens presented by MHC class I. In the 
absence of MHC class I expression of cells in the thymus, CD8+ T cells do not develop 
(Huesmann et al., 1991); conversely the interaction between the TCR and the 
MHC/peptide complex must not be too strong as this leads to negative selection of the T 
cell. This negative selection eliminates T cells whose TCR has a high affinity for self­
antigens and is thought to be an important defense mechanism against autoimmunity 
(Kappler et al., 1987). Naive CD8+ T cells, which have successfully undergone this 
selection process leave the thymus and enter the circulation. In order to become 
activated and produce effector cells, T cells must encounter specific antigen presented 
in the correct context. This is thought to involve presentation of specific antigen usually 
by dendritic cells (DCs) (Rock et al., 1993) (Irwin et al., 1989) in conjunction with 
danger signals such as TLRs (Toll-Like Receptors) and cytokines. Once activated, T 
cells circulate in the periphery and upon recognition of specific antigen at the surface of 
target cells they can finally undertake killing.
Until recently, most work on the interactions between class I and the TCR focused on 
presentation of antigen by the target cell. This process requires the classical pathway of 
class I antigen presentation, whereby intracellular proteins are broken down by the 
proteasome and antigens derived from these proteins are transported into the ER by 
TAP and loaded onto developing class I molecules (Fig. 1.1). This process probably 
occurs in the majority of nucleated cells in the body and is sensitive to brefeldin A, 
which blocks transport through the Golgi body, and to lactacystin and other proteasome 
inhibitors. However, this model, in which class I is responsible only for presentation of 
intracellular antigens, cannot adequately explain the efficacy of many vaccines or the
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development of immunity against pathogens, which do not infect macrophages or 
dendritic cells. Development of immunity in these situations necessitates the processing 
of extracellular antigens on class I molecules, a phenomenon termed ‘cross 
presentation’ (Bevan, 1976). Some research has suggested that cross presentation by 
dendritic cells and other cells might simply involve the release of phagocytosed proteins 
into the cytosol followed by presentation via the classical pathway for presentation of 
intracellular antigens (Kovacsovics-Bankowski and Rock, 1995). But other research has 
shown that some antigens can be cross-presented on class I molecules in the presence of 
the Golgi blocker brefeldin A, suggesting a separate pathway for presentation, which 
does not involve transport through the Golgi (Pfeifer et al., 1993). It was suggested that 
an alternative pathway might exist where class I molecules enter the normal pathway of 
class II molecules and become loaded with antigens in the phago-lysosomal pathway, 
allowing cross presentation of exogenous antigens on class I.
Recent work has to some extent combined some of the ideas of these two pathways. 
During phagocytosis in macrophages there was shown to be a fusion between 
membrane of the ER and the developing phagosome (Gagnon et al., 2002). A similar 
process was demonstrated in dendritic cells where the phagosome formed was shown to 
contain the ER proteins known to be necessary for antigen processing such as TAP, 
tapasin, calreticulin, ERp57 and ERAAP but not general ER proteins such as 
(Ackerman et al., 2003). Furthermore, the presence of Sec61 on and the close 
association of proteasomes with phagosomes indicated that there was an efficient 
system for retrotranslocation and degradation of phagocytosed proteins (Houde et al.,
2003). It may be that these phagosomes therefore constitute a specialised compartment 
to allow the highly efficient presentation of exogenous antigens, which has been 
demonstrated by dendritic cells (York et al., 2005;Kovacsovics-Bankowski et al., 1993). 
In this model loading would occur in phagosomes but still requires the normal 
machinery for class I presentation including the proteasome and TAP. Although 
proteins exported from the phagosome and broken down by the proteasome could in 
theory then enter the ER pathway for antigen presentation, it seems that the majority of 
class I becomes loaded with peptides that have returned to the phagosome (Ackerman et 
al., 2003). Another separate pathway for cross presentation, which is independent of 
TAP and the proteasome, but dependent on cathepsin S is still thought to exist in 
macrophages but its contribution to immunity in vivo remains unclear (Huang et al., 
1996;Shen et al., 2004). An understanding of the events of class I presentation at this
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priming stage is crucial to the design of vaccines, which aim to exploit the presentation 
of antigens by dendritic cells to produce a strong CD8+ T cell response.
Many viruses and tumour cells have developed strategies to avoid detection and the 
diversity and widespread use of these mechanisms give us an insight into the 
importance of class I antigen presentation. Class I presentation is subverted by different 
viruses at almost every stage, regulation of transcription of antigen presentation genes is 
altered (Tortorella et al., 2000), class I molecules are degraded by being rerouted from 
the ER to the lysosome by HIV protein Nef 1 (Kasper et al., 2005) or from the ER to the 
cytosol by HCMV proteins US2 and US11 (Wiertz et al., 1996). Endocytosis of class I 
from the cell surface is increased by K3 and K5 in sarcoma-associated herpes virus 
(Coscoy and Ganem, 2003), the import of peptides by TAP is blocked by HSV-1 
protein ICP47 (Neumann et al., 1997) and HCMV protein US6 (Hewitt et al., 2001), 
while HCMV protein US3 interacts with and may interfere with the function of tapasin 
(Park et al., 2004). The fact that the highly compact genome of viruses contains these 
class I evasion mechanisms shows how important avoidance of CTL detection has been 
to their survival, and it is important to take these mechanisms into account when 
thinking about vaccination. After all, even if a vaccine successfully primes T cells, the 
T cell response will not be effective unless target cells also display the specific antigen 
recognised by effector T cells.
In the future it would be interesting to study the ability of PB constructs similar to that 
used in this work, in which peptide is attached to to stimulate T cell responses. The 
transfection of HCT cells with PB restored surface class I to normal levels and since all 
the class I molecules at the surface of these cells are presenting the same peptide this 
could provide powerful stimulation for T cells. In vitro it would be possible to introduce 
the PB construct into dendritic cells and assess their ability to stimulate naive T cells. 
During this project, high titre virus expressing the linked chain construct PB and also a 
virus able to coexpress PB and the TAP inhibitor ICP47 (data not shown) have been 
produced and these viruses could be used in for this purpose. Coexpression of PB and 
ICP47 would be an interesting tool for the stimulation of CD8+ T cells. In culture it has 
been possible to expand T cell clones to great efficiency (100-fold expansion / 2 week 
stimulation -  data not shown) using the anti-CD3 antibody OKT-3 and carefully 
controlled culture conditions. In vitro stimulation of patient T cells, with known 
antigens derived from overexpressed proteins has been trialled for the treatment of 
cancers such as melanoma (Yee et al., 2002). One of the limiting factors in this process
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Xis the generation of sufficient numbers of good antigen presenting cells (usually 
dendritic cells) to stimulate extracted T cells in vitro. If a melanoma specific peptide 
was linked to P2m in a fusion protein in a parallel way to the PB construct used in this 
work, then it could be introduced into antigen presenting cells and would not require 
TAP to express at the cell surface. Coexpression with ICP47 would block the 
presentation of other peptides by inhibiting the function of TAP. This could be 
beneficial in two ways. Firstly, it might increase the amount of specific peptide 
presented at the cell surface, since the introduced PB construct would not be competing 
with other peptides for heavy chain, and secondly it might allow the use of allogeneic 
dendritic cells as antigen presenting cells. These dendritic cells would need to be 
matched for the heavy chain allele required to bind to the specific peptide used but 
could be easily obtained in large quantities from normal blood banks. A strong mixed 
lymphocyte reaction between the patient CD8+ T cells and the allogeneic antigen 
presenting cells might be avoided, since the only class I expressed by antigen presenting 
cells would be in association with the PB construct.
Expression of PB in tapasin deficient cell lines or in combination with the HLA-A2 
mutant allele T134K would also be interesting as it would allow an analysis of the 
importance of interactions of class I molecules with the peptide-loading complex 
independent of the process of peptide loading. This is an interesting question since it 
has been reported that regardless of their peptide status at the cell surface, class I 
molecules which have been processed in the presence of tapasin are more stable than 
those that are processed in the absence of tapasin or in the presence of soluble tapasin 
(Zarling et al., 2003).
Preliminary DNA vaccinations using the PB construct have been carried out in HLA-A2 
transgenic mice to determine its ability to generate effective immunity in vivo. The 
results from the first set of mice indicated an increase in the number of flu-specific T 
cells in immunised mice but the results are so far inconclusive (data not shown). This 
work is now being continued by collaborators in The Institute of Microbiology of the 
Chinese Academy of Science in Beijing.
As discussed earlier, generation of a stable Daudi cell line expressing PB would be 
useful for purposes of comparison with HCT PB cells. Since the genotype of Daudi 
cells does not include HLA-A2, immunoprecipitation of TAP and tapasin in Daudi cells
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expressing PB would provide direct evidence showing whether PB can associate with 
other heavy chain alleles in the peptide-loading complex.
The stable cell lines generated in this work could also be used in further experiments. 
There are a number of further experiments that could be carried out using HCT cells 
expressing different class I fusion proteins. Since p2fti-A2 seems to be expressed at such 
a high level it would be interesting to measure its half-life at the cell surface. This can 
be done by blocking Golgi transport using a reagent such as brefeldin A, and 
monitoring the loss of surface class I over time by flow cytometry. A similar 
experiment could be performed for cells expressing the PB construct. Together this 
would allow an assessment of the contributions of stably bound peptide and of 
association in the rate that heavy chain class I molecules are turned over from the cell 
surface.
Transduction of murine K41 cells with the linked chain molecule p2fli-B44 , has shown 
that K41 cells are deficient in a component required for presentation of HLA-B44. It 
would be of interest to explore this defect further. By immunoprecipitation it would be 
possible to determine whether or not p2m-B44 reaches the peptide-loading complex. A 
library approach could also be used to introduce human proteins into K41 cells to try 
and identify the component needed for processing of HLA-B44 and other primate 
alleles. Although it is unclear which proteins might fulfil this role possible candidates 
might include Bap29/31 and ERp57, which are both known to interact with HLA-B44.
It would also be interesting to further characterise the loss of murine class I from K41 
cells endogenously expressing P2m-B4 4 . For instance, does the loss of murine class I 
lead to a failure in antigen presentation, and are all mouse class I alleles affected equally 
by the expression of p2m-B44  in K41 cells. In order to explore further the requirements 
for expression of p2m-B44  it would be interesting to introduce it into other murine cell 
lines. Separate expression of human p2m and HLA-B44 should also be investigated in 
K41 cells to confirm that failure to express it is not a merely a property of the linked 
chain p2in-B44 molecule, but also extends to wild type class I. To this end K41 cells 
expressing human p2m have already been generated using virus produced in chapter 4 
(data not shown).
In summary, the work presented in this thesis has contributed to the understanding of 
the processes involved in class I antigen processing in the ER and has addressed several 
key stages in the regulation of class I folding. Work in the murine K41 cell line has 
demonstrated that HLA-B*4402 has a requirement for hitherto unknown component of
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Xclass I antigen processing. In cooperation with other researchers in the group the role of 
calreticulin has been better characterised. Data presented here were able to show that 
peptide could stabilise class I molecules at the cell surface of calreticulin deficient cells 
and excluded failure in 02m recruitment as the reason for decreased expression of class I 
in these cells. Instead it was shown (by H. Fu) that calreticulin enriches or somehow 
facilitates binding of scarce peptides to class I molecules.
Using linked chain molecules it was shown that class I molecules follow a default 
pathway during their synthesis involving interactions with both calnexin and the 
peptide-loading complex. 021*1-A2 was shown to bind to calnexin, which is surprising 
since for human alleles 02m associated heavy chain molecules are not normally found 
bound to calnexin (Sadasivan et al., 1996). Linked chain p2m-HC heterodimers were 
also shown to bind to the peptide-loading complex and to be dependent on both TAP 
and tapasin for optimal class I expression.
It has also been possible to show that class I fusion constructs consisting of peptide 
linked to p2in (PB) and p2m linked to HLA-A2 (BA) can express normally in human 
cells. They are fully functional and can be used to stimulate powerful T cell responses 
in vitro. Such constructs may be powerful tools in the future for use in vaccination as 
they may allow presentation of specific peptides at high density at the cell surface. 
Linked chain constructs may also prove useful in tetramer technology where separate 
expression and refolding of the three components of the mature class I molecule is both 
laborious and costly.
Most interestingly, the construct consisting of peptide linked to 02m (PB) was recovered 
from the peptide-loading complex. Having excluded the possibility that PB is paired 
with other heavy chain alleles and shown that the peptide groove of HLA-A2 is bound 
to the peptide of the PB construct and is not available for peptide binding, it is 
hypothesised from these data that class I molecules bound to high affinity peptide can 
be retained by the peptide-loading complex. This supports an automatic pathway of 
class I folding, where the peptide-loading complex acts as a passive catalyst for loading 
of peptide cargo.
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8889 nucleotides
CMV promoter: b a s e s  1-747  
TATA box: b a s e s  648 -651  
Human p-globin intron: b a s e s  8 8 0 -1 3 2 0  
HIV-1 gag/pol s e q u e n c e s :  b a s e s  1355-5661  
gag  coding se q u e n c e : b a s e s  1 3 5 5 -2 8 5 7  
gag/pol frameshift: b a se  2 6 5 0  
pol coding se q u e n c e : b a s e s  2 6 5 0-5661  
HIV-1 R ev re sp o n se  e lem en t (RRE): b a s e s  5 6 8 6 -5 9 1 9  
Human p-globin polyadenylation signal: b a s e s  6 0 7 2 -6 8 3 7  
pUC origin: b a s e s  6 9 9 5 -7 6 6 8  (C)
Ampicillin {bla) re sista n ce  g en e: b a s e s  7 8 1 3 -8 6 7 3  (C) 
bla promoter: b a s e s  8 6 7 4 -8 7 7 2  (C)
C =com plem entary strand
(§) Invitroger
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Com m ents for pLP2 
4180 nucleo tides
RSV enhancer/prom oter: b a s e s  1-271  
TATA box: b a s e s  2 0 0 -2 0 7  
Transcription initiation site: b a se  229  
RSV UTR: b a s e s  230-271  
HIV-1 R ev ORF: b a s e s  391-741  
HIV-1 LTR polyadenylation  signal: b a s e s  850-971  
bla promoter: b a s e s  1 9 1 6 -2 0 1 4  
Ampicillin (bla) r e sista n ce  g en e: b a s e s  2 0 1 5 -2 8 7 5  
pUC origin: b a s e s  3 0 2 0 -3 6 9 3
pLP2
4180 bp
(§) Invitrogen
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Com m ents for pLP/VSVG 
5821 nucleotides
CMV promoter: b a s e s  1-747  
TATA box: b a s e s  648-651  
Human (3-globin intron: b a se s  8 8 0 -1 3 2 0  
VSV  G glycoprotein (VSV-G): b a s e s  1346-2881  
Human p-globin polyadenylation signal: b a s e s  3 0 0 4 -3 7 6 9  
pUC origin: b a s e s  3 9 2 7 -4 6 0 0  (C)
Ampicillin {bla) resistan ce gen e: b a s e s  4 7 4 5 -5 6 0 5  (C) 
bla promoter: b a s e s  5 6 0 6 -5 7 0 4  (C)
C =com plem entary strand
pLP/VSVG
5821 bp
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